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CHAPTER 1 
 
 
 
Introduction 
 
 1
1.1 Prion Protein (PrP) & Disease 
 
Structural rearrangement or genetic mutation of the cellular prion protein (PrPC) is 
implicated in several human diseases, including kuru, Creutzfeldt-Jakob Disease (CJD), 
Fatal Familial Insomnia (FFI), and Gerstman-Straussler-Sheinker disease (GSS).  These 
neurological disorders are pathologically characterized by intracerebral spongiform 
change, neuronal loss, PrP deposition, and astrogliosis (Figure 1).  Dementia and ataxia 
are present as general features in all of these disorders, with each disease exhibiting 
distinctive clinical markers.  Symptoms for CJD include memory loss, weakness, 
involuntary muscle contraction or muscle paralysis, and pseudo-periodic discharges on 
electroencephalogram.  GSS patients display many of the same clinical features as CJD, 
but are defined neuropathologically by widespread multicentric amyloid plaques (Collins 
et al. 2001).  FFI patients are marked by severe insomnia, hallucinogenic episodes, and a 
strong family history of the same disease (Schenkein and Montagna 2006).   
 Prion diseases extend to the animal domain, and are significant in light of the 
possible transmissibility of these diseases into humans.  Sheep, cattle, elk, rodents, and 
non-human primates are also affected by prion disorders, which are grouped under the 
title of transmissible spongiform encephalopathies (TSEs).  The most newsworthy 
example of transmission in recent decades includes the Bovine Spongiform 
Encephalopathy (BSE), or Mad Cow Disease, epidemic in England in the mid-1990’s.  A 
new variant of CJD was introduced into the human population by ingestion of BSE-
infected meat, stimulating drastic modifications in the practice of large-scale cattle 
production and the governmental safety policies and regulations on the beef industry not 
only in Britain, but across the globe.  More recently, chronic wasting disease (CWD) has  
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Figure 1.  Prion Disease Neuropathology.  Brain sections from a CJD patient reveal the typical 
hallmarks of prion disease, including spongiform degeneration (A), glial cell proliferation (B), and PrP 
deposition (C).  In some cases, like kuru, PrP may also form florid plaques (D, arrow). 
From the Lab of Stephen DeArmond, MD, PhD
http://missinglink.ucsf.edu/lm/ids_104_neurodegenerative/Case3/Case3MicroPath.htm
A. B.
C. D.
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been detected in elk and deer in the Midwest and northern regions of the United States, 
generating a healthy concern amongst hunters, venison eaters, and the Center for Disease 
Control, who fear consumption of meat from infected game may expose humans to yet 
another variant of prion disease.   
In addition to digestion, prion exposure may also occur iatrogenically.  Several 
cases of CJD transmission have occurred through human growth hormone transplants, 
dura mater grafts, and infected cranio-surgical instruments.  Clinical reports from the UK 
and France have demonstrated the development of prion disease in human patients who 
received blood transfusions from subclinical CJD patients (Wroe et al. 2006; Turner and 
Ludlam 2009), confirming previous reports in animals that infectivity is possible via 
blood transfer (Mathiason et al. 2006; Houston et al. 2008).  
Prion disease acquired by ingestion or exposure to infected material account for 
only a small fraction of known prion disease patients.  Many cases cannot be traced to a 
source of infectivity and are thought to occur spontaneously, with one person per million 
per year diagnosed with prion disease.  Sporadic cases of prion disorders account for the 
majority of prion illness, and predominantly affect those in the sixth or seventh decade of 
life.  The remaining number of prion disease cases are attributed to inheritance of 
autosomal dominant mutations in the PrP gene, PRNP, located on human chromosome 
21.  Over 50 distinct mutations have been identified as causative agents of familial CJD 
(fCJD), FFI, and GSS.   
All prion diseases are associated with aberrations in the prion protein (PrP).  
Infectious and sporadic prion diseases are correlated with the post-translational 
conversion of cellular prion protein (PrPC) to an alternate, more β-sheet rich 
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conformation, named scrapie prion protein (PrPSc), which has the ability to bind PrPC 
molecules and replicate itself by conferring its rogue conformation onto endogenous PrPC 
templates.  In familial disorders, it is speculated that PrP mutants are inherently 
predisposed to adopt pathogenic PrPSc-like conformations, which induce spontaneous 
neurodegenerative disease.   
Despite intense investigation since the discovery of PrP’s association with 
infectious disease in the 1980’s (Prusiner 1982; Prusiner et al. 1982), the mechanisms 
defining prion toxicity are ambiguous, whether the disorder is acquired sporadically, 
through infectious material, or through genetic inheritance.  Thus, attempts to find 
effective therapeutics for prion disorders are limited.  The anti-malarial quinacrine held 
great potential when studies demonstrated inhibition of PrPSc conversion in scrapie-
infected neuroblastoma cells (Korth et al. 2001; Klingenstein et al. 2006) and in mice 
(Spilman et al. 2008).  When applied to patients, the drug was able to restore voluntary 
movement in response to verbal cues in some patients during the first month of enteric 
administration (Nakajima et al. 2004).  Although quinacrine is tolerated reasonably well, 
continued treatment fails to significantly altar clinical progression in patients affected 
with sporadic, iatrogenic, or familial prion diseases (Collinge et al. 2009).  Alternative 
candidates for therapy include pentosan polysulphate and flupirtine, but the impact of 
these at the patient level have not been robust (Gilch et al. 2008).  Given the severe lack 
of therapeutics for prion diseases, further studies are necessary to dissect the cellular, 
molecular, and neurophysiological components involved with prion pathogenesis.  
Investigations into prion disorders may prove insightful for other more common 
neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, and Huntington’s Disease, 
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given that all share the common characteristic of protein aggregation associated with 
dementia and kinetic impairment.  
 
1.2 The cellular prion protein (PrPC) 
A.  Synthesis & Cellular Trafficking 
PrPC expression begins early in embyrogenesis, and is expressed in many tissue 
types, including heart, kidney, and testes.  The highest expression levels are found within 
the central nervous system in adults, specifically in neuronal cells.  Murine PrPC is 
synthesized as a 254 amino acid polypeptide by ribosomal translation (Figure 2A).  Upon 
translocation into the endoplasmic reticulum, both the amino-terminal signal peptide and 
carboxy-terminal GPI attachment sequence are cleaved.  A GPI anchor is subsequently 
attached while high-mannose carbohydrate structures are appended onto two asparagines 
that serve as N-linked glycosylation sites.  These underdeveloped oligosaccharide chains 
are sensitive to Endoglycosidase H until further modification and processing.  In the 
Golgi, mannose structures are trimmed, and fructose and sialic acid moieties are added to 
yield more complex oligosaccharide branches (Caughey et al. 1989).  Over 50 unique 
antennary structures have been associated with PrPC, and these are sensitive to 
deglycosylation by enzyme PNGase F (Rudd et al. 1999; Stimson et al. 1999).  The GPI 
anchor core structure is modified by addition of mannose, ethanolamine, and sialic acid 
residues, and is susceptible to cleavage when treated with bacterial enzyme 
phosphatidylinositol-specific phospholipase C (PIPLC) (Stahl et al. 1992).  PrPC is then 
organized into cholesterol and sphingolipid-rich detergent-resistant membrane (DRM) 
microdomains, or “lipid rafts” (Taylor and Hooper 2006).  PrP transits via the secretory 
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pathway to the plasma membrane, where the protein establishes itself on the extracellular 
face of the lipid bilayer, attached by its GPI anchor.  After delivery to the surface, PrPC 
can transfer from DRMs to clathrin-coated pits, where it is constitutively endocytosed 
and recycled back onto the plasma membrane (Shyng et al. 1993).   
The mature PrP protein contains a flexible N-terminal end, which encompasses a 
series of five proline- and glycine-rich repeating octapeptide motifs that are able to bind 
copper (Figure 2B).  The C-terminal end of PrP is globular in structure, and contains a 
highly conserved hydrophobic segment, two glycosylation sites, and a carboxy-terminal 
glycophosphatidylinositol (GPI) anchor.  NMR studies demonstrate that the globular 
domain also carries two anti-parallel β-sheet sub-structures and three α-helical 
arrangements (Riek et al. 1997; Zahn et al. 2000).  A disulfide bond linking amino acids 
178 and 213 further enhances structural stability of the C-terminal end.     
 
B.  PrP Function 
PrP is a membrane-bound glycoprotein that can be found in almost all vertebrate 
species, and prion-like proteins that have similar sequence homology have been identified 
in several species of birds and zebrafish (Gabriel et al. 1992; Miesbauer et al. 2006).  
Across species, PrP displays comparable structural features, including repeating motifs 
able to bind copper, N-linked glycosylation, α-helical and β-sheet arrangements, and a 
notably well-conserved hydrophobic domain (Cotto et al. 2005; Shields and Franklin 
2007; Blinov et al. 2009).  Together, these observations suggest that the prion protein 
provides a significant function that merits both genetic and structural conservation 
through evolution.  
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Adapted from Caughey & Baron (2006) Nature 443:803-810.
Figure 2.  Cellular Prion Protein (PrPC).  (A) The structural features of murine PrPC include an N-
terminal signal peptide (white), five endogenous octapeptide repeats (yellow), two N-linked 
glycosylation sites (CHO), a disulfide bond (S-S), and a C-terminal end GPI anchor attachment signal 
(orange.)  Numbers indicate amino acid positions.  (B) A PrPC protein schematic reveals that the N-
terminal portion of the protein, which is able to bind copper, is mostly flexible.  The C-terminal end 
forms a globular structure composed of three alpha helices (pink) and two beta sheet strands (yellow).  
The GPI anchor (black) is embedded at the extracellular face of the plasma membrane.  
Adapted from Manson & Tuzi (2001) Expert Reviews in Molecular Medicine 3(12):1-15.
A.
B.
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 PrPo/o Knockout Mice 
In order to dissect the physiological purpose of PrP in vivo, several lines of PrP 
knockout mice have been independently generated.  Genetic ablation of coding sequences 
within the open reading frame (ORF) of the murine PrP gene, Prn-p, has been 
accomplished by homologous recombination (Bueler et al. 1992; Manson et al. 1994).  
ORF disruption led to abolition of mRNA transcripts, which completely abrogated prion 
protein synthesis in mice.  Interestingly, mice homozygous for the inactivated gene (Prn-
po/o) were born in expected Mendelian ratios, completed development with no grossly 
abnormal physical defects, and continued to live normal life spans without any indication 
of prion disease.  Additionally, null mice performed equally well compared with their 
wild-type counterparts when challenged with a battery of neurological tests for behavior, 
spatial learning, and memory (Bueler et al. 1992; Lipp et al. 1998).  Collectively, these 
studies strongly argue that PrP holds a non-essential function in development or 
adulthood.  It was speculated that redundant proteins could compensate for the lack of 
PrP at the early stages of biogenesis and then uphold this function into adulthood.  
Mallucci and colleagues utilized Cre-LoxP technology to test this theory and induced 
genetic Prn-p deletion in a time- and cell-specific manner, abrogating PrP protein 
synthesis in neurons of mice only at adulthood (Mallucci et al. 2002).  The post-natal 
deletion strategy resulted in no significant neurophysiological changes, arguing against 
the idea that independent factors substitute for, and then sustain, PrP function (Mallucci 
et al. 2002).   
Several additional lines of PrPo/o mice were generated by deleting an extended 
stretch of DNA that encompassed not only the ORF but portions of the flanking regions 
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as well.  These mice also developed normally, but displayed severe ataxia and Purkinje 
cell loss as they aged (Sakaguchi et al. 1996).  It was later found that neurodegeneration 
in these mice was not due to loss of PrP, but of upregulation of the Prnd gene that lies 
downstream of Prn-p (Moore et al. 1999; Rossi et al. 2001).  As a result of the extended 
genetic deletion, Prnd expression was placed in control of the Prn-p promoter, leading to 
novel expression of PrP-like protein Doppel in brain and other tissues where PrP is 
detected.  Doppel is structurally similar to the C-terminal end of PrP, and is usually 
expressed mainly in the testes.  When expressed in brain, it is capable of producing 
spontaneous neurodegeneration in transgenic mice.  Thus, expression of Doppel, and not 
loss of PrP, was the cause of disease in these mice.  Because several lines of PrPo/o mice 
carrying the shorter ORF deletion show a lack of any grossly abnormal phenotype, it is 
reasonable to conclude that PrP holds no essential function for development or viability.    
 
Putative Functions for PrP 
There is wide-ranging evidence implicating the involvement of PrP in a variety of 
biological activities, including neuronal defense against apoptosis, cellular protection 
from oxidative stress, copper homeostasis, transmembrane signaling, and synaptic 
operation.  PrP function in each of these pathways has been studied in vivo in knockout 
and transgenic mice and in vitro in primary neurons and immortalized cell culture 
systems.  A general overview of investigations is provided below, highlighting that the 
strongest evidence thus far connects PrP function with a role in neuroprotectivity and 
synaptic activity.   
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In several cell culture systems, PrP expression protects against pro-apoptotic 
cellular stresses.  In human primary neurons and in yeast, cells microinjected or 
transfected with a plasmid encoding pro-apoptotic factor Bax succumbed to cell death 
(Bounhar et al. 2001; Li and Harris 2005).  However, PrP expression rescued cells from 
Bax-mediated cell death in both cell models, in a manner that was found to be 
independent of anti-apoptotic factor Bcl-2 in yeast (Bounhar et al. 2006).  Additional 
protective effects of PrP expression have been reported in MCF-7 cells treated with 
apoptosis-inducing tumor necrosis factor (TNF-α) (Diarra-Mehrpour et al. 2004), and in 
immortalized hippocampal neurons susceptible to serum deprivation-triggered cell death 
(Kuwahara et al. 1999; Sakudo et al. 2003).  Although these latter studies reported robust 
anti-apoptotic PrP activity, a more recent article attempting to reproduce these 
experiments showed only modest, if any, PrP-mediated rescue (Christensen and Harris 
2008).   
Indeed, the strongest arguments for PrP as a neuroprotective agent lie mainly in in 
vivo studies that demonstrate PrP alleviation from mutation-induced neurological prion 
disease.  For example, Doppel mice (described above) spontaneously develop late-onset 
ataxia and Purkinje cell degeneration when expressed on a  PrP-null background 
(Sakaguchi et al. 1996).  These symptoms can be relieved by co-expression of WT PrP in 
a dose-dependent manner.  Similarly, transgenic mice expressing PrP harboring large 
deletions at the N-terminus (“F35”, ∆32-134) or within the highly conserved 
transmembrane domain (“∆CR”, ∆105-125) display severe ataxia, as well as cerebellar 
granule loss and white matter vacuolation (Shmerling et al. 1998; Li et al. 2007).  Re-
introduction of PrP by crossing transgenic animals with WT PrP+/+ mice significantly 
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delays disease onset and progression as well as neuropathological defects.  PrP can also 
rescue effects from disease-associated PrP mutants in transgenic mice, such as GSS 
mutant P101L (Telling et al. 1996).   Collectively, these examples reveal that WT PrP 
protects neurons at the cellular level and prevents mutation-induced toxicity.   
Consistent with its localization at the cell surface, some evidence suggests that 
PrPC acts as a receptor for transmembrane signaling.  Although specific mechanisms of 
activation have not yet been detailed, antibody-mediated crosslinking of PrPC was found 
to trigger tyrosine kinase fyn signaling, mainly at neurites, which lead to downstream 
activation of extracellular-regulated kinases (ERKs) and NADPH oxidase and the 
production of reactive oxidative species (ROS) (Mouillet-Richard et al. 2000; Schneider 
et al. 2003).  Confirmation of fyn activation was demonstrated in studies showing that 
PrP binding with neuronal cell adhesion molecule (NCAM) led to fyn stimulation and 
PrP/NCAM-dependent neuritic outgrowth (Santuccione et al. 2005).  Several other 
investigations have implicated PrP-induced signaling of several kinases, which was 
associated with neuronal development and survival in cultured neurons (Chen et al. 2003; 
Kanaani et al. 2005).  Given that PrP lies entirely at the extracellular face of the lipid 
bilayer, one or more transmembrane adaptor proteins, such as NCAM, would presumably 
be necessary to fulfill this function.  It is also speculated that PrP localization to lipid 
rafts may facilitate such interactions, as signal transduction molecules, such as Fyn and 
Src kinases, cluster within lipid rafts (Taylor and Hooper 2006). 
Recent evidence implicates PrP as a mediator of cell-to-cell adhesion, either by 
itself or in conjunction with another factor.  PrP-overexpressing neuroblastoma cells 
incubated in single cell suspension increased cation-independent aggregation, which was 
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disrupted by PIPLC-mediated PrP release from the cell surface and by PrP antibody 
preincubation (Mange et al. 2002).  Additionally, PrP-null zebrafish are arrested in the 
gastrulation phase due to loss of embryonic cell adhesion.  This phenotype can be rescued 
by expression of both zebrafish and mouse PrP, arguing for a conserved function in cell 
adhesion (Malaga-Trillo et al. 2009).  Interactions with N-CAM may mediate this 
function (Schmitt-Ulms et al. 2001).  Evidence for PrP involvement with cellular 
adhesion is preliminary, and the mechanisms underlying PrP-mediated cell-to-cell contact 
have yet to be elucidated. 
Some data suggest that PrP may help regulate copper homeostasis, perhaps by 
acting as a receptor or transporter for cupric ions.  The octapeptide repeat region of PrP 
contains histidine, and is able to bind up to four Cu2+ ions in a pH-dependent manner 
with an affinity as high as 0.1 nanomolar both in vitro and in vivo (Brown et al. 1997; 
Jackson et al. 2001; Kramer et al. 2001; Walter et al. 2006), with PrP residues 96 and 
111 also acting as additional binding sites (Jackson et al. 2001).  Copper binding causes 
conformational changes in the N-terminal tail of PrP and stimulates the exit of cell-
surface PrP from lipid rafts and into clathrin-coated pits for endocytosis (Pauly and 
Harris 1998; Brown and Harris 2003; Taylor et al. 2005).  In support for PrP regulation 
of metal ions, early investigations demonstrated a decrease in copper content within 
brains of PrPo/o mice (Brown et al. 1997; Herms et al. 1999).  However, subsequent 
studies were unable to authenticate a significant correlation between cerebral copper 
activity and PrP expression level in transgenic mice (Waggoner et al. 2000).  Further 
investigations have not yet yielded substantial evidence directly connecting PrP function 
with copper regulation.   
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Accumulating evidence suggests that PrP mediates synaptic development or 
transmission.  Localization studies at the light and electron microscope level indicate that 
PrP is highly enriched along axonal tracts and in pre-synaptic terminals in developing and 
mature neurons in vivo (Moya et al. 2000; Laine et al. 2001; Ford et al. 2002; Sales et al. 
2002).  PrP can also be transported via fast axonal transport mechanisms in the retrograde 
and anterograde directions (Borchelt et al. 1994; Rodolfo et al. 1999; Moya et al. 2004).  
In cell culture studies, exposure of rat hippocampal neurons to recombinant prion protein 
resulted in rapid polarization, axonal extension, and an increase in synapse formations 
(Kanaani et al. 2005), indicating PrP participation in synaptic development.   
Several lines of evidence also exist associating PrP with synaptic maintenance.  
PrP crosslinking also modulates activity of several G protein-coupled serotonin receptors 
(Mouillet-Richard et al. 2005; Mouillet-Richard et al. 2007), suggesting that PrP may aid 
in serotonergic transmission (Schneider et al. 2003).  Other examples indicating in vivo 
PrP involvement in neurophysiological regulation include the increase of glutamatergic 
transmission in hippocampi of PrP-overexpressing mice (Carleton et al. 2001) and 
disrupted calcium-activated potassium currents in PrPo/o hippocampus and in cerebellar 
Purkinje cells (Colling et al. 1996; Herms et al. 2001).  More recently, it was also found 
that Alzheimer’s disease-associated amyloid-beta oligomers can bind to PrPC molecules, 
which then act as receptors mediating oligomer-induced synaptic dysfunction (Lauren et 
al. 2009).  These data argue strongly for a PrP function regulating neuronal excitability at 
the synapse.    
Subtle behavioral anomalies have been identified in PrP knockout mice, many of 
which correlate with abnormal neuronal physiology, thus indirectly supporting a role for 
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PrP in synaptic function.  For instance, alterations in circadian rhythm activity are 
associated with sleep pattern irregularities in PrP-null animals (Tobler et al. 1996).  PrPo/o 
mice also display decreased olfactory sensitivity compared with PrP+/+ animals when 
challenged with odor-guidance tasks, and reveal correlating aberrations in synaptic 
transmission between olfactory bulb granule and mitral cells (Le Pichon et al. 2009).  
Both behavioral and neurophysiological irregularities were rescued by re-introduction of 
PrP protein expression.  In juvenile PrP KO mice, altered synaptic plasticity and neuronal 
excitability affected performance on rotarod and movement tests, although these were 
corrected when animals reached 50 days of age (Prestori et al. 2008).  Additionally, PrP 
null mice demonstrate increased susceptibility to pentylenetetrazol- or kainic acid-
induced seizures (Walz et al. 1999).  These data in vivo cumulatively support a role for 
PrP in synaptic homeostasis in neurons, although the molecular details underlying these 
phenotypes have yet to be clarified. 
This summary of potential functions for PrP demonstrates that the prion protein is 
an elusive molecule that is associated with a wide variety of cellular activities, which 
vary depending on assay type and model system used in each study.  Although several 
hypotheses regarding function have been presented, the most frequently observed and 
most convincing evidence implicates PrP as having a role in neuroprotectivity or synaptic 
formation or maintenance.  The proposed roles for PrP may not be mutually exclusive, as 
many studies have discovered multiple consequences of PrP loss, mutation, or 
overexpression.   
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1.3 PrPSc & Infectious Prion Disease 
A.  History of PrPSc and the Prion Hypothesis 
Transmissibility of scrapie was demonstrated in the 1940s when 10% of a flock of 
Scottish sheep developed neurological disease after injection with a vaccine created from 
infected sheep brain extract (Gordon 1946).  Continued investigation on scrapie revealed 
that brain homogenate containing the infectious agent was resistant to UV irradiation 
(Alper et al. 1967), suggesting that nucleic acids were not necessary for disease 
transmission.  In the 1980’s, Stanley Prusiner and colleagues further isolated the source 
of scrapie infectivity through the fractionation of diseased golden Syrian hamsters 
(Bolton et al. 1982; Prusiner et al. 1982).  They confirmed that the infectious agent 
resisted inactivation by irradiation, as well as DNAse and RNAse treatments, providing 
support for a non-nucleic acid-based mode of infection.  Furthermore, they found that 
infectivity was reduced when purified scrapie components were subjected to conditions 
that disrupt and degrade proteins, such as denaturing detergent sodium dodecyl sulfate 
(SDS) (Prusiner et al. 1980; Prusiner 1982).   
This led Prusiner and colleagues to support a protein-only hypothesis, whereby 
scrapie transmission was due exclusively to the actions of an infectious protein, or 
‘prion‘ (Griffith 1967; Prusiner 1982), capable of infecting similar protein molecules.  
This novel concept was initially met with mockery from fellow investigators at a time 
when scientific dogma stipulated that only pathogens with nucleic acids, such as bacteria 
and viruses, were capable of communicating disease.  However, to date there is a very 
conspicuous lack of convincing evidence supporting a role for nucleic-acid based 
pathogens that are specific for prion disease transmission, despite persistent efforts to 
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detect them (Safar et al. 2005).  Although the hypothesis was first ridiculed, 
investigations eventually revealed a single protein that was recognized as the main 
infectious agent and named “PrPSc”, for prion protein in scrapie-infected animals 
(McKinley et al. 1983).  Subsequent studies identified a PrP gene as the template which 
encoded PrPSc.  PrP gene expression was also confirmed in healthy, non-infected animals, 
generating an endogenous cellular isoform, PrPC (Oesch et al. 1985; Basler et al. 1986).    
The prion hypothesis postulates that PrPSc self-propagates by converting native 
PrPC molecules into PrPSc.  Consistent with this theory, knockout mice deficient for PrP 
are unable to sustain infectious PrPSc propagation and do not contract neurological 
disease when inoculated with scrapie prions (Bueler et al. 1993; Prusiner et al. 1993; 
Sailer et al. 1994; Weissmann et al. 1994).  Additionally, a murine 89-231 PrP fragment 
synthesized and polymerized in vitro is able to cause neurological dysfunction when 
inoculated into transgenic animals expressing similar PrP fragments.  Analysis of brain 
homogenates derived from these animals revealed the presence of aggregated and 
infectious PrPPSc, demonstrating the generation of the first infectious synthetic mammalian 
prion (Legname et al. 2004).  Stronger support for the prion hypothesis was exhibited by 
the genesis of full-length hamster PrPSc in a biochemical system that utilized protein 
misfolding cyclic amplification (PMCA) reactions.  In a PCR-like manner, aggregated 
PrPSc “seeds” are fragmented through a series of sonication steps, with each cycle of 
sonication generating new PrPSc  templates to serve as scaffolds for PrPC conversion 
(Kocisko et al. 1994).  Using this system, investigators isolated PrPSc synthesized de 
novo, injected the material into wild-type hamsters, and demonstrated that their 
artificially constructed PrPScP  induces neurological illness and replicates itself in vivo 
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(Castilla et al. 2005; Barria et al. 2009).  Data from these studies and others collected 
over the past decades have established the prion hypothesis as the most widely accepted 
model of prion transmission.   
The primary structures of PrPSc and PrPC are identical.  However, their tertiary 
conformations and biochemical properties are distinct (Figure 3).  NMR studies of 
recombinant PrPC demonstrate the presence of three α-helices and a short anti-parallel β-
sheet (Riek et al. 1997; Zahn et al. 2000).  In contrast, pathogenic PrPSc exhibits 45% β-
sheet content and reduced α-helical content (Pan et al. 1993).  These conformational 
disparities likely account for the unique PrPSc biochemical properties that allow 
distinction from PrPC.  PrPSc has a protease-resistant core, encompassing residues 89-231, 
that resists digestion by proteinase K (Bolton et al. 1982; McKinley et al. 1983).  PrPSc is 
also insoluble in non-ionic detergents, and has a propensity to form aggregate structures 
both in vivo, in cells, and in biochemical preparations (Prusiner 1989).  Additionally, the 
majority of antibodies traditionally used to detect PrPC are unable to recognize PrPSc in 
non-denaturing conditions, indicating recognition of epitopes that are exposed in the 
endogenous, but not infectious, aggregated PrP isoforms.  Reciprocally, there are several 
antibodies able to bind PrPSc conformers, but not PrPC (Korth et al. 1997; Moroncini et 
al. 2004).  
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Adapated from Prusiner, S. (2001) N Engl J Med 344:1516.
Figure 3.  PrPC and Scrapie Prion (PrPSc).  (A) Recombinant PrPC is mostly alpha-helical by 
nature.   Upon conversion to PrPSc (B), PrP adopts a more beta-sheet rich conformation.  (C) 
Structural rearrangement of PrP results in alterations of the biochemical nature of the protein.  
Biochemical Properties
PrPC PrPSc
α-helix rich β-sheet rich
Soluble Insoluble
PK-sensitive PK-resistant
Not aggregated Aggregated
A.  PrPC B.  PrPSc
C.
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B.  PrPSc Propagation 
 It is generally accepted that PrPSc is able to replicate itself by stimulating a post-
translational conformational change in PrPC molecules within the host organism, wherein 
PrPC is structurally rearranged to adopt the infectious conformation.  Two main model 
mechanisms offer explanations for molecular PrPSc replication through direct physical 
interaction with PrPC (Figure 4).     
In the template-centered refolding model, PrPSc is able to bind PrPC post-
translationally, starting a catalytic reaction that converts a single PrPC molecule to a 
protease-resistant entity, which is capable of binding to and converting yet another 
molecule (Figure 4A) (Griffith 1967).  Presumably, PrPC rearrangement is normally 
inhibited by a high activation energy barrier, which may be decreased upon the formation 
of a PrPSc / PrPC heterodimer (Aguzzi et al. 2008).  Sporadic cases of CJD, which occur 
with a frequency of approximately one case per million people per year, are thought to 
arise from rare spontaneous conversions of PrPC to PrPSc due to stochastic fluctuations in 
protein conformation (Kahana et al. 1974).  Mutations in the PRNP gene in humans may 
also destabilize PrP protein conformation such that conversion to the PrPSc form requires 
less activation energy as well (Surewicz et al. 2006).   
 A second model proposes that conversions between PrPC and PrPSc are reversible, 
but that nucleated “seeds” of oligomeric PrPSc recruit monomeric PrPC molecules that 
then convert to PrPSc upon introduction into the PrPSc aggregate (Figure 4B) (Jarrett and 
Lansbury 1993).  Acceleration of monomer incorporation, and hence PrPSc conversion, 
occurs only in the presence of oligomeric, fibrillar, or aggregated PrPSc.  In this model, 
the PrPSc conformation is only stabilized in the form of multimers, with individual PrPPSc  
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Figure 4.  Models of PrPSc Replication.  In the template-centered refolding model (A), PrPC and PrPSc
molecules bind and form a heterodimer, which stimulates conversion of PrPC to PrPSc.  Increased 
concentrations of PrPSc lead to aggregate formation.  In the nucleation-polymerization model (B), PrPC
molecules can convert to PrPSc, but the reaction is unfavorable.  PrPSc “seeds” are slow to develop, but 
once formed, catalyze PrPSc conversion by recruiting PrPC molecules.  
Adapated from Soto, C. (2004) Nature Reviews Microbiology 2:809-819.
A. Template-Centered Model  
B. Nucleation-Polymerization Model
Heterodimer
PrPC
PrPSc
PrPC
PrPSc “seed”
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21
monomers posing little threat of infectivity until seed formation with other PrP molecules 
of similar conformation.  Breakage of aggregates may explain the exponential increase of 
PrPSc during infection (Orgel 1996), and the success of in vitro generation of PrPSc 
through PMCA reactions (described above) demonstrates that PrPSc can be produced by 
this mode of nucleated polymerization (Castilla et al. 2005; Barria et al. 2009). 
In both of these models, direct physical interaction between PrPSc and PrPC is 
assumed.  Antibodies directed against PrP fragments 96-104 and 133-158 interfere with 
scrapie replication in infected neuroblastoma cells, supporting this postulation (Peretz et 
al. 2001).  Additionally, separate antibody scaffolds displaying murine PrP fragments 
composed of sequences 89-112 and 136-158 are able to recognize and bind PrPSc, but not 
PrPC, suggesting that these areas are interfaces for murine PrPSc interaction (Moroncini et 
al. 2004; Moroncini et al. 2006).   
Successful conversion of PrPC to PrPSc depends largely on the homology of host 
and template PrPs.  The most efficient conversions occur when both the PrPSc seed and 
PrPC target are of identical amino acid sequence.  Variation of even a single amino acid 
may alter the PrP structure, and although the structural difference may be slight, 
disruption of the PrPC / PrPSc interface can produce a negative effect on the rate of PrP 
recognition and binding (Priola et al. 2001).  Additionally, some PrPC’s bind 
heterologous PrPSc, but resist conversion to the infectious form (Horiuchi et al. 2000; 
Barmada and Harris 2005), indicating that subsequent reactions are necessary for 
complete rearrangement to the PrPSc conformation after the initial binding step.   
Indeed, PrP heterology accounts for the “species barrier” effect observed in 
interspecies transmission of TSE infection.  The species barrier is a phenomenon 
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whereby incubation time increases and attack rate decreases when prion disease is 
transmitted from one species to another.  For example, inoculation of prions derived from 
mice into hamsters results in prolonged time to appearance of clinical symptoms and 
decreased proportion of animals affected by disease (Prusiner et al. 1990).  In some 
cases, the species barrier can be overcome by successive passaging of the original 
inoculum through the target species, resulting in prion adaptation (Kimberlin and Walker 
1979).  In others, infection may be abrogated altogether, as is the case with wild type 
mice inoculated with prions from mule deer infected with chronic wasting disease 
(CWD) (Raymond et al. 2007).  This effect is abolished in transgenic mice carrying the 
PrP gene from mule deer (Tamguney et al. 2006) because PrPSc from inocula and PrPC 
targets are then identical in amino acid sequence.  Parallel experiments demonstrate that 
murine-PrP null mice transgenic for bovine, ovine, and human PrP genes easily succumb 
to scrapie prions prepared from cognate donors (Scott et al. 1999; Crozet et al. 2001; 
Mastrianni et al. 2001).   
Within species of animals, there exist “strains” of prions that are distinguished by 
their incubation times and PrPSc deposition patterns, despite having identical primary 
structures.  For example, distinct human PrPSc types associated with different CJD 
neuropathologies have unique glycoform ratios and proteolytic fragment size patterns 
after digestion with protease K.  One group has been able to demonstrate that PrPSc 
molecules from eight different hamster prion strains retain distinct conformations, 
supporting the idea that strain properties are enciphered solely within protein structure 
(Safar et al. 1998).  Furthermore, several murine PrPSc conformations are faithfully 
maintained and propagated in cell-free PMCA reactions, and these in vitro-generated 
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PrPSc molecules maintain their specific strain properties when inoculated into mice, 
arguing against the influence of other cellular factors in determining biological properties 
associated with strains (Castilla et al. 2008).   
 
C.  PrPSc Localization 
Investigation of intracellular PrPSc localization is essential for understanding the 
nature of transmission and disease pathology.  However, localization by visualization in 
fixed samples show varied results, depending on cell type and detection protocol.  In 
scrapie-infected neuroblastoma cells, PrPSc mainly localizes intracellularly within 
lysosomes, but not the cell surface (McKinley et al. 1991).  In vivo, mice inoculated with 
87V scrapie displayed prion aggregation in the form of plaques and amyloid fibrils at the 
extracellular face of the plasmalemma along neurites (Jeffrey et al. 1994).  Recently,  one 
group of investigators conducted a series of experiments in infected neuronal cell lines 
where protein trafficking was selectively impaired at different points (Marijanovic et al. 
2009).   Marijanovic et al. determined that PrPC ? PrPSc conversion occurred in specific 
endosomal recycling compartments, but not early or late endosomes.   
The variable conclusions from each of these experiments may partially stem from 
the different techniques used to overcome the technical difficulties associated with 
recognizing aggregated PrP.  The majority of antibodies commonly used to detect PrPPC 
are rendered ineffective for PrPSc detection, likely due to the inaccessibility of epitopes 
that become hidden or buried within the rogue folding pattern of aggregated PrPSc 
(Williamson et al. 1998).  Thus, antigen retrieval (AR) techniques are necessary to 
denature PrPSc molecules, leading to epitope exposure and allowing subsequent antibody 
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recognition.  Procedures such as hydrolytic autoclaving or treatment with high 
concentrations of guanidine thiocyanate are successful at denaturing PrPSc (Van 
Everbroeck et al. 1999), but at the expense of sometimes severe and irreversible cellular 
damage and at the risk of PrP redistribution or antigen loss (Moroncini et al. 2006).   
Several studies have been able to bypass the use of AR and identify PrPSc 
aggregates with the use of fluorescence technology.  Genetically engineered Tg(WT-
EGFP) mice express a murine PrP protein fused with an enhanced jellyfish-derived green 
fluorescent protein (EGFP).  Although unable to convert to the infectious form, WT-
EGFP was able to bind PrPC-derived infectious prions in vivo.  In brain sections of prion-
inoculated mice co-expressing both WT-EGFP and endogenous PrP, PrPSc aggregates are 
visualized in the form of fluorescent puncta in the neuropil, axonal regions, and Golgi 
apparatus of neurons (Barmada and Harris 2005).  In another study involving scrapie-
infected neuroblastoma cells, PrPC containing a tetracysteine (TC) tag was expressed, 
then able to convert into a PK-resistant form (Taguchi et al. 2009).  Upon addition of a 
biarsenical fluorophore derivative, tagged PrPSc was identified at the cell surface.  In 
SN56 neuronal cell lines, Magalhaes et al. labeled PK-resistant PrP, derived from brain 
homogenate of prion-infected animals, by covalent linkage with a primary amine-reactive 
analog of Alexa Fluor 568 (PrP-resA568).  Non-infected cells exposed to PrP-resA568 were 
able to internalize the aggregates, which subsequently colocalized with late endosomes 
and lysosomes.  PrP-resA568 aggregates also traveled along neurites to points of contact 
with other cells, suggesting a direct cell-to-cell mode of transfer and propagation 
(Magalhaes et al. 2005).    These studies set a good foundation for PrPSc visualization, 
and further clarification of PrPSc localization and transfer at the cellular and anatomical 
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levels will greatly facilitate understanding key concepts of disease pathogenesis, 
transmission, and possible therapeutics.   
 
D.  Possible Mechanisms of Infectious Prion Disease Toxicity 
 Prion diseases are usually defined in part by the presence and propagation of 
PrPSc within the central nervous system.  There are many examples that associate PrPSc 
accumulation with neurodegeneration, suggesting that PrPSc is not only infectious, but 
also causes disease toxicity directly.  In support of this, immunohistochemical studies in 
infected brain show PrPSc aggregates before symptom onset and within or near areas of 
CNS degeneration, including neuronal loss and neuropil vacuolation (Jeffrey et al. 2001; 
Ersdal et al. 2004).  PrPC (subsequently converted to PrPSc) is absolutely necessary for 
disease toxicity, as demonstrated by the lack of susceptibility in PrP knockout mice 
exposed to PrP PSc by intracerebral inoculation (Bueler et al. 1993; Sailer et al. 1994; 
Weissmann et al. 1994).  Additionally, synthetically-derived PrPSc molecules generated 
in vitro are capable of inducing prion disease when inoculated into mice (Castilla et al. 
2005), supporting the idea of direct PrPSc toxicity.  However, these latter studies are 
accomplished within brain homogenates, and the influence of other unknown CNS 
factors on toxicity cannot be excluded.   
Although PrPSc was initially thought to be the prime candidate for prion disease 
pathogenicity, there are a number of examples that reveal a large discrepancy between the 
amount of PrPSc and the extent of neurodegeneration and brain damage, arguing that the 
model of PrPSc-only toxicity is oversimplified.  Tga20 transgenic mice express 10X the 
amount of endogenous PrPC, and display highly accelerated disease progression 
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compared to WT mice, but accumulate only ~50% of PrPSc material (Fischer et al. 1996).   
Additionally, inoculation of mice with bovine spongiform encephalopathy (BSE) resulted 
in 100% transmission of disease, but over 55% of clinically symptomatic animals did not 
display protease-resistant PrPSc (Lasmezas et al. 1997).  These models illustrate that 
toxicity exists even in the absence, or limited accumulation, of PrPSc.   
Reciprocally, there are examples of animals ridden with PrPSc in the absence of 
clinical symptoms of prion disease. RML-inoculated transgenic mice expressing an 
anchorless form of PrP accumulate massive PrPSc deposition within the cerebellum, 
hippocampus, and cortex, but remain free of neurological illness for the duration of their 
lifetimes (Chesebro et al. 2005).  Additionally, brain extracts from a human GSS patient 
carrying the P102L mutation were able to induce PrPSc amyloid deposition when 
inoculated into mice carrying the murine form of the same mutation, but failed to 
transmit clinical disease (Piccardo et al. 2007).  In another stunning example, 
neurotoxicity and spongiosis in inoculated animals were abrogated and reversed by 
depleting PrPC expression post-natally, despite the accumulation of PrPSc to intensities 
observed in terminally ill wild-type animals (Mallucci et al. 2003).  These investigations 
strongly argue that PrPPSc as conventionally defined cannot account for prion 
neurotoxicity.   
What then, is the toxic species (PrPtoxic) involved with prion disease?  There is an 
emerging viewpoint implicating small oligomeric complexes in the induction of toxicity 
in several neurodegenerative diseases, including prion disorders (Caughey and Lansbury 
2003; Haass and Selkoe 2007).  In this model, transient oligomeric PrPSc intermediates, 
or protofibrils, are the active components of cellular interaction and neurotoxicity.  
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Consistent with this hypothesis, small soluble or partially PK-resistant PrP oligomers 
have displayed toxicity in cell culture and in primary neurons from PrP+/+ mice 
(Novitskaya et al. 2006; Simoneau et al. 2007).  In principal, continuous PrPC expression 
would be necessary to maintain the pool of transitory oligomers, and large PrPSc 
aggregates could serve as reservoirs of these toxic intermediates upon disassembly.   
Interestingly, membrane attachment seems to play a role in PrPSc aggregation and 
toxicity.  In cells, proper GPI anchorage of PrP to the extracellular face of the plasma 
membrane is necessary for efficient PrPSc conversion (Caughey and Raymond 1991; 
Borchelt et al. 1992).  Deletion or substitution of the anchor with a transmembrane 
domain in scrapie-infected neuroblastoma cell lines leads to impaired PrPSc formation 
and accumulation (Rogers et al. 1993).  In transgenic mice that express a C-terminally 
truncated PrP lacking the GPI anchor signal sequence, inoculation with scrapie results in 
extensive plaque formation.  These plaques are larger and more dense than plaques found 
in scrapie-inoculated wild-type counterparts.  Surprisingly, inoculated Tg(PrPΔGPI) 
animals exhibit no clinical symptoms for the duration of their lifetimes, while inoculated 
wild-type mice typically survive only five months.   PrPSc derived from brain 
homogenates of prion-infected Tg(PrPΔGPI) mice is less infectious when sequentially 
passaged, despite its extensive accumulation in the brain (Chesebro et al. 2005; Trifilo et 
al. 2008).  Collectively, these data reveal that the GPI anchor affects PrPSc conversion, 
aggregation, toxicity, and transmissibility.   
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1.4  PrPM & Inherited Prion Disease 
A.  Genetic Mutations in the PrP Gene and PrPM
Ten to fifteen percent of reported cases of prion diseases in humans are caused by 
mutations in the PRNP gene on chromosome 20 (Mead 2006).  Mutations result in 
dominantly inherited neurodegenerative disorders, categorized either as familial CJD 
(fCJD), Fatal Familial Insomnia (FFI), or Gerstman-Straussler-Sheinker disease (GSS).  
There is high phenotypic variability between patients, even by those carrying the same 
mutations within the same family (Young et al. 1999).  Ages of onset have been observed 
from mid-twenties to late into the eighties, with the majority of cases reported in the 
fourth and fifth decades of life (Mead 2006).  Disease severity can also range from mild 
to fatal, likely depending on as-of-yet unidentified genetic, epigenetic, and environmental 
factors.   
 Over 50 PRNP mutations have been associated with prion disease (Figure 5A).  
These include point mutations that lead to amino acid substitutions, amber mutations that 
cause truncated PrP transcripts, and insertions of the N-terminal octapeptide (OR) motifs 
result in repeat collapses or expansions.  Mutations are found throughout the PRNP 
coding sequence, suggesting that instead of having primary sites of functional activity 
that are disrupted by mutation, structural integrity of the entire protein is necessary to 
maintain non-pathologic behavior.   
Several non-pathogenic polymorphisms exist within the PRNP locus, including 
four that result in single amino acid substitutions.  Of significant note, a common 
polymorphism at codon 129 determines whether methionine (M) or valine (V) is present 
at this position.  Although neither variant causes disease by itself, the codon 129 
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genotype plays a critical role in susceptibility, severity, and incubation period of prion 
diseases, both familial and infectious (Mead 2006).  For example, codon 129 specifies the 
disease phenotype of the D178N mutation: patients with a 129V allele display familial 
CJD, while those with the 129M allele result in FFI (Kong et al. 2004).  In transfected 
cells and in patient brain samples, D178N displays different glycoform ratios and 
cleavage products after protease K digestion, dependent on the codon 129 polymorphism, 
indicating that phenotypic heterogeneity of the mutant is due to conformational effects of 
the M/V 129 polymorphism (Petersen et al. 1996).  Additionally, new variant CJD, which 
affects only a subset of people who have ingested BSE-infected beef, has thus far only 
been detected in individuals homozygous for the 129M allele (Mead 2006).   
  
B.  Molecular Basis for PrPM  Toxicity 
 Point mutations in the prion protein gene are thought to encourage spontaneous 
PrP conversion to pathogenic PrPSc-like conformations (Figure 5B).  Misfolding of 
mutated PrP (PrPM) may lead to decreased stability of endogenous PrPC conformation, 
thus increasing the likelihood of conversion to a pathological PrPSc-like malconformer 
over time (Kong et al. 2004).   
The highly variable biochemical and cell biological properties between different 
mutations render it difficult to understand the exact molecular mechanism of PrPM 
toxicity.  PrPSc from infectious disease is defined by resistance to protease digestion, 
insolubility in nonionic detergents, and ability to form aggregate structures.  However, 
mutant PrPs, designated PrPM, are not as easily categorized.  Biochemically, some 
mutations such as D197N, V179I, and V209I resemble endogenous PrPC more than PrPPSc  
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Adapted from Manson & Tuzi (2001) Expert Reviews in Molecular Medicine 3(12):1-15.
Figure 5.  Genetic PrP mutants (PrPM).  (A) Over 50 pathological mutations are associated with 
familial prion disease, a subset of which are indicated along a schematic representation of human PrP.  
Several  polymorphisms that do not inherently cause disease are also listed. (B) PrP mutants may not 
be stable in PrPC-like conformations, thus increasing the likelihood of adopting a more PrPSc-like 
structural arrangement .
PrPC-like 
conformation
PrPSC-like 
conformation
A.  
B.  
PrPM PrPM
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because they are sensitive to degradation by protease K (PK), remain soluble in 
detergents, and display correct PrP localization.  Others, like PG14, D177N, and E199K 
exhibit PK resistance, are partially insoluble in detergent, and present aberrant PrP 
trafficking patterns, but are not infectious (Ivanova et al. 2001; Chiesa et al. 2003; 
Biasini et al. 2008).   
Adding to the variability, there is a wide range of phenotypic inconsistency in 
patients carrying the same mutation.  Even within the same families, symptoms can 
extend from mild to severe.  In at least one case, phenotypic variability in patients sharing 
the same mutation can be explained by conformational differences in PrPM structure. One 
particular GSS-associated mutant PrP, 102L, can fold into at least two different 
pathogenic conformers in human patients, with each variant correlating with the presence 
or absence of spongiform degeneration (Piccardo et al. 1998).  Mice inoculated with 
brain homogenates carrying either conformation displayed variable pathologies (Piccardo 
et al. 2007).  Thus, like prion “strains” in infectious disease, some speculate that 
differential mutant conformations may contribute to the clinical and neuropathological 
variability observed in patients (Piccardo et al. 2007).  
  
C.  Mouse Models of Inherited Prion Disease 
In an effort to comprehend the pathogenic mechanisms underlying familial prion 
disorders, several transgenic mouse models have been generated to express disease-
associated genetic PrP mutants. 
 Transgenic mice overexpressing the mouse version of GSS-associated PrP mutant 
P102L, MoPrP-P101L spontaneously develop neurological disease, as evidenced by the 
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presence of PrP plaques and spongiform degeneration (Telling et al. 1996).  This 
phenomenon was dependent on expression level, as mice expressing lower levels of the 
mutation remained healthy.  Although P101L in diseased animals is sensitive to PK 
digestion, the mutant protein accumulates as aggregates in sick mice, as demonstrated by 
its reactivity with PrP aggregate-specific antibody 15B3 (Nazor et al. 2005).  
Interestingly, inoculation of P101L brain homogenate from spontaneously sick animals to 
transgenic mice expressing the same mutation accelerated disease (Nazor et al. 2005), 
consistent with the nucleated polymerization model of prion replication (Figure 2B) 
whereby aggregate seeds increase the rate of PrPC polymerization and conversion to 
disease-associated PrPM.  Like other artificial mutations such as ΔCR or F35, P101L 
disease can be abrogated by coexpression with WT PrP (Telling et al. 1996). 
 The GSS phenotype is also recapitulated in another transgenic mouse expressing 
disease-associated Prn-p mutation A117V (Hegde et al. 1998).  Spongiosis and astrocytic 
gliosis were prominent features in sick animals, although brain homogenates contained 
no PK-resistant, infectious material.  In transfected cells and in brain homogenates of 
Tg(A117) mice, the mutation demonstrated a unique characteristic whereby a 
subpopulation of PrPs adopted a transmembrane form of PrP (CtmPrP) post-translationally 
within the ER (Hegde et al. 1998).  To investigate whether the altered transmembrane 
topology was responsible for disease induction, a separate, yet similar, line of 
Tg(L9R/3AV) mice were created.  These expressed a mutant PrP containing several 
nonconservative amino acid changes within the transmembrane region to produce a 
homogenous population of CtmPrP molecules.  In mice, CtmPrP developed progressively 
fatal ataxia and demonstrated hippocampal atrophy and cerebellar granule loss, leading to 
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the notion that CtmPrP may be the neurotoxic intermediate that induces neurodegeneration 
universally in prion disorders (Stewart et al. 2001).  However, several other disease-
associated PrP mutants did not adopt the transmembrane formation (Stewart and Harris 
2001), and inoculation of Tg(L9R/3AV) mice with scrapie did not shorten PrPSc 
incubation times.  Together these data argue against CtmPrP playing a major role in prion 
pathogenesis.     
Mutations resulting in the addition of more than three extra octapeptide repeats 
are associated with prion disease, with age of onset negatively correlating with increasing 
numbers of ORs (Yu et al. 2007).  The PG14 mutation, which adds an additional nine 
ORs, is the largest disease-associated insertion reported thus far in cases of CJD.  
Tg(PG14) animals expressing the murine form of PG14 develop spontaneous disease at 
around 270 days.  Diseased mice display cerebellar atrophy, massive apoptosis of 
cerebellar granule cells, and extensive intracerebral PG14 deposition (Chiesa et al. 1998) 
(Figure 6A-C), which are likely due in part to intracellular retention and aggregation of 
the mutant PrP (Lehmann and Harris 1996; Ivanova et al. 2001).   
Investigations in cultured cells and in primary neurons show that PG14 has 
distinct trafficking patterns and biochemical properties compared with PrPC.  PG14 
accumulates intracellularly, showing delayed progression through the ER and hindered 
ability to localize to the cell surface.  A subset of molecules, named PG14agg, 
spontaneously becomes PK-resistant, detergent insoluble, and 15B3-reactive while in 
transit through the secretory pathway.  However, a fraction of molecules remain soluble 
(PG14sol) and have biochemical properties similar to PrPC (Biasini et al. 2008) (Figure 
6D).  Although PG14sol is readily detectable by standard immunohistochemistry, PG14agg 
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localization, like PrPSc, is difficult to detect because of its aggregate nature and is not 
easily recognized by traditional PrP antibodies without antigen retrieval (Chiesa et al. 
1998; Medrano et al. 2008). 
Unlike PrPSc, PG14 is not infectious.  When co-expressed with endogenous PrP in 
Tg(PG14) PrP+/+ mice, PG14 does not convey its PK-resistant conformation onto WT 
PrP, indicating that PG14 serves as a prion mutant model where infectivity and toxicity 
are distinct (Chiesa et al. 2003).  Not surprisingly then, PG14 pathogenesis in transgenic 
mice begins and proceeds at the same rate of neurodegeneration in the presence or 
absence of PrPC, indicating a lack of interaction with, and neuroprotective effect from, 
WT PrP.  Interestingly, infectivity can be introduced into PG14 molecules through 
inoculation of Tg(PG14) animals with RML scrapie prions (Biasini et al. 2008).  The 
resulting PG14RML molecules are both toxic and infectious, suggesting that RML is able 
to bind and rearrange PG14 molecules to a more PrPSc-like configuration (Figure 6E). 
 The most recently generated transgenic mice are those that express the fCJD 
mutant D178N with the V129 polymorphism (Dossena et al. 2008).  In addition to motor 
dysfunction and PrP deposition, Tg(D178N/V129) mice also displayed abnormal EEG 
patterns and memory impairment, similar to symptoms found in D178N/V129 CJD 
patients.  GABAergic neuronal loss, a distinctive feature in CJD, was also noted in 
transgenic animals.  Electron microscopy of cerebella in sick animals revealed gross 
dilation of the endoplasmic reticulum, indicating that ER dysfunction may contribute or 
underlie cellular pathogenesis.  Coexpression of WT PrP also failed to rescue symptoms 
in this mouse model, suggesting a lack of interaction with endogenous PrPs.   
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Figure 6.  The PG14 mutation.  (A) Transgenic mice expressing PrP with the PG14 mutation develop 
kyphosis and ataxia, while wild-type (WT) counterparts remain healthy.  (B)  H&E-stained cerebellum 
derived from a WT mouse demonstrates a full cerebellar granule layer (dark purple), while cerebellum 
from a Tg(PG14) mouse (C) shows severe atrophy and massive loss of cerebellar granule neurons.  (D)  
PG14 is synthesized as a soluble molecule, which over time spontaneously aggregates into a toxic, but 
not infectious, form.  (E) Tg(PG14) mice inoculated with RML scrapie prions produce PG14RML, 
which is both toxic and infectious.  RML prions likely convert PG14 molecules into adopting more 
RML-like conformations.  
D.
PG14sol PG14agg PG14RML
E.
PG14PrPSc
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PG14
Adapted from Chiesa et al. (1998) Neuron 21(6):1339-51.
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Transgenic mice expressing prion mutations mimic the toxicity and disease 
phenotypes observed in human illness.  Collectively, these models demonstrate that prion 
toxicity can occur in the absence of PrPSc, and that the biochemical properties, trafficking 
patterns, and infectivity of PrPM vary depending on mutation type.   
 
D.  Possible Mechanisms of Familial Prion Disease Toxicity 
Like infectious PrPSc, the molecular, cellular, and physiological details underlying 
inherited prion disease remains ambiguous.  It is generally thought that the root of 
inherited mutant prion disease stems from PrP misfolding.  PrPs are synthesized and 
immediately translocated into the lumen of the ER, where protein folding occurs.  Several 
genetic PrP mutants, including PG14 and CtmPrP, have displayed delayed exit from the 
ER when transfected into cells (Singh et al. 1997; Ivanova et al. 2001), supporting the 
idea that the ER quality control is capable of recognizing and retaining misfolded PrPs.  
The ER has several systemic mechanisms to correct any improperly folded protein 
products, including chaperone assistance, ER-associated degradation (ERAD), and 
unfolded protein response (UPR) pathways (Scheper and Hoozemans 2009).  
For this reason, several groups have investigated the role of possible ER stress 
and dysfunction in prion pathology.  Cultured cells challenged with chemicals that induce 
ER stress, such as tunicamycin, produce protease-resistant mature PrPs.  Further 
investigation prompted authors to postulate that the unfolded protein response (UPR) was 
activated in these cells, inducing PrP retrotranslocation into the cytosol where it formed a 
PrPSc –like infectious molecule (Ma et al. 2002).  The same group demonstrated that 
transgenic mice expressing a cytosolic form of PrP developed severe ataxia and 
 37
cerebellar neurodegeneration (Ma et al. 2002).  However, multiple reports from several 
other investigators contend that only a small portion of PrP molecules, mutant and wild-
type, are degraded by the proteasome and that these represent transcripts that had never 
been translocated in the ER.  Pharmacological inhibition of proteasome activity in cells 
expressing wild-type and several mutant PrPs retained within the ER affects neither 
maturation nor turnover of these proteins, and does not decrease cell viability (Drisaldi et 
al. 2003; Fioriti et al. 2005), refuting the hypothesis that proteasomal degradation plays a 
major role in prion pathogenesis.  Additionally, no activation of UPR-related signal 
proteins, such as PERK or eIF2α, were detected in brains from patients with inherited 
prion disease (Unterberger et al. 2006), and no upregulation of UPR-associated genes, 
including Grp78/Bip, have been identified in Tg(D178N/V129), Tg(PG14), and 
Tg(CtmPrP) mice compared with wild-type controls (Dossena et al. 2008) (and Stewart & 
Harris, unpublished). These data argue against a significant role for proteasomal 
dysfunction as a causative agent for familial prion disease.  However, other ER-stress 
induced neurodegenerative effects cannot be excluded.  It is possible that mutant protein 
accumulation within the ER interferes with ER-mediated calcium signaling necessary for 
basic neuronal function (Mattson et al. 2000).  Alternatively, PrPM aggregation at the 
lipid bilayer may interfere with assembly and transportation of other membrane proteins, 
for example transmembrane receptors or interlocking ion channel subunits, thus 
interfering with cell signaling or synaptic transmission (Schwappach 2008). 
PG14 aggregation and massive apoptosis in cerebellar granule neurons are 
hallmark pathologies described in transgenic mice, prompting the investigation for a pro-
apoptotic pathway involved in neuronal death (Chiesa et al. 1998; Chiesa et al. 2000).  
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PG14 animals bred onto a Bax knockout background resulted in a rescue of the neuronal 
apoptosis phenotype, but did not inhibit clinical presentation of prion disease, indicating 
that Bax-dependent signaling pathways were not involved with the inherited disorder.  
Synaptic abnormalities were evident in PG14 mice on both Bax+/+ and Baxo/o 
backgrounds, but not in controls, indicating that impaired neuronal excitability could 
account for dysfunction, with apoptosis being a secondary effect (Chiesa et al. 2005).  
Additionally, Bax deletion does not abrogate or delay clinical disease or Purkinje cell 
degeneration in Tg(Doppel) mice, suggesting that Bax-dependent pro-apoptotic pathways 
are unlikely major players in prion toxicity (Dong et al. 2007).  
Recently, another group has proposed that the expression of PrPM interferes with 
proper PrPC localization within detergent-resistant membrane microdomains (DRMs), 
which may be involved with disease progression (Schiff et al. 2008).  Association of WT 
PrPC and several GSS-associated PrP mutants (A117V, E200K, or T182A) was increased 
when WT and PrPM mutants were co-expressed in Fischer Rat Thyroid (FRT) cells, and 
the ratio of intracellular vs. surface PrPs was altered as well. Authors postulate that 
mislocalization of mutant and wild-type PrPs may alter membrane equilibrium in lipid 
rafts, thus leading to a toxic effect in neurons by an unknown mechanism.   
Collectively, these data show that ER retention and Bax-dependent apoptotic 
pathways are features of some familial prion disease mutants, but are not the main 
causative agents of toxicity. PrPM DRM mislocalization may provide some clues as to 
pathogenicity, but many more investigations using other PrP mutants will be necessary to 
substantiate whether the phenomenon is common between PrPM models and whether it is 
contributory to disease.   
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One major difficulty in studying familial prion disease and attempting to find a 
universal explanation for pathogenicity is the wide range of biochemical properties and 
cellular properties that exist between the 50+ different PrPM mutations.  Molecular and 
cellular variables such as increased β-sheet structure, aggregation, infectivity, abnormal 
glycosylation, PK resistance, and aberrant trafficking behavior can influence PrPM 
toxicity (Prusiner 1998).  Given the extensive assortment of cellular and biochemical 
characteristics of disease-associated PrP mutants, none of these factors alone are 
sufficient to cause the clinical and neurodegenerative pathologies observed in all familial 
prion disorders.  Thus, the main mode of PrPM toxicity, like PrPSc, remains unknown.   
Whether familial and infectious prion diseases are governed by the same 
mechanism(s) is indefinite.  It is possible that PrPM and PrPSc induce pathology by 
differential mechanisms.  The lack of infectious PrPM in some mutants indicates that 
infectivity is not inherently linked with pathogenicity in familial prion disease.  This is 
distinct from PrPSc, which by definition is transmissible.  PrPM can also be soluble or 
partially insoluble, suggesting that these forms may represent misfolded PrPSc 
intermediates capable of toxicity.  Alternatively, PrPPM may increase formation of PrP 
oligomers, causing toxicity in a manner similar to that described in the emerging 
“oligomeric toxicity” hypothesis for infectious disease.  However, because the mode of 
pathogenicity is equally ambiguous for PrPM and PrPSc, further study in both fields is 
necessary for understanding disease toxicity.   
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1.5  Focus of Thesis Research 
 Mechanisms underlying sporadic, infectious, and inherited prion diseases remain 
ambiguous.  Further exploration of PrPM especially is necessary to understand genetic 
prion pathogenesis and any mechanisms that distinguish inherited versus infectious 
toxicity.  Thus, the objectives of my thesis work revolve around the study of PrP mutant 
PG14 and the role of aberrant trafficking and accumulation in disease.  Localization of 
aggregated mutant PrP is essential for elucidating the pathological mechanisms at the 
physiological and neuronal levels.  In Chapter 2, I describe experiments characterizing 
the clinical and neuropathological progression of disease in transgenic mice expressing 
fluorescently-tagged PG14.  Tg(PG14-EGFP) mice allow the in vivo examination of 
PG14 aggregate localization, which clarifies PG14 distribution in primary neurons and in 
brain  section without the use of antigen retrieval techniques.  PG14 was observed for the 
first time in axon-dense regions of the brain, suggesting that PrPM may interfere with 
neuronal signaling or synaptic transmission by blocking axonal transport mechanisms.   
 I also initiate investigation into the role of membrane attachment in PG14 
aggregation, cell behavior, and toxicity.  Previous work has demonstrated that GPI-
mediated membrane attachment plays a significant role in PrPPSc aggregation, 
transmission, and disease pathogenesis.  Because PrPSc and PrPM can differ in their 
cellular and biochemical characteristics, the significance of GPI anchorage in aggregated 
PrPM cell trafficking, behavior, and toxicity are unknown.  In Chapter 3, I investigate the 
function of the GPI anchor in PG14 cell localization, glycosylation, and aggregation in 
cells.  These experiments set the foundation for parallel studies to be continued in vivo.  
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Tg(PG14∆GPI) mice are currently being generated to study the effect of GPI anchor loss 
in PG14 aggregation and disease in a physiologically relevant setting.   
Finally, in the appendices, I present continued attempts to visualize both 
aggregated mutant PG14 and infectious PrPSc in cells and in mice using green fluorescent 
protein (GFP) technology.  Live imaging of fluorescently labeled mutant PG14 within 
neurites in cell culture would give greater insight into how and when PG14 aggregates, 
and how axon-specific accumulation influences cellular behavior.  Similarly, the GFP-
tagged PrPSc  would permit imaging of intra- and inter-cellular transfer of the infectious 
protein, thus facilitating visualization of PrPSc transmission.  
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2.1  Summary 
A nine-octapeptide insertional mutation in the prion protein (PrP) causes a fatal 
neurodegenerative disorder in both humans and transgenic mice.  To determine the 
precise cellular localization of this mutant PrP (designated PG14), we have generated 
transgenic mice expressing PG14-EGFP, a fluorescent fusion protein that can be directly 
visualized in vivo.  Tg(PG14-EGFP) mice develop an ataxic neurological illness 
characterized by astrogliosis, PrP aggregation, and accumulation of a partially protease-
resistant form of the mutant PrP.  Strikingly, PG14-EGFP forms numerous fluorescent 
aggregates in the neuropil and white matter of multiple brain regions.  These aggregates 
are particularly prominent along axonal tracts in both brain and peripheral nerve, and 
similar intracellular deposits are visible along the processes of cultured neurons.  Our 
results reveal intra-axonal aggregates of a mutant PrP, which could contribute to the 
pathogenesis of familial prion disease by disrupting axonal transport. 
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2.2  Introduction 
Prions are infectious proteins associated with several fatal neurodegenerative 
diseases in mammals (Prusiner, 2004).  Prion diseases result from conversion of the 
cellular prion protein (PrPC) into a conformationally altered isoform (PrPSc) that is 
aggregated and protease-resistant.  Dominantly inherited mutations in the gene encoding 
PrP are responsible for familial forms of prion disease (Kong et al., 2004).   One mutant, 
designated PG14, harbors a nine-octapeptide repeat insertion in the N-terminal region of 
PrP that is associated with ataxia, dementia, and cerebellar PrP plaques in several 
families (Duchen et al., 1993; Krasemann et al., 1995; Owen et al., 1992).  Tg(PG14) 
mice expressing the mouse homolog of the PG14 mutant develop an ataxic neurological 
illness characterized by non-amyloid PrP deposits, apoptosis of cerebellar granule 
neurons, and loss of synaptophysin-positive nerve terminals (Chiesa et al., 2000; Chiesa 
et al., 2005; Chiesa et al., 1998). 
Elucidating the mechanisms by which PG14 and other mutant PrPs induce 
neuropathology requires information about the localization of these molecules at the 
anatomical and subcellular levels.  However, immunolocalization of PG14 PrP deposits 
in brain tissue has proven to be technically challenging due to the poor antibody 
reactivity of the mutant protein as a result of conformational changes and/or aggregation.  
Like PrPSc, PG14 PrP possesses hidden epitopes that prevent antibody recognition 
without the use of harsh antigen retrieval techniques, such as hydrolytic autoclaving or 
treatment with guanidine thiocyanate (Kitamoto et al., 1987; Kitamoto et al., 1992; Van 
Everbroeck et al., 1999).  However, these techniques, which denature or partially 
hydrolyze proteins, necessarily introduce a number of potential artifacts. 
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Our previous immunohistochemical studies identified punctate, most likely 
extracellular deposits of PG14 PrP in the cerebellum and other brain regions of Tg(PG14) 
mice (Chiesa et al., 2000; Chiesa et al., 1998).  However, intracellular aggregates of the 
protein in neuronal cell bodies or axons were never observed.  This result is surprising, 
given the known cellular trafficking patterns of PrP along secretory, endocytic and axonal 
transport pathways (Harris, 2003), as well as our own previous observation that mutant 
PrP molecules are partially retained in the endoplasmic reticulum of cultured cells 
(Ivanova et al., 2001).  These considerations suggest that conventional 
immunohistochemical methods may be providing an incomplete picture of the 
localization of PG14 in brain tissue. 
To overcome the limitations of immunocytochemical detection, we have 
developed lines of transgenic mice expressing PrP-EGFP, a fusion protein incorporating 
enhanced green fluorescent protein (EGFP) inserted near the C-terminal, glycolipid 
attachment site of PrP.  In mice that express PrP-EGFP incorporating wild-type (WT) 
PrP, the fluorescent protein is correctly synthesized and posttranslationally modified, and 
is distributed in an anatomic and subcellular pattern similar to that of untagged PrP 
(Barmada et al., 2004).  In addition, the fusion protein retains functional activity, as 
assayed by a genetic test (Barmada et al., 2004).  We have used Tg(WT-EGFP) mice to 
monitor the distribution of PrPSc after scrapie inoculation (Barmada and Harris, 2005).  
In the present study, we report the construction and characterization of transgenic 
mice expressing the PG14 version of WT-EGFP.  Our results provide, for the first time, 
evidence for an intra-axonal localization of a mutant PrP, and they suggest that disruption 
of axonal transport may play a role in the phenotype of familial prion disorders. 
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 2.3  Materials & Methods 
Transgenic mice.  The PG14-EGFP construct was generated as described by 
Ivanova et al. (2001) by inserting the EGFP open reading frame into the StuI site (within 
codon 223, wild-type numbering) of a plasmid encoding murine PG14 PrP tagged with 
the 3F4 epitope. The PG14-EGFP open reading frame was then amplified by PCR with 
SalI ends, and cloned initially into pGEM-T and then into the XhoI site of the 
MoPrP.XhoI transgenic vector (Borchelt et al., 1996) as described by Barmada et al. 
(2004).  The transgene was excised with NotI and microinjected into the pronuclei of 
fertilized eggs from an F2 cross of C57BL/6J X CBA/J F1 parental mice. Founder animals 
were identified by PCR screening of tail DNA using primers P1 
(AACCGAGCTGAAGCATT) and P4 (CACGAGAAATGCGAAGGAACAAGC).  
Tg(PG14-EGFP) lines were established by breeding transgene-positive founders to a 
recombinant inbred strain of C57BL/6J X CBA/J mice.  All mice used in this study were 
bred onto a  Prn-p+/+ (C57BL/6J X CBA/J) background, with the exception of one 
(Figure 3D), which had been bred onto a Prn-p0/0 (C57BL/6J x 129) background (Büeler 
et al., 1992).  All mice were housed in a pathogen-free environment and were cared for 
following the guidelines set forth by the Washington University Policy on Animal Care. 
The following mouse lines have been described previously: Tg(WT-EGFP) (line 
A) (Barmada et al., 2004), Tg(PG14) (line A2) (Chiesa et al., 1998), Tg(WT) (line E1) 
(Chiesa et al., 1998), and Prn-p0/0 (Büeler et al., 1992). 
Mice were checked weekly for symptoms of neurological dysfunction.  Kyphosis, 
seizure, foot clasp, and hyperexcitability were determined by visual observation, while 
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ataxia was tested by placing mice in the center of a horizontally oriented grill (45 x 45 
cm) consisting of 3 mm diameter steel rods spaced 7 mm apart.  Mice unable to 
maneuver around the grid were scored as ataxic.  Animals that exhibited at least two 
symptoms were scored as ill. 
Paraffin sections.  Mice were injected intraperitoneally with heparin anticoagulant 
(1,000 U/ml), then  anesthetized by injection of ketamine (Fort Dodge Animal Health, 
Fort Dodge, IA) and xylazine (Butler Animal Health Supply, Dublin, OH).  Animals 
were perfused intracardially with 50 ml of saline solution, followed by 40 ml of 4% 
paraformaldehyde in 0.1M sodium phosphate buffer (pH 7.2).  Brains were removed and 
then post-fixed in the same solution for 48 hrs.  After bisecting the brain along the mid-
sagittal plane, each hemisphere was dehydrated in graded ethanol solutions, cleared in 
xylene, and then embedded in paraffin.  Six μm sagittal sections were cut and mounted 
on polylysine coated glass slides. 
Hematoxylin and eosin staining was performed after dewaxing sections in xylene 
and rehydrating them in graded ethanol solutions.  For assessing astrocytosis, dewaxed 
and rehydrated sections were stained with anti-GFAP monoclonal antibody (DAKO, 
Carpinteria, CA), followed by incubation with Alexa 594-coupled goat anti-mouse IgG 
(Molecular Probes, Eugene, OR).  Sections were imaged using a Nikon TE2000-E 
inverted fluorescence microscope. 
Fluorescence microscopy.  Animals were fixed by intracardiac perfusion as 
above.  Brains were then removed and then post-fixed in the same solution for 2 hrs 
before transfer to 0.1M sodium phosphate buffer (pH 7.2) containing 0.02% sodium azide 
for storage at 4°C.  A vibratome (The Vibratome Company, St. Louis, MO) was used to 
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cut the tissue into 60 μm thick sagittal sections.  Sections were mounted on glass slides 
using Gel/Mount (Biomeda, Foster City, CA).  Intrinsic EGFP fluorescence was imaged 
using a Zeiss LSM 510 inverted confocal microscope with an Axiovert 200 laser 
scanning system. 
To visualize PrP, vibratome sections were stained with antibodies P45-66 
(Lehmann and Harris, 1995), 3F4 (Bolton et al., 1991), or 8H4 (Zanusso et al., 1998).  
Some sections were stained with antibodies directed against giantin (Covance, Berkeley, 
CA), TRAP (Upstate, Charlottesville, VA), LAMP1 (1D4B, Developmental Studies 
Hybridoma Bank, Univ. of Iowa, Iowa City, IA), MAP2 (Sigma, St. Louis, MO), or GFP 
(gift of Maurine Linder, Washington University).  Primary antibodies were visualized 
using Alexa 488-coupled goat anti-rabbit IgG (P45-66, GFP), Alexa 488-coupled anti-
mouse IgG (3F4, 8H4), or Alexa 594-coupled goat anti-mouse IgG (giantin, TRAP, 
LAMP1, MAP2).  Sections were then imaged as described above. 
Biochemical analyses.  Brain homogenates (10% w/v) were prepared in ice-cold 
PBS using a Teflon-glass apparatus with pestle revolving at 3,500 rpm (Wheaton Science 
Products, Millville, NJ).  A postnuclear supernatant was obtained by centrifuging 
homogenates at 1,000 x g for 5 min.  Protein concentration was determined using a BCA 
assay (Pierce, Rockford, IL).  Homogenates were analyzed by SDS-PAGE followed by 
Western blot using anti-PrP antibodies 8H4 (Zanusso et al., 1998) or 3F4 (Bolton et al., 
1991).   
To quantitate protein expression levels, serial dilutions of  Tg(PG14-EGFP)+/o 
mouse brain homogenate were analyzed by Western blot using Image J software 
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(National Institutes of Health, USA).  The amount of PG14-EGFP was calibrated by 
comparison to the level of endogenous PrP. 
 To assay protease resistance, frozen brain hemispheres were homogenized in 
detergent buffer (DB: 10 mM Tris-HCl, pH 7.4, 0.5% sodium deoxycholate, 0.5% NP-40, 
150 mM NaCl), then assayed for protein concentration as described above.  Two hundred 
μg of total protein were diluted in DB to a final concentration of 1 μg/μl.  The solution 
was mixed for 10 min at 4°C, then centrifuged at 1,500 x g for 5 min at 4°C.  0.5-2 μg/ml 
of proteinase K was added to the supernatant and the mixture was incubated at 37°C for 
30 min.  Phenylmethylsulfonyl fluoride (PMSF; 10 mg/ml) was added to terminate 
digestion.  Proteins were isolated using methanol precipitation, then analyzed by SDS-
PAGE and Western blotting. 
 To assay detergent insolubility, brain homogenates prepared in DB were diluted 
to 0.4 μg/μl in the presence of protease inhibitors (1 μg/ml pepstatin and leupeptin, 0.5 
mM PMSF, and 2 mM EDTA), then incubated for 20 min at 4°C.  The sample was 
centrifuged at 1,500 x g for 5 min at 4°C.  The supernatant was then recovered and 
centrifuged for 75 min at 135,000 x g at 4°C to separate soluble and insoluble fractions.  
Proteins from the supernatant of this subsequent centrifugation were recovered by 
methanol precipitation, and then both the supernatant and pellet fractions were analyzed 
by SDS-PAGE.   
 To test sensitivity to phosphatidylinositol-specific phospholipase C (PIPLC), 200 
μg of postnuclear supernatant was centrifuged at 16,000 x g at 4°C for 5 min to collect 
membranes.  Membrane pellets were resuspended in PBS with B. thuringiensis PIPLC 
(prepared as described in Shyng et al. (1995)) at a final concentration of 1 unit/ml, then 
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incubated on ice for 2.5 hrs.  Membranes were then collected again by centrifugation at 
16,000 x g, and proteins released into the supernatant were precipitated with methanol.  
Membrane pellets and proteins precipitated from the supernatant were resuspended in gel 
loading buffer and analyzed by SDS-PAGE and Western blotting. 
To immunoprecipitate aggregated PrP with antibody 15B3, we followed the 
procedure recommended by Prionics (Zurich, Switzerland), utilizing the buffers supplied 
by them.  First, a 100 μl aliquot of mouse anti-IgM Dynabeads (Dynal, Carlsbad, CA) 
was coated with 20 μg of mAb 15B3.  Ten μl of 15B3-coated Dynabeads were then 
added to 200 μg of total protein from brain homogenates.  Samples were incubated on a 
rotating wheel for 2 hr at 25°C, after which beads were washed three times with 1 ml of 
15B3 Wash Buffer (Prionics, Zurich, Switzerland).  Washed beads were suspended in 40 
μl of 2X 15B3 Loading Buffer (Prionics) and heated for 5 min at 96°C. 
Immunoprecipitated proteins were resolved by SDS-PAGE followed by Western blotting 
with 6D11 antibody (Pankiewicz et al., 2006). 
 Neuronal cell culture and transfection.  Cerebellar granule neurons (CGNs) were 
isolated from 4 day old mouse pups according to methods described previously (Miller 
and Johnson, 1996).  Neurons were plated in CGN medium (basal medium Eagle’s with 
Earle’s salts, 10% fetal calf serum, 2 mM glutamine, 25 mM KCl, 0.1 mg/ml 
gentamycin).  Cells were plated at a density of 375,000-450,000/cm2 onto 35 mm glass-
bottom dishes pre-coated with poly-D-lysine.  Cultures were stained with FM 4-64 
(Invitrogen) according to the manufacturer’s directions. 
 EGFP-WT and EGFP-PG14 constructs (in which EGFP is inserted near the N-
terminus of PrP) were generated by first cleaving the EGFP open reading frame from the 
 64
pEGFP-C1 plasmid (Clontech, Mountain View, CA) using restriction enzymes NcoI and 
EcoRI.  Both ends were blunted, then ligated into the AgeI site (within codon 33) of a 
pcDNA3 plasmid encoding murine WT or PG14 PrP tagged with the 3F4 epitope.  The 
resulting plasmids were introduced into CGNs cultured from non-transgenic mice by 
transfection using Lipofectamine 2000 (Invitrogen, Carlsbad, CA).  Cells were analyzed 
24 hrs after transfection. 
Primary neurons were imaged in the living state using a Zeiss LSM 510 inverted 
confocal microscope with an Axiovert 200 laser scanning system using LSM Image 
Browser software.  For kymograph analysis, we used a Nikon TE-2000E inverted 
fluorescence microscope, and images were captured and analyzed with Metamorph 
imaging software. 
 
2.4  Results 
Weak immunostaining of native PG14 PrP in brain sections.  In all of our 
previous studies using immunostaining to localize PG14 PrP in paraffin-embedded brain 
sections from Tg(PG14) mice, antigen retrieval treatments (guanidine thiocyanate plus 
hydrolytic autoclaving) were applied to partially denature the mutant PrP and so enhance 
its immunoreactivity (Chiesa et al., 2000; Chiesa et al., 2005; Chiesa et al., 1998; Chiesa 
et al., 2003).  To test the reactivity of PG14 PrP in the native state, we immunostained 
vibratome sections without pre-treatment.  We observed that, while brain sections from 
Tg(WT) mice (expressing wild-type PrP) stained strongly with antibodies directed 
against three different regions of the PrP molecule (supplemental Figure 1A, D, G), 
sections from Tg(PG14) mice produced only a low level of fluorescence (supplemental 
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Figure 1B, E, H).  Western blots confirmed that the expression levels of PG14 and WT 
PrP are similar (Chiesa et al., 1998).  We noted that, although the fluorescence signal 
observed in Tg(PG14) brains was low with all three antibodies, it was detectably above 
the background level seen in Prn-p0/0 mice that do not express any PrP (supplemental 
Figure 1C, F, I).  This residual signal is most likely due to the presence of a sub-
population of PG14 PrP molecules (designated PG14Sol) that are soluble and that possess 
all of the biochemical properties of PrPC, including reactivity with antibodies that 
recognize PrPC-accessible epitopes (Biasini et al., manuscript submitted). 
 
Construction of Tg(PG14-EGFP) mice.  To allow antibody-independent 
localization of PG14 PrP, we generated transgenic mice expressing PG14-EGFP, a fusion 
protein in which the EGFP moiety is inserted near the C-terminal glycolipid attachment 
site of PrP harboring the PG14 mutation (Figure 1A).  For comparison, we used Tg(WT-
EGFP) mice expressing the wild-type version of PrP-EGFP, which have been described 
previously (Barmada et al., 2004) (Figure 1A).  Both WT-EGFP and PG14-EGFP were 
constructed with an epitope tag for the 3F4 antibody (Bolton et al., 1991), which allows 
discrimination of transgenically encoded PrP from endogenous PrP.  The PG14-EGFP 
fusion construct was cloned into the MoPrP.XhoI vector (Borchelt et al., 1996), which 
contains a partial promoter sequence from the endogenous PrP gene.  This promoter 
drives protein expression in a developmental and tissue-specific pattern comparable to 
that of endogenous PrP, with the exception that the transgene is not expressed in Purkinje 
cells (Barmada et al., 2004; Fischer et al., 1996). 
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Four separate lines of Tg(PG14-EGFP) mice were established (D, X1, X3, and 
X4).  Anatomical localization of PG14-EGFP within the brain was unusual in line D, 
which showed preferential expression of the fluorescent protein in the mossy fibers, 
alveus, and stratum lacunosum moleculare, but low expression elsewhere (supplemental 
Figure 2B).  This unusual expression pattern is likely due to the site of transgene 
integration.  In contrast, the gross neuroanatomical distribution of fluorescent protein in 
the X1, X3 and X4 lines was similar to that of WT-EGFP (Barmada et al., 2004) 
(supplemental Figure 2D-O), and to the known distribution of endogenous PrPC (Moya et 
al., 2000; Salès et al., 1998).  However, only the X4 line expressed PG14-EGFP at a 
sufficiently high level to be detected by fluorescence microscopy without the aid of anti-
GFP labeling (supplemental Figure 2).  Although the X4 line served as the primary 
source of data for the experiments described below, the subcellular distribution of PG14-
EGFP (including the presence of axonal aggregates, see results) was confirmed in the D 
line using the intrinsic fluorescence of EGFP and in the X1 and X3 lines by staining with 
anti-GFP antibody (supplemental Figure 2, and data not shown). 
Western blot analysis of brain homogenates confirmed expression of PG14-EGFP 
protein in transgenic animals.  PG14-EGFP migrates at approximately 85 kDa, larger 
than WT-EGFP which migrates at 60-70 kDa (Figure 1B,C).  Antibody 8H4 recognizes 
both endogenous and transgenic PrPs (Figure 1C), whereas 3F4 identifies only 
transgenically encoded PrP molecules (PG14, WT-EGFP and PG14-EGFP), each of 
which carries the 3F4 epitope tag (Figure 1B).  Based on quantitative Western blotting, 
we determined that expression of PG14-EGFP in animals of the X4 line was ~0.15X that  
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FIGURE 1.  Structure and expression of WT-EGFP and PG14-EGFP in transgenic mice. (A) 
Schematic of the structures of WT-EGFP and PG14-EGFP.  WT-EGFP contains an N-terminal signal 
sequence (SS), five octapeptide repeats (OR, blue), and a C-terminal GPI addition signal (GPI).  The 
EGFP tag is inserted at codon 223.  PG14-EGFP is similar to WT-EGFP, but contains nine additional 
octapeptide repeats (OR, red), resulting in a total of 14 repeats.  (B, C) Expression of WT-EGFP and 
PG14-EGFP.  Brain homogenates from non-transgenic (lane 1), Tg(PG14) (lane 2), Tg(WT-EGFP) 
(lane 3), and Tg(PG14-EGFP) (lane 4) mice were analyzed by Western blotting using anti-PrP 
antibodies 3F4 (B) and 8H4 (C).  All mice were on the Prn-p+/+ background.  ?, PG14-EGFP; ?, 
WT-EGFP; solid bracket, PG14 PrP; dotted bracket, endogenous WT PrP.  Molecular size markers are 
given in kilodaltons. 
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of endogenous PrP in mice carrying a hemizygous transgene array, and ~0.3X in those 
carrying a homozygous transgene array (data not shown). 
 
Tg(PG14-EGFP) mice develop a spontaneous neurological illness.  Tg(PG14-
EGFP) mice that were homozygous for the transgene array developed spontaneous 
neurological disease at 391 ± 54 days (Table 1).  Symptoms in these animals included 
kyphosis, ataxia, foot clasp, poor grooming, hyperexcitability, and seizures.  The same 
clinical features were also present in approximately 10% of Tg(PG14-EGFP) 
hemizygotes, but they appeared only at much later ages (~630 days).   All Tg(WT-EGFP) 
mice remained healthy (Table 1), as reported previously (Barmada et al., 2004).  
Histological analysis revealed prominent astrogliosis in the cerebella and 
hippocampi of homozygous Tg(PG14-EGFP) mice compared with Tg(WT-EGFP) 
controls (Figure 2A, C, D, F).  Healthy Tg(PG14-EGFP) heterozygotes exhibited some 
astrogliosis, although of a lesser severity than their homozygote counterparts (Figure 2B, 
E).  Cerebellar sections from either homozygous or heterozygous Tg(PG14-EGFP) mice 
stained with hematoxylin and eosin did not show significant granule cell loss or other 
obvious histological abnormalities (Figure 2G-I).  Consistent with these observations, we 
did not detect positive staining in the cerebellum by the TUNEL method, which reveals 
dying cells undergoing DNA fragmentation (data not shown). 
 
PG14-EGFP possesses PrPSc-like biochemical properties.  To investigate 
whether PG14-EGFP displays abnormal biochemical properties like untagged PG14 PrP,  
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Genotype Age of Onset
WT-EGFP+/o >600 (0/7)
PG14-EGFP+/+ 391 ± 54 (6/7)
PG14-EGFP+/o 630d ± 43 (2/27)
PG14+/o 235 ± 10 (61/61)a
Table 1. Disease onset in Tg(PG14-EGFP) animals
Age of onset is recorded in days.  Numbers in parentheses indicate the number of ill mice over the total 
number of animals observed.  a Data taken from Chiesa et. al. (2000). 
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FIGURE 2.  Tg(PG14-EGFP) mice exhibit astrogliosis but not loss of cerebellar granule cells.
Paraffin sections from cerebellum (A-C, G-I) and dentate gyrus (D-F) were stained with an antibody 
against GFAP (A-F), or with hematoxylin and eosin (G-I).  Sections were obtained from age-matched 
healthy Tg(WT-EGFP+/0) mice (A, D, G), healthy Tg(PG14-EGFP+/0) mice (B, E, H), and clinically ill 
Tg(PG14-EGFP+/+) mice (C, F, I).  The abbreviations are: ML, molecular layer; CGL, cerebellar 
granule cell layer; DGL, dentate granule cell layer; MF, mossy fibers.  Scale bars are 20 μm for A-F 
and 200 μm for G-I.
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we performed assays for protease resistance, detergent insolubility, phospholipase 
sensitivity, and immunoprecipitation by the PrPSc-reactive antibody 15B3. 
Like untagged PG14 PrP, PG14-EGFP is weakly protease resistant, producing a 
PrP 27-30 core fragment when subjected to digestion with proteinase K (PK) 
concentrations of 0.5-2 μg/ml (Figure 3A, lanes 1-4, 9).  In contrast, WT-EGFP was 
completely digested by PK under the same conditions (Figure 3A, lanes 5-8). 
To test detergent insolubility, detergent lysates of brain were subjected to 
ultracentrifugation to separate soluble from insoluble protein fractions.  As expected, 
WT-EGFP is recovered almost entirely in the supernatant (S, soluble) fraction in this 
assay (Figure 3B, lanes 5, 6).  In contrast, PG14-EGFP, like untagged PG14 PrP, was 
found in both supernatant and pellet (P, insoluble) fractions (Figure 3B, lanes 1-4).  In 
multiple experiments, the proportion of insoluble PG14-EGFP varied from 25-50% (data 
not shown). 
PIPLC is a bacterial enzyme that cleaves the glycosylphosphatidylinositol (GPI) 
anchor that attaches PrP to cellular membranes, thereby releasing the protein into the 
extracellular medium.  PG14 PrP is partially resistant to the action of PIPLC, probably 
due to aggregation and/or conformational changes at the C-terminus of the protein, as 
opposed to aberrant GPI anchor incorporation (Chiesa et al., 1998; Lehmann and Harris, 
1995; Narwa and Harris, 1999).  After PIPLC treatment of brain membranes, 
approximately half of the total amount of WT-EGFP shifts into the supernatant (S) 
fraction, indicating partial release of the protein (Figure 3C, lanes 1, 2, 5, 6).  Incomplete 
release of WT PrP from brain membranes has been observed previously (Chiesa et al., 
1998; Ivanova et al., 2001), and is probably attributable to the mixed topology of the 
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membranous vesicles produced by homogenization.  In contrast, the majority of PG14-
EGFP remains associated with the membrane (P) fraction, demonstrating that the protein 
is partially resistant to PIPLC cleavage, like untagged PG14 (Figure 3C, lanes 3, 4, 7, 8).  
Also similar to untagged PG14, a small fraction of PG14-EGFP is found to be PIPLC-
sensitive (Figure 3C, lane 7), demonstrating that the protein contains a functional GPI 
anchor.  Thus, the presence of the EGFP tag does not interfere with GPI anchoring of 
either WT or PG14 PrP.  
15B3 is a monoclonal antibody that was originally reported to react specifically 
with PrPSc and not PrPC (Korth et al., 1997).  Recently, we have shown that this antibody 
recognizes multiple forms of aggregated PrP, both infectious and non-infectious, 
including PG14 PrP from both transfected cells and transgenic mouse brain (Biasini et 
al., manuscript submitted).  The antibody shows no reactivity with monomeric PrPC, even 
when present in vast excess.  We found that 15B3 immunoprecipitated both PG14-EGFP 
and untagged PG14 PrP, but did not recognize wild-type PrP from both Tg(WT) and non-
transgenic mice (Figure 3D).  Thus, PG14-EGFP and PG14 PrP share aggregation-
specific, 15B3-reactive epitopes. 
Collectively, these results show that PG14-EGFP behaves like untagged PG14 in 
four different assays that measure PrPSc-like biochemical properties. 
 
PG14-EGFP forms aggregates in multiple brain regions.  To compare the 
distributions of PG14-EGFP and WT-EGFP in brain tissue, vibratome sections from 
transgenic mice were examined using fluorescence microscopy.  Consistent with our 
previous analysis (Barmada et al., 2004), we found that WT-EGFP was concentrated  
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FIGURE 3.  PG14-EGFP displays abnormal biochemical properties like untagged PG14 PrP.  (A) 
Assay for protease resistance.  Brain homogenates from Tg(PG14-EGFP) mice (lanes 1-4), Tg(WT-
EGFP) mice (lanes 5-8) and Tg(PG14) mice (lane 9) were treated with the indicated concentrations of 
PK, and then subjected to Western blotting with 3F4 antibody.  PG14-EGFP and PG14, but not WT-
EGFP, give rise to PrP 27-30 fragments.  (B) Assay for detergent insolubility.  Brain homogenates 
from Tg(PG14-EGFP) mice (lanes 1, 2), Tg(PG14) mice (lanes 3, 4) and Tg(WT-EGFP) mice (lanes 5, 
6) were subjected to ultracentrifugation, followed by Western blotting of supernatant (S lanes) and 
pellet fractions (P lanes) using 3F4 antibody.  PG14-EGFP and PG14 PrP, but not WT-EGFP, are 
partially detergent insoluble.  (C) Assay for PIPLC release.  Brain membranes from Tg(WT-EGFP) 
mice (lanes 1, 2, 5, 6) and Tg(PG14-EGFP) mice (lanes 3, 4, 7, 8) were incubated without (lanes 1-4) 
or with (lanes 5-8) PIPLC.  Membranes were then collected by centrifugation, and PrP in pellets (P 
lanes) and supernatants (S lanes) was analyzed by Western blotting with 8H4 antibody.  WT-EGFP, but 
not PG14-EGFP, is partially released by PIPLC.  (D) Test of reactivity with antibody 15B3.  Brain 
homogenates from the following mice were subjected to immunoprecipitation with 15B3, followed by 
Western blotting with 6D11 antibody: Tg(PG14)/Prn-p0/0 (lane 1); Tg(PG14-EGFP)/Prn-p+/+ (lane 2); 
Tg(PG14-EGFP)/Prn-p0/0 (lane 3); non-Tg (lane 4); and Tg(WT-EGFP) (lane 5).  One-fifth as much 
brain homogenate was used as starting material in lane 1 as in the other lanes.  All Tg(PG14-PrP) mice 
were hemizygous for the transgene array, and all had a Prn-p+/+ genetic background unless otherwise 
stated.
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primarily in neuropil areas that are rich in synapses as well as along axon tracts, and was 
present only at low levels in dendrites and neuronal somata.  In the hippocampus, for 
example, fluorescence was distributed in the stratum oriens and stratum radiatum of the 
CA1 region (Figure 4A).  Mossy fibers in the dentate gyrus were also fluorescent (Figure 
4C).  In the cerebellum, WT-EGFP was present in the molecular layer, as well as in 
neuropil of the granule cell layer (Figure 4E).  In these three brain regions, the 
fluorescence signal had a relatively uniform distribution, with the exception of 
fluorescent puncta in the cell bodies of pyramidal and granule neurons, corresponding to 
the location of the Golgi apparatus in these cells (Barmada et al., 2004) (arrows in Figure 
4A, C, E). 
The distribution PG14-EGFP was markedly different from that of WT-EGFP.  In 
Tg(PG14-EGFP) mice, bright, intensely fluorescent aggregates were visible in multiple 
brain areas.  In the CA1 region of the hippocampus, PG14-PrP aggregates were found in 
the stratum oriens, and to a lesser extent in the stratum radiatum and the pyramidal cell 
layer (Figure 4B).  Intensely fluorescent aggregates of PG14-EGFP were also evident 
along mossy fibers of the hippocampus (Figure 4D, K, L), as well as in the molecular 
layer of the cerebellum (Figure 4F), the neocortex (Figure 4G. H), and the striatum 
(Figure 4I, J).  In general, PG14-EGFP aggregates were concentrated in the same brain 
regions that displayed high levels of WT-EGFP in Tg(WT-EGFP) mice (Barmada et al., 
2004).  The aggregates were often distributed in a linear pattern that seemed to 
correspond to the course of individual neuronal processes (arrowheads in Figure 4D, J).  
Although much of the PG14-EGFP signal was present in the form of discrete fluorescent 
aggregates, these aggregates were superimposed on a more uniform, but less intense  
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FIGURE 4.  PG14-EGFP forms aggregates in multiple brain regions. (A-F) Comparison of the 
distributions of WT-EGFP and PG14-EGFP in brain sections.  Vibratome sections from healthy 
Tg(WT-EGFP+/0) mice (A, C, E) and ill, age-matched Tg(PG14-EGFP+/+) mice (B, D, F) were 
prepared from the CA1 region of the hippocampus (A, B), the dentate gyrus (C, D), and the cerebellar 
cortex (E, F), and were imaged by fluorescence microscopy.  The inset in panel A shows a brain 
section from a non-transgenic, Prn-p+/+ mouse, to illustrate the background level of fluorescence.  
PG14-EGFP forms numerous fluorescent aggregates, whereas WT-EGFP has a much more uniform 
distribution.  (G-L) The number of PG14-EGFP aggregates is higher in mice with a homozygous 
transgene array.  Sections from healthy Tg(PG14-EGFP+/0) mice (G, I, K) and ill, age-matched 
Tg(PG14-EGFP+/+) mice (H, J, L) were prepared from the neocortex (G, H), the striatum (I, J), and the 
CA3 region of the hippocampus (K, L).  Aggregate concentration is increased in animals expressing 
twice the amount of the transgenic mutant protein.  The arrowheads in D and J indicate linear 
aggregates of PG14-EGFP that probably lie within individual axons.  The arrows in A, C and E 
indicate accumulations of WT-EGFP in the Golgi apparatus of neuronal cell bodies.  The abbreviations 
are: OR, stratum oriens; PYR, pyramidal cell layer; RA, stratum radiatum; DGL, dentate granule cell 
layer; MF, mossy fibers; CGL, cerebellar granule cell layer; ML, molecular layer, PC, Purkinje cell 
layer.  All scale bars represent 20 μm.
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background of fluorescence that was similar in appearance to the pattern observed in 
Tg(WT-EGFP) mice (Figure 4A-F).  This latter signal was specific, since it was absent in 
non-transgenic mice (inset, Figure 4A), and is likely attributable to non-aggregated forms 
of PG14-EGFP (see Discussion). 
Although fluorescent aggregates were observed in all Tg(PG14-EGFP) animals, 
we found that aggregate concentration was directly correlated with the level of transgene 
expression.  Thus, Tg (PG14-EGFP) animals that were homozygous for the transgene 
array accumulated more numerous fluorescent aggregates than animals that were 
hemizygous for the transgene array (Figure 4G-L). 
 
PG14-EGFP aggregates are present in axons but not dendrites.  Aggregates of 
PG14-EGFP were found at highest density in myelinated and unmyelinated axon bundles, 
and could often be observed arrayed along the course of individual axons.  In the 
striatum, axonal fibers cut in cross-section were intensely fluorescent, and fibers cut 
longitudinally displayed bright fluorescent puncta along their length (Figure s. 4J, 5F).  
Aggregates were also visible in the alveus (Figure 5G) and corpus callosum (Figure 5H) 
which contain myelinated axons, as well as along unmyelinated mossy fibers in the 
hippocampus (Figure 4D).  Aggregates were prominent in peripheral as well as central 
axons, for example, along fibers of the sciatic nerve (Figure 5J).  PG14-EGFP deposition 
did not occur along all axonal tracts, however.  For example, aggregates were sparse 
along white matter tracts of the cerebellum (Figure 5I).  In contrast to PG14-EGFP, WT-
EGFP displayed a relatively homogeneous, non-aggregated distribution in each of these 
areas (Figure 5A-E).  While WT-EGFP appeared to uniformly coat the surface of axonal 
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fibers, PG14-EGFP fluorescence was restricted to punctate deposits that seemed to be 
intra-axonal.  This conclusion was borne out by analysis of neurons in culture (see 
below). 
To determine whether PG14-EGFP aggregates were present in dendrites as well 
as axons, we stained brain sections with an antibody to MAP2, a somatodendritic marker 
protein.  We found that fluorescent deposits of PG14-EGFP did not co-localize with 
MAP2, for example in the apical dendrites of pyramidal neurons in the stratum lucidum 
of the CA3 region of the hippocampus (Figure 5K-M).  We conclude that PG14-EGFP, 
like WT-EGFP (Barmada et al., 2004), is present primarily in axons, and is largely absent 
from dendrites. 
 
PG14-EGFP aggregates do not co-localize with markers for the ER, Golgi, or 
lysosomes.  We reported previously that mutant PrP molecules, including those harboring 
the PG14 mutation, are partially retained in the ER of non-neuronal cells (Ivanova et al., 
2001).  In addition, PrPSc has been localized to the Golgi apparatus (Barmada and Harris, 
2005) as well as to lysosomes (Laszlo et al., 1992) in brain tissue.  To determine if PG14-
EGFP is found in these intracellular organelles in neurons, we analyzed the distribution 
of the fluorescent protein in brain sections that were stained for markers representing the 
ER, Golgi, and lysosomes.  We found that most PG14-EGFP aggregates did not co-
localize in neuronal cell bodies with markers for the ER (TRAP), Golgi (giantin), or 
lysosomes (LAMP1) (Figure 6).  As is the case for WT-EGFP (Barmada et al., 2004), a 
few PG14-EGFP puncta in the perinuclear region of large neurons appeared to co- 
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FIGURE 5. PG14-EGFP aggregates are present in axons but not dendrites.  (A-J) Comparison of 
the distributions of WT-EGFP and PG14-EGFP in several axon-rich regions of the brain, and in 
peripheral nerve.  Vibratome sections from healthy Tg(WT-EGFP+/0) mice (A-E) and ill, age-matched 
Tg(PG14-EGFP+/+) mice (F-J) were prepared from the striatum (A, F), the alveus (B, G), the corpus 
callosum (C, H), and the cerebellar white matter (D, I).  Sciatic nerves were examined as whole mounts 
(E, J).  (K-M) PG14-EGFP does not co-localize with a somatodendritic marker.  A section from the 
CA3 area of the hippocampus from an ill Tg(PG14-EGFP+/+) mouse was immunostained for MAP2.  
The section was then viewed for EGFP fluorescence (K), MAP2 staining (L), and as a merged image of 
the two signals (M).  The abbreviations are: PYR, pyramidal cell layer; LUC, stratum lucidum.  The 
scale bars in A (applicable to A, C-F, H-J), B (applicable to B, G), and K (applicable to K-M) represent 
20 μm.  
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FIGURE 6.  PG14-EGFP aggregates do not co-localize with markers for the ER, Golgi, or 
lysosomes.  Vibratome sections from the brains of ill Tg(PG14-EGFP+/+) mice were stained with 
antibodies to TRAP (an ER marker) (A-C), giantin (a Golgi marker) (D-F), or LAMP1 (a lysosomal
marker) (G-I).  Sections were derived from the CA3 area of the hippocampus (A-F) or the dentate 
gyrus (G-I).  Sections were viewed for EGFP fluorescence (A, D, G), for marker protein staining (B, E, 
H), or as a merged image of the two signals (C, F, I).  The abbreviations are: PYR, pyramidal cell 
layer; LUC, stratum lucidum; DGL, dentate granule cell layer; MF, mossy fibers.  The scale bar is 20 
μm (applicable to all panels).
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localize with the Golgi marker, giantin, presumably representing protein in transit 
through the secretory pathway (not shown). 
 
PG14-EGFP forms aggregates along neurites of cultured neurons and is 
decreased at the cell surface.  To determine the subcellular localization of WT-EGFP 
and PG14-EGFP more precisely, we analyzed cultures of cerebellar granule neurons 
(CGNs) prepared from neonatal transgenic mice.  WT-EGFP was distributed in a rim 
around neuronal cell bodies, as well as along neuritic processes (Figure 7A, B).  The 
protein showed a relatively uniform distribution, with only a few, small, perinuclear 
puncta corresponding to the location of the Golgi apparatus (not shown).  In contrast, 
PG14-EGFP was distributed in numerous, large, intensely fluorescent aggregates along 
neuritic processes (Figure 7C, D). 
In order to visualize the fluorescence signal in individual neurons more clearly, 
we transiently transfected cultures of non-transgenic CGNs with EGFP expression 
constructs.  Because of the low efficiency of transfection (~1%), isolated, fluorescent 
neurons could then be observed against a background of non-fluorescent neurons.  For 
these experiments, we employed plasmids encoding C-terminal PrP-EGFP fusions 
analogous to those used to construct the Tg(WT-EGFP) and Tg(PG14-EGFP) mice (data 
not shown), as well as N-terminal fusions in which EGFP was fused at codon 33, ten 
amino acids beyond the signal peptide cleavage site (Figure 7E, F).  N- and C-terminal 
fusion proteins displayed similar distributions, arguing that the location of the EGFP 
moiety has no effect on protein localization.  We observed that EGFP-WT uniformly 
filled the entire neuritic tree out to the smallest, terminal branches, and also formed a rim 
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around the cell soma (Figure 7E).  In contrast, EGFP-PG14 was distributed in numerous, 
fluorescent puncta along the length of individual neurites, and was also visible in the cell 
soma in the form of cytoplasmic aggregates that were located at a distance from the 
surface membrane (Figure 7F). 
To determine whether the fluorescent proteins were localized on the plasma 
membrane, we stained cultures with FM 4-64, a red fluorescent dye that selectively 
integrates into the lipid bilayer at the cell surface (Betz et al., 1992).  We found that while 
WT-EGFP almost completely co-localized with FM 4-64 (Figure 7G-I), aggregates of 
PG14-EGFP showed little co-localization (Figure 7J-L). 
Taken together, our studies of cultured CGNs demonstrate that neuronal PG14-
EGFP aggregates are primarily intracellular (not on the cell surface), and are 
concentrated in neuritic processes.  Since the culture conditions we used do not induce 
axo-dendritic polarization of CGNs (Powell et al., 1997), it is not possible to specify 
whether the neuritic PG14-EGFP aggregates we observe are in axons or dendrites. 
 
2.5  Discussion 
In this study, we have characterized Tg(PG14-EGFP) mice that express the 
EGFP-tagged version of a mutant PrP molecule carrying a nine-octapeptide insertion.  
This PG14 mutant is associated with an inherited dementia in humans (Duchen et al., 
1993; Krasemann et al., 1995; Owen et al., 1992), and we have reported previously that it 
causes a strong neurodegenerative phenotype when expressed as a non-EGFP-tagged 
molecule in Tg(PG14) transgenic mice (Chiesa et al., 2000; Chiesa et al., 2005; Chiesa et 
al., 1998).  We show here that Tg(PG14-EGFP) mice recapitulate key clinical,  
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FIGURE 7.  PG14-EGFP forms aggregates along neurites of cultured neurons and is decreased 
at the cell surface. (A-D) Comparison of the distribution of WT-EGFP and PG14-EGFP.  Cerebellar 
granule neurons were cultured from neonatal Tg(WT-EGFP) mice (A, B) or Tg(PG14-EGFP) mice (C, 
D).  After 4 days in culture, cells were viewed by fluorescence (A, C), or by fluorescence 
superimposed on phase contrast (B, D).  The arrow in A points to a neuronal cell body, which is 
rimmed by fluorescence.  (E, F) Distribution of N-terminal EGFP fusion proteins in individual neurons.  
Cerebellar granule neurons cultured from non-Tg mice were transfected with plasmids encoding 
EGFP-WT (E) or EGFP-PG14 (F), and were viewed 24 hrs later by fluorescence microscopy.  The 
arrow in E points to a neuronal cell body, which is rimmed by fluorescence.  The arrow in F points to 
the position of the surface membrane of the soma (visible in phase contrast; not shown), which is 
devoid of fluorescence.  The arrowhead in F indicates intracellular accumulations of EGFP-PG14.  (G-
L) Localization of EGFP fusion proteins with respect to the plasma membrane.  Cerebellar granule 
neurons cultured from Tg(WT-EGFP) mice (G-I) or Tg(PG14-EGFP) mice (J-L) were stained with FM 
4-64 dye at 4°C, and then imaged to reveal EGFP fluorescence (G, J), FM 4-64 staining (H, K), or a 
merge of the two signals (I, L).  WT-EGFP co-localizes extensively with FM 4-64, while PG14-EGFP 
shows little overlap.  All scale bars represent 20 μm.
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neuropathological and biochemical features of our original Tg(PG14) mice.  However, 
the presence of the EGFP moiety has allowed us to visualize the anatomical and 
subcellular localization of the mutant protein without the need for antigen retrieval 
techniques typically required for immunohistochemical detection of aggregated, 
misfolded forms of PrP.  Using Tg(PG14-EGFP) mice, we describe for the first time 
intracellular aggregates of mutant PrP in central and peripheral axons.  Our results 
provide an entirely new picture of the localization of mutant PrP molecules in a familial 
prion disease, and they suggest a novel mechanism by which these proteins might induce 
neuropathology via interference with axonal transport. 
 
Tg(PG14-EGFP) mice model a familial prion disease.  Like Tg(PG14) mice, 
Tg(PG14-EGFP) animals spontaneously develop a progressive neurological disease 
characterized clinically by ataxia, kyphosis, and seizure.  In addition, both kinds of mice 
exhibit astrogliosis and PrP deposition. Finally, PG14-EGFP displays abnormal 
biochemical properties like PG14 PrP.  In contrast, Tg(WT-EGFP) mice do not develop 
neurological illness or neuropathology, and they do not accumulate biochemically 
abnormal PrP.  Taken together, these results argue that the C-terminal addition of EGFP 
does not significantly alter the molecular properties or pathogenic effects of PG14 PrP.  
Thus, Tg(PG14-EGFP) mice, like the original Tg(PG14) animals, model key features of 
the corresponding human prion disease.  
Tg(PG14-EGFP+/+) mice (X4 line) develop disease at ~390 days of age, much 
later than Tg(PG14+/+) or Tg(PG14+/-) mice (65 or 240 days, respectively, for the A2 and 
A3 lines) (Chiesa et al., 1998).  This difference is most likely attributable to the 
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significantly lower transgene expression level in the Tg(PG14-EGFP) X4 line compared 
to the Tg(PG14) lines (0.3X vs. 2X endogenous PrP levels when the transgene arrays are 
homozygous).  We have previously observed a strong inverse correlation between protein 
expression level and age at disease onset in Tg(PG14) mice (Chiesa et al., 1998).  Thus 
far, we have not recovered lines of Tg(PG14-EGFP) mice with higher transgene 
expression levels, but it is uncertain whether this reflects a particular toxicity of the 
PG14-EGFP molecule or other factors. 
The relatively low transgene expression level in Tg(PG14-EGFP) mice is also 
likely to explain why these animals did not exhibit granule cell degeneration in the 
cerebellum, in contrast to Tg(PG14) mice which show dramatic granule cell apoptosis 
(Chiesa et al., 2000; Chiesa et al., 1998).  In a previous study, we found that deletion of 
the Bax gene rescued granule cell death without altering clinical symptoms or synaptic 
degeneration in Tg(PG14) mice (Chiesa et al., 2005).  We thus concluded that synaptic 
loss makes an important contribution to the Tg(PG14) phenotype that can account for the 
persistence of neurological symptoms in the absence of granule cell death.  We 
hypothesize that in Tg(PG14-PrP) mice, which display a much more indolent clinical 
course compared to Tg(PG14) mice, the low expression level of the mutant protein 
produces synaptic degeneration before granule cell loss can ensue. 
 
PG14-EGFP forms aggregates in axons.  A major conclusion of our study is 
that PG14-EGFP forms prominent intra-axonal aggregates.  These aggregates were 
visible in axon-rich areas of the brain such as the molecular layer of the cerebellum, 
striatum, corpus callosum, and mossy fibers of the hippocampus.  They were also 
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prominent in peripheral axons, in particular those of the sciatic nerve.  In cultured 
cerebellar granule neurons, PG14-EGFP aggregates were evident within neurites, where 
they did not colocalize with a marker for the plasma membrane, demonstrating that the 
deposits are intracellular.  The fluorescent aggregates visible microscopically presumably 
correspond to those that are defined biochemically by detergent insolubility, protease and 
PIPLC resistance, and 15B3 reactivity.  In brain sections from Tg(PG14-EGFP) mice, we 
observed, in addition to aggregates, a more uniform, but weaker fluorescence pattern 
similar to the one seen in Tg(WT-EGFP) mice.  This fluorescence signal presumably 
corresponds to the proportion (50-75%) of PG14-EGFP that is soluble (see Figure 3B).  
We have referred to the soluble form of PG14 PrP as PG14Sol, and have shown that it 
possesses all of the biochemical properties of PrPC (Biasini et al., manuscript submitted). 
It is likely that PG14-EGFP aggregates contribute to the disease phenotype, 
although the precise relationship requires further investigation.  We observed that the 
number of PG14-EGFP aggregates is positively correlated with transgene expression 
level: Tg(PG14-EGFP+/+) mice, most of which become ill, displayed more aggregates 
than Tg(PG14-EGFP+/-) mice, most of which remain healthy.  However, aggregation of 
PG14 PrP occurs long before the onset of neuropathology or clinical disease, as indicated 
by the existence of fluorescent aggregates in neonatal neurons (Figure 7) and by the 
presence of detergent-insoluble protein in neonatal brain tissue (Chiesa et al., 1998).  
These observations suggest that the pathological consequences of PrP aggregation may 
take an extended time to evolve.  Alternatively, aggregates may increase in size or 
number over time until a critical threshold level is reached for induction of disease.  
When we compared young and old animals, we did not observe dramatic differences in 
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the number, size, or distribution of aggregates (data not shown), although careful 
quantitation will be required to test the possibility that subtle alterations may occur 
slowly with aging. 
Because PrP is a GPI-linked membrane protein, the intra-axonal deposits of PrP-
EGFP we observe presumably reside in the lumen of intracellular transport vesicles.  
These deposits may represent aggregates of the mutant protein within individual vesicles, 
or possibly collections of multiple vesicles.  The axonal localization of PG14-EGFP 
aggregates is consistent with evidence from immunolocalization studies demonstrating 
that endogenous PrP is present on axons and pre-synaptic nerve terminals (Moya et al., 
2000; Salès et al., 1998), and that it is subject to both anterograde and retrograde fast 
axonal transport (Borchelt et al., 1994; Moya et al., 2004; Rodolfo et al., 1999). 
 
New insights into mutant PrP localization and trafficking.  The picture of 
PG14 PrP localization in brain provided here using the intrinsic fluorescence of an EGFP 
fusion protein differs markedly from the one suggested by previous studies of Tg(PG14) 
mice, all of which relied upon immunostaining following application of antigen retrieval 
techniques.  These earlier studies revealed punctate deposits of the mutant protein in 
numerous brain regions, including the cerebellum, hippocampus and neocortex.  The 
deposits, which were present primarily in neuropil regions and were largely absent from 
white matter, were characterized as “synaptic-like”, since they had a distribution 
reminiscent of synaptic terminals (Chiesa et al., 2000; Chiesa et al., 1998).  Recent 
electron microscopic studies indicate that these deposits are primarily extracellular (M. 
Jeffrey, A.Z. Medrano, S. Barmada, and D.A. Harris, unpublished data).   
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Although intracellular deposits of misfolded forms of PrP, including PrPSc, have 
been described in a few conventional immunohistochemical studies of brain (Kovacs et 
al., 2005; Laszlo et al., 1992), such deposits may be particularly susceptible to loss or 
redistribution induced by antigen retrieval methods, explaining why most studies have 
emphasized extracellular aggregates.  Thus, we believe that PrP-EGFP fusion proteins 
provide a more accurate representation of the distribution of PrP aggregates, particularly 
those localized to intracellular compartments, than conventional immunocytochemistry.  
Recently, we have identified prominent intraneuronal deposits of PrPSc in scrapie-
infected Tg(WT-EGFP) mice (Barmada and Harris, 2005).  Some of these deposits were 
localized to the Golgi apparatus in neuronal cell bodies, and some were also present 
along axons.  Thus, intra-axonal aggregation may be common to both PrPSc and mutant 
forms of PrP. 
The findings reported here also significantly extend our previous studies of mutant 
PrP molecules in non-neuronal cell lines, which indicated altered localization and 
trafficking of these proteins.  Consistent with the results presented here for neurons, 
immunostaining of transfected BHK and CHO cells revealed markedly reduced levels of 
PG14 and other mutant PrPs at the plasma membrane (Ivanova et al., 2001).  This 
phenomenon is correlated with delayed maturation of mutant PrP molecules in 
biosynthetic labeling experiments (Drisaldi et al., 2003), and with evidence that mutant 
PrPs begin to aggregate very soon after synthesis in the ER (Daude et al., 1997).  In 
contrast to our observations in neurons, however, the only abnormal intracellular 
accumulations of mutant PrP identified by immunostaining of CHO and BHK cells were 
localized to the ER (Ivanova et al., 2001).  We think it likely that, since the 
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immunostaining experiments using transfected cells did not employ antigen retrieval 
techniques, they detected primarily soluble forms of mutant PrP in transit through the 
secretory pathway, and missed more highly aggregated deposits such as those visualized 
here using EGFP fusion proteins.  The same limitation may apply to a previous 
immunolocalization study of PG14 PrP in cultured neurons (Fioriti et al., 2005). 
 Taken together, the available data suggest that, although PG14 PrP molecules 
may transit the secretory pathway more slowly than WT PrP, in neurons they are 
eventually delivered to axonal transport vesicles which are thought to bud from the trans-
Golgi (Calakos and Scheller, 1996).  Since PG14-EGFP aggregates can be observed 
arrayed along the length of axons in vivo and in culture, axonal transport of the mutant 
protein is not completely blocked.  However, there is clearly a defect in delivery of PG14 
PrP molecules to the surface membrane of axons and nerve terminals, perhaps due to 
retarded axonal transport or to failure of transport vesicles to fuse with axonal or synaptic 
target membranes. 
 
A novel pathogenic mechanism.  The results reported here suggest the novel 
hypothesis that PG14 and other aggregation-prone PrP molecules induce pathology by 
blocking or altering normal axonal transport processes.  For example, vesicles laden with 
PG14 aggregates may fail to reach nerve terminals, or they may cause “traffic jams” of 
other axonally transported organelles, thereby preventing delivery of essential cargo 
molecules to synapses.  As a consequence of these abnormalities, structural or functional 
abnormalities in axons or synapses may ensue.  Our study of Bax-deficient Tg(PG14) 
mice, highlighting the importance of synaptic loss in the neurodegenerative process 
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(Chiesa et al., 2005), is consistent with this model, as are reports demonstrating a role for 
PrP in axon outgrowth and synaptic function (Herms et al., 1999; Kanaani et al., 2005; 
Moya et al., 2005; Salès et al., 2002).  Interestingly, deficiencies in axonal transport have 
been associated with several other neurodegenerative diseases caused by protein 
aggregation, including Huntington’s and Alzheimer’s diseases (Goldstein, 2003; 
Gunawardena et al., 2003; Roy et al., 2005; Stokin et al., 2005).  The availability of 
Tg(PG14-EGFP) mice will now make it possible to perform real-time, fluorescence 
imaging of the axonal transport of mutant PrP to determine whether abnormalities in 
cellular trafficking contribute to the disease phenotype. 
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Supplemental Figure 1. PG14 PrP in brain sections stains weakly using conventional 
immunohistochemistry.  Vibratome sections from the brains of Tg(WT) mice (A, D, G), Tg(PG14) 
mice (B, E, H), or Prn-p0/0 mice (C, F, I) were immunostained using the following anti-PrP antibodies: 
P45-66 (which recognizes residues 45-66; (Lehmann and Harris, 1995)) (A-C); 3F4 (which recognizes 
residues 105-111; (Lund et al., 2007)) (D-F); or 8H4 (which recognizes residues 147-200; (Zanusso et 
al., 1998)) (G-I).  The transgenically encoded PrP expressed by both Tg(WT) and Tg(PG14) mice 
carries an epitope tag for the 3F4 antibody (Chiesa et al., 1998).  Sections were derived from the 
dentate gyrus (A-C), or the cerebellar cortex (D-I).  Tg(WT) sections stain strongly with all three 
antibodies.  Tg(PG14) sections stain weakly, but above background levels seen in Prn-p0/0 mice.  
Abbreviations are: MF, mossy fibers; DGL, dentate granule cell layer; ML, molecular layer; PC, 
Purkinje cell layer; CGL, cerebellar granule cell layer.  The scale bar in A (applicable to all panels) is 
20 μm.
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Supplemental Figure 2.  Characterization of PG14-EGFP distribution in four lines of Tg(PG14-
EGFP) mice.  Vibratome sections were cut from the brains of Tg(WT-PrP) mice (A, D, H, L), as well 
as the following lines of Tg(PG14-EGFP) mice: line D (B); line X4 (C, E, I, M); line X1 (F, J, N); line 
X3 (G, K, O).  The panels show the whole hippocampus (A-C), the dentate gyrus (D-G), the CA1 sub-
field of the hippocampus (H-K), and the cerebellar cortex (L-O).  Due to low transgene expression, it 
was necessary to stain sections from the X1 and X3 lines with anti-GFP antibody in order to detect 
PG14-EGFP.  The abbreviations are: LAC, stratum lacunosum moleculare; AL, alveus; MF, mossy 
fibers; DGL, dentate granule cell layer; OR, stratum oriens; PYR, pyramidal cells; RA; stratum 
radiatum; PC, Purkinje cell layer; CGL, cerebellar granule cell layer; ML, molecular layer.  The scale 
bar in A (applicable to A-C) is 200 μm and in D (applicable to D-O) is 20 μm.
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CHAPTER 3 
 
 
 
The role of the GPI anchor in the cellular behavior of a 
disease-associated familial prion protein mutant  
 
 
A Medrano & DA Harris.   
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3.1  Summary 
Prion protein (PrP) is a GPI-anchored sialoglycoprotein involved in the 
pathogenesis of infectious and inherited forms of transmissible spongiform 
encephalopathies (TSEs).  Wild-type PrP molecules lacking the GPI anchor (WT∆GPI) 
display aberrant glycosylation and are secreted into the extracellular space.  When 
inoculated with scrapie, transgenic mice expressing WT∆GPI display dense intracerebral 
plaques that are larger and denser than those found in their wild-type counterparts, 
suggesting that GPI anchor deletion promotes aggregation in infectious prion disorders.  
Thus far, the role of the GPI anchor has not been determined for disease-associated 
familial mutants of PrP.  PG14 is a disease-associated PrP mutant which contains a 217 
base pair insertion resulting in a repeat expansion of endogenous octapeptide motifs.  
PG14 becomes glycosylated, forms spontaneous aggregates, and is partially retained 
within the ER and Golgi in cells.  To determine whether the GPI anchor affects cellular 
behavior of the protein, we generated a PG14ΔGPI construct and investigated its 
glycosylation, localization, and spontaneous aggregation in transfected mammalian cells.  
We demonstrate that deletion of the GPI anchor impairs PG14 glycosylation, but has no 
effect the mutant’s ability to aggregate, as assayed by detergent insolubility and sucrose 
gradient assays in cells.  Furthermore, PG14∆GPI shows similar intracellular retention 
and localization compared with full-length PG14.  These studies show that the GPI 
anchor is crucial for proper glycosylation of PG14, but does not affect aggregation or 
localization of a genetic PrP mutant.  Whether the GPI anchor affects clinical progression 
of familial prion disease remains to be determined.  Our analysis provides foundational 
 98
information for the continued study of the role of the GPI anchor in familial prion disease 
pathogenesis. 
 
 3.2  Introduction 
 Prion diseases, such as bovine spongiform encephalopathy in cattle, Creutzfeldt-
Jakob Disease, Fatal Familial Insomnia, and Gerstman-Straussler-Shenker syndrome in 
humans, are fatal neurodegenerative disorders that result in progressive dementia and 
motor dysfunction.  These diseases can be acquired sporadically, through genetic 
mutation of the cellular prion protein (PrPC), or by exposure to infectious scrapie 
molecules (PrPSc).  The hallmarks of neuropathology include vacuolation and aggregation 
of the prion protein, presumably caused by the misfolding of the alpha-helical PrPPC into 
the more β-sheet rich PrPSc  form (Prusiner et al. 1998).  PrPC, which is highly expressed 
in the central nervous system, is a cell surface sialoglycoprotein implicated in cell signal 
transduction (Westergard et al. 2007).   
PrPC is firmly attached to the plasma membrane via a glycophosphatidylinositol 
(GPI) anchor, a complex glycolipid structure linking the C-terminal end of the protein 
with the outer leaflet of the lipid bilayer.  This anchor is responsible for tethering PrPC to 
the membrane and localizing the protein to detergent-resistant membrane (DRM) 
microdomains (Taylor and Hooper 2006).  GPI anchor loss caused by genetic deletion, 
chemical cleavage, or substitution with a foreign transmembrane domain, results in PrPPC 
detachment from the cell surface (Rogers et al. 1993; Kaneko et al. 1997; Campana et al. 
2007).  The GPI anchor also affects PrP glycosylation, as expression of anchorless forms 
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of PrP result in mainly unglycosylated protein products (Walmsley et al. 2001; Walmsley 
et al. 2003)  
The exact location and mechanisms underlying the transition of PrPC to PrPSc in 
infectious disease are ambiguous, but previous studies suggest that membrane attachment 
by GPI anchor plays a role in conversion and in disease.  In cell-free experiments, the 
GPI anchor has a protective effect over PrPC, embedding the protein in sphingolipid-
cholesterol-rich raft-like liposomes (SCRLs) which prevent conversion to PrPSc (Baron 
and Caughey 2003).  Conversely, investigations in cells demonstrate that proper 
localization at the cell surface is crucial for efficient PrPSc conversion (Caughey and 
Raymond 1991; Borchelt et al. 1992), and that loss of the GPI anchor impairs PrPSc 
formation and accumulation (Rogers et al. 1993; Kaneko et al. 1997).  In transgenic mice 
that express a GPI anchorless form of PrP (PrPΔGPI), inoculation with scrapie results in 
the formation of PrPSc plaques that are larger and more dense than those of their wild-
type counterparts.  Interestingly, inoculated Tg(PrP∆GPI) animals remained healthy up to 
500 days past their wild-type controls, which succumbed to sickness within 5 months.  
PrPSc in Tg(PrP∆GPI) animals is less infectious when tested in sequential passaging, 
despite its robust accumulation in brain (Chesebro et al. 2005; Trifilo et al. 2008), 
demonstrating that GPI anchor loss also affects PrPSc transmissibility.   
Collectively, these data demonstrate that modifications in the GPI anchor affect 
glycosylation and localization of prion protein molecules, and have the ability to 
influence aggregation and infectivity in prion disease.  Thus far, the relevance of GPI 
anchor-mediated membrane attachment for non-infectious mutant PrPs in glycosylation, 
localization, and aggregation has not been elucidated.  In this work, we attempt to better 
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understand the role of the GPI anchor in the cellular behavior of mutant prion protein 
PG14 in cells.   
PG14 is an insertion of 217 bp within the prion protein, and is associated with a 
variant of Creutzfeldt-Jakob disease in humans (Lehmann and Harris 1996; Lehmann and 
Harris 1996; Chiesa et al. 1998; Biasini et al. 2008).  The mutation results in the 
expansion of five endogenous octapeptide repeat (OR) motifs, rich in proline and glycine, 
from five to fourteen.  It is thought that the mutation alters the conformation of PrP such 
that it is more prone to misfolding and subsequent adoption of a more PrPSc-like pattern.  
PrP molecules containing the PG14 mutation are partially PK-resistant and detergent 
insoluble in cell lines and in transgenic mice (Lehmann and Harris 1996).  Although 
biochemically similar to PrPSc  in this regard, PG14 differs from scrapie in that it is non-
infectious and forms aggregates spontaneously inside cells (Bolton et al. 1991).  
Aggregates are retained intracellularly, with only a small fraction of molecules reaching 
the surface in cells and neurons (Lehmann and Harris 1995; Lehmann and Harris 1996; 
Lehmann and Harris 1996; Lehmann et al. 1997).  Aggregated PG14 also accumulates 
over time and in transgenic mice to form small intracerebellar plaques displaying a 
synaptic-like distribution (Rogers et al. 1993; Walmsley et al. 2001; Walmsley et al. 
2003; McNally et al. 2009).  Although the localization and biochemical properties of PrP 
are altered in both infectious and familial forms of TSEs, it is unknown whether the 
mechanisms of aggregation or disease are similar. 
To investigate the role of GPI anchor attachment in the cellular behavior of a 
disease-associated mutant PrP model, we constructed a PG14∆GPI molecule and 
observed protein processing and trafficking in transfected CHO cells.  PNGase and Endo 
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H assays demonstrate that PG14∆GPI is predominantly unglycosylated.  Analyses of cell 
and media fractions, as well as immunocytochemical studies, show that PG14∆GPI is 
largely retained intracellularly.  PG14∆GPI is partially detergent insoluble and 
colocalizes with the dense fractions of sucrose gradients, demonstrating that the GPI 
anchor does not affect intracellular aggregation.  Collectively, these data show that 
deletion of the GPI anchor affects PG14 protein glycosylation, but does not interfere with 
its intracellular localization or aggregation formation.  These studies provide the 
foundation for future studies investigating the role of the GPI anchor in familial prion 
disease transmission.    
 
3.3  Methods 
PrP Constructs.  Figure 1 shows the structure of all murine PrP constructs used in 
this study.  All constructs were cloned into the pCDNA3.1(+) Hygromycin plasmid 
vector (Invitrogen), which drives high levels of protein expression through a CMV 
promoter.  WT and PG14 sequences were excised from pCDNA3 vector (Ivanova et al. 
2001), and inserted directly into pCDNA3.1(+)Hygromycin using restriction sites BamHI 
and HindIII, which flank the PrP sequences.  WT∆GPI was constructed by amplifying 
DNA sequences encoding WT PrP codons 1-230, using primers encoding BamHI and 
HindIII at the 5’  and 3’ ends, respectively.  PG14∆GPI was generated by a XmaI/KpnI 
excision of the octarepeat region from the PG14 template, with subsequent insertion into 
the same restriction sites within the WT∆GPI plasmid.  Both anchorless constructs were 
made within the pCDNA3.1(+) Hygromycin plasmid. 
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Cell Lines and Reagents.  For biochemical and immunofluorescence experiments, 
PrP constructs were transiently transfected into Chinese Hamster Ovary (CHO) or 
African green monkey kidney (COS7) cells using Lipofectamine 2000 (Invitrogen).  
CHO cells were maintained in MEM-Alpha media containing 10% fetal bovine serum 
and antibiotics; COS7 cells in DMEM media containing 10% fetal bovine serum a 
antibiotics.  Protein concentrations from each  transfection was measured using a BCA 
Assay (Pierce, Rockford, IL).  PrP was detected using antibodies 3F4 (Stewart et al. 
2001) or 6H4 (Prionics, Zurich, Switzerland). 
Deglycosylation of PrP.  Cell lysates were first denatured, then treated with 
PNGase F and Endo Hf (New England Biolabs, Ipswich, MA) according to the 
manufacturer’s directions.  Reactions were terminated by addition of 2X SDS sample 
buffer, then analyzed by SDS-PAGE and Western blot. 
Detergent Insolubility assay.  200µg total protein from cell lysates were diluted in 
detergent buffer (DB: 0.5% sodium deoxycholate, 0.5% NP-40, 150mM NaCl, 10mM 
Tris-HCl, pH 7.4) with complete Mini EDTA-free protease inhibitors (Roche) to obtain a 
final protein concentration of 0.4 µg/µL.  Samples were rotated at 4C for 20 minutes, 
then centrifuged at 1500 x g for 10 min.  Supernatants were recovered and centrifuged for 
1 hr at 89,000 x g at 4C to separate soluble and insoluble fractions.  Supernatants (S) 
from this centrifugation were methanol precipitated, then analyzed along with the pellet 
(P) fractions by SDS-PAGE and Western Blot. 
Sucrose Gradient Sedimentation.  Lysates of transiently transfected CHO cells 
were cleared by centrifugation at 16,000 rcf for 2 min.  150ug protein was then loaded on 
a 5 mL step gradient of 10-60% sucrose in DB buffer supplemented with protease 
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inhibitors.  After centrifugation at 163,000 x g for 1 hr at 4C, 400μL fractions were 
methanol-precipitated then analyzed by Western Blot.   
Florescence Microscopy.  COS7 were seeded on flame-sterilized glass coverslips 
and transfected.  For surface staining, cells were washed with PBS, incubated with 
monoclonal antibody 3F4 diluted in 5% goat serum in Opti-MEM (Invitrogen) for 1 hr at 
4C, rinsed with PBS, then fixed in 4% paraformaldehyde solution for 10 min.  Cells were 
again rinsed with PBS, blocked with 5% goat serum in PBS for 15 min, then incubated 
with 1:500 Alexa 488-conjugated goat anti-mouse IgG (Molecular Probes, Inc.) and 
DAPI in block solution.  Coverslips were washed with PBS and mounted onto Superfrost 
glass microscope slides (Fisher Scientific) using Gel/Mount (Biomeda, Foster City, CA).   
 For intracellular colocalization studies, cells were grown on coverslips, washed 
with PBS, then fixed with 4% paraformaldehyde for 10 min.  Cells were exposed to 0.1% 
TX-100 in PBS for 10 min for permeabilization, washed with PBS, blocked in 5% goat 
serum in PBS, then incubated with primary and secondary antibodies as described above, 
with the exception of the endosomes colocalization experiments, where polyclonal PrP 
antibody P45-66 (Rogers et al. 1993; Walmsley et al. 2001; Chesebro et al. 2005) was 
used in place of 3F4.  Additional antibodies directed against calreticulin (polyclonal, 
Affinity Bioreagents), giantin (polyclonal, Covance, Berkeley, CA), or EEA1 
(monoclonal, BD Biosciences) were used to detect the ER, Golgi, and endosomes, 
respectively.  Alexa 594-conjugated anti-rat or anti-rabbit IgG (Molecular Probes, Inc) 
was used to detect these primary antibodies.   
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3.4  Results 
PG14ΔGPI is mostly unglycosylated when expressed in cells.  To investigate 
the effects of GPI deletion on a familial prion mutant, we constructed anchorless forms of 
WT PrP and PG14 PrP by abolishing amino acids 231-254, which encode the signal for 
GPI anchor attachment (Figure 1A).  These constructs, along with their full-length 
counterparts, were transfected into Chinese Hamster Ovary (CHO) cells, which lack 
detectable levels of endogenous PrP and which have previously been used to 
biochemically characterize several inherited disease-associated PrP mutants, including 
PG14 (Campana et al. 2007).   
In cells, full-length WT and PG14 molecules display typical patterns of 
unglycosylated and glycosylated forms of PrP, whereas only one predominant band is 
evident for both WT∆GPI and PG14∆GPI cell lysates (Figure 1B).  WT∆GPI has been 
shown previously to be expressed mainly in its unglycosylated form in cells and in mice 
(Rogers et al. 1993; Chesebro et al. 2005; McNally et al. 2009).  However, because full-
length PG14 is known to be partially retained within the ER (Walmsley et al. 2001), it 
was possible that the predominant band from PG14∆GPI represented an incompletely 
glycosylated form of molecule, containing the only high-mannose type sugars normally 
attached in the ER.  Indeed, another familial PrP mutant, T182A, is expressed primarily 
as a single glycoform that is Endo H-, but not neuraminidase-, sensitive (Lehmann and 
Harris 1995; Drisaldi et al. 2003).  To rule out the possibility of incomplete 
glycosylation, we treated PrP-expressing cells with Endo H, an enzyme which cleaves 
only high-mannose type glycans (Figure 2).  Full-length WT and PG14 molecules that 
have successfully processed through the Golgi are Endo H-resistant (see asterisks in  
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Figure 1.  Structure and expression of WTΔGPI and PG14ΔGPI in CHO cells.  (A)  Schematic of 
structures of full-length WT PrP, full-length PG14, and anchorless constructs WTΔGPI and 
PG14ΔGPI.  WT PrP protein contains an N-terminal signal sequence (SS), five octapeptide repeats (5X 
OR).   PG14 contains an insertion encoding nine additional octapeptide repeats (14X OR), resulting in a 
totoal of 14 repeats.  Anchorless versions of both WT and PG14 lack the C-terminal signal sequence for 
the GPI anchor (black box), and are truncated at amino acid 230. (B)  Expression of PrP constructs in 
CHO cells.  Cell lysates from transiently transfected CHO cells were analyzed by Western blot using 
anti-PrP antibody 3F4.  Asterisks indicate unglycosylated PrP forms. Molecular size markers are given 
in kilodaltons.  
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Figure 2A, lanes 3,4 and 5,6).  As a positive control, we used lysates of cells expressing 
L9R PrP, a PrP mutant known to be immaturely glycosylated due to complete ER 
retention (Medrano et al. 2008).  There was no evident shift in the PG14∆GPI band after 
deglycosylation treatment, indicating that the band did not represent immaturely 
glycosylated mutant PrPs.   
When treated with PNGase, an enzyme which completely removes both high 
mannose and complex N-linked oligosaccharides from parent glycoproteins, all full-
length WT and PG14 glycoforms were reduced to the non-glycosylated state (Figure 2B, 
lanes 3-6).  However, the single bands evident from WT∆GPI or PG14∆GPI cell lysates 
were not reduced after deglycosylation digestion, indicating that the anchorless forms of 
both are predominantly unglycosylated and do not represent altered glycoforms (Figure 
2B, lanes 7-10).   
Monoglycosylated forms of both WTΔGPI and PG14ΔGPI proteins was observed 
in overexposed blots (data not shown), but these fractions comprise >10% of the 
molecule populations.  These results support previous evidence that the GPI anchor is 
crucial for proper N-linked glycosylation in both cells and animals (Ivanova et al. 2001).   
 
PG14ΔGPI is retained intracellularly and is localized similarly to full-length 
PG14.  The GPI anchor is crucial for proper WT PrP localization at the plasma 
membrane.  PrP molecules lacking the signal sequence for the anchor are only loosely 
associated with lipid rafts during the processing pathway (Ivanova et al. 2001; Medrano 
et al. 2008), and are secreted into extracellular space upon reaching the surface  
(Campana et al. 2007).  Full-length PG14 is retained intracellularly, with little to no  
 107
A.
B.
- + - + - + - + - + - +
V WT PG14
WT
ΔGPI
PG14
ΔGPI L9R
35
28
1 2 3 4 5 6 7 8 9 10 11 12
PNGase
V WT PG14
WT
ΔGPI
PG14
ΔGPI L9R
Endo H- + - + - + - + - + - +
35
28
1 2 3 4 5 6 7 8 9 10 11 12
*
*
Figure 2.  PG14ΔGPI is mainly unglycosylated.  (A) Endo H deglycosylation.  Cell lysates from cells 
expressing vector (lanes 1,2), WT PrP (lanes 3,4), PG14 (lanes 5,6), WTΔGPI (lanes 7,8), PG14ΔGPI 
(lanes 9,10), and L9R (lanes 11,12) were treated with deglycosylation enzyme Endo H, and then 
analyzed by Western blotting with 3F4 antibody.  Immature glycoforms of WT, PG14, and L9R bands 
shifted, but ΔGPI molecules remained the same size.  (B)  PNGase F deglycosylation.  Similar to (A), 
but cell lysates were treated with PNGase F and analyzed in the same manner.  WT, PG14, & L9R 
glycoforms shift, but ΔGPI bands do not.  Molecular size markers are given in kilodaltons.  
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protein reaching the cell surface (Lehmann and Harris 1997).  In order to investigate 
cellular retention vs. secretion of PrPs lacking a GPI anchor, we collected cell and media 
fractions of transiently transfected CHO cells and compared expression levels of full-
length and anchorless proteins by western blot (Figure 3).  Our results confirm previous 
studies that show that large amounts of WT∆GPI molecules are secreted into the media 
(Yin et al. 2006), while full-length WT and PG14 remain associated  with cells, either on 
the surface or intracellularly.  PG14∆GPI, unlike WT∆GPI, is not secreted in appreciable 
amounts, and the majority of protein remains in or on cells.  However, the amount of 
PG14∆GPI that is secreted is noticeably more than full-length PG14, indicating that the 
small fraction of PG14∆GPI protein that does reach the surface is shed more easily than 
membrane-bound PG14.   
To determine PG14ΔGPI localization in cells, we conducted several co-
localization experiments using immunofluorescent cytochemistry.  The first was to 
determine whether PG14ΔGPI was present at the cell surface.  CHO cells were 
transiently transfected with WT, PG14, WTΔGPI, and PG14ΔGPI.  All cells were co-
transfected with a dsRed marker to serve as positive identification of transfected cells.  
After 24 hours, cells were incubated with α-PrP antibody 6H4, fixed, incubated with a 
green fluorescent secondary antibody, then analyzed by fluorescence microscopy (Figure 
4).  Surface staining in these non-permeabilized cells show that WT was present in 
appreciable amounts at the plasma membrane, but not PG14, WT∆GPI, nor PG14∆GPI.  
Along with Figure 3, these data demonstrate that ΔGPI proteins are loosely associated 
with the membrane, if at all, and are secreted into the media upon exposure to the 
extracellular space.   
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Figure 3.  PG14ΔGPI is mainly intracellular. Equal amounts of protein from cell lysates (1-5) and 
equal volumes of media (lanes 6-10) from cells expressing vector (lanes 1,6), WT PrP (lanes 2,7), 
PG14 (lanes 3,8), WTΔGPI (lanes 4,9), and PG14ΔGPI (lanes 5,10) were treated with PNGase F, 
then analyzed by Western blotting with 3F4 antibody.  Large amounts of WTΔGPI are secreted into 
the media, whereas PG14ΔGPI remains mostly intracellular.  Molecular size markers are given in 
kilodaltons.  
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Figure 4.  PG14ΔGPI is not detectable at the cell surface. CHO cells were co-transfected with   PrP 
construct and dsRed-ER to detect transfected cells.  Cells expressing vector (insert), WT (a,b), PG14 
(c,d), WT∆GPI (e,f), and PG14ΔGPI (g,h) were stained with PrP primary antibody 6H4, fixed, then 
incubated with fluorescent green Alexa 488 secondary antibody and DAPI.  Analysis by fluorescence 
microscopy allows observation of PrP (a, d, g, j) and dsRed marker with DAPI (b, d, f, h), revealing 
that only WT PrP is detectable at the cell surface.  
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The majority of PG14ΔGPI is associated with cells, but is not present at the cell 
surface.  To determine where PG14ΔGPI was retained intracellularly, we performed 
colocalization studies in transfected cells.  Cells transfected with full-length or anchorless 
PrP constructs were probed with α-PrP antibody 6H4 and α-calreticulin, a marker for 
endoplasmic reticulum (Figure 5).  The large stores of intracellular WT and WTΔGPI do 
not colocalize with ER.  However, both PG14 and PG14ΔGPI partially colocalize with 
calreticulin, indicating that these proteins are partially retained within the ER.  There are 
pools of PG14 and PG14ΔGPI that do not correlate with ER, suggesting that the proteins 
are located elsewhere as well.  
To determine whether PG14ΔGPI transits through the Golgi, we performed a 
similar colocalization experiment using an antibody directed against giantin (Figure 6).  
Staining in permeabilized cells demonstrates some full-length WT PrP in the Golgi, 
which likely corresponds to a pool of WT PrP molecules traveling within the secretory 
pathway.  PG14 and PG14ΔGPI molecules also partially colocalize with Golgi, indicating 
that these proteins are able to escape the ER.     
 
PG14∆GPI forms aggregates.  To ascertain whether PG14∆GPI molecules 
aggregate in cells, we performed a detergent insolubility assay.  Cell lysates and media 
from transfected cells were diluted in detergent buffer containing 0.5% NP-40 and 0.5% 
sodium deoxycholate, then subjected to high speed ultracentrifugation to separate 
insoluble from soluble material.  Pellets (P) and supernatant (S) fractions were analyzed 
by Western Blot (Figure 7).  Whereas full length WT and WT∆GPI proteins were entirely 
soluble (Figure 7A, lanes 3,4,7,8), both PG14 and PG14∆GPI proteins were partially  
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PrP Calreticulin Merge
Figure 5.  PG14ΔGPI partially colocalizes with ER. Cells expressing vector (inset), WT PrP (a-c), 
PG14 (d-f), WTΔGPI (g-i), and PG14ΔGPI (j-l) were fixed, permeabilized, then stained with PrP 
primary antibody 6H4 and α-calreticulin (b, e, h, k). Analysis by fluorescence microscopy allows 
observation of PrP (a, d, g, j), ER (b, e, h, k), and merged pictures (c, f, i, l).  Both full-length PG14 and 
PG14ΔGPI partially colocalize with ER, WT and WTΔGPI do not.
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Figure 6.  PG14ΔGPI partially colocalizes with the Golgi apparatus. Cells expressing vector 
(inset), WT PrP (a-c), PG14 (d-f), WTΔGPI (g-i), and PG14ΔGPI (j-l) were fixed, permeabilized, then 
stained with PrP primary antibody 6H4 and α-giantin (b, e, h, k). Analysis by fluorescence microscopy 
allows observation of PrP (a, d, g, j), Golgi (b, e, h, k), and merged pictures (c, f, i, l).  All constructs 
show colocalization with the Golgi apparatus.  PG14 and PG14ΔGPI can be found in Golgi and 
elsewhere.
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insoluble in cell lysates (Figure 7A, lanes 5,6,9,10).  These results demonstrate that loss 
of the GPI anchor does not interfere with the ability of PG14 to aggregate within cells.  In 
media, WT and WTΔGPI were also entirely soluble (Figure 7B, lanes 3,4,7,8).  Full-
length PG14 is rarely detected in the media (Figure 7B, lanes 5,6), however on occasion 
we noticed a faint band that correlated with the soluble fraction (data not shown).  
Interestingly, the small amount of PG14ΔGPI that escaped into the media was also found 
to be entirely soluble (Figure 7B, lanes 11,12), suggesting that PG14 aggregates remain 
retained, and only soluble molecules are able to reach the cell surface.   
 In transgenic mice inoculated with scrapie, WT∆GPI molecules formed larger 
aggregates than mice expressing endogenous WT PrP, suggesting that the GPI anchor 
affects aggregate size in vivo.  To investigate whether the size of PG14∆GPI aggregates 
in cells were larger compared with full length PG14, cell lysates were centrifuged at high 
speeds in sucrose step-gradients that ranged from 10% to 60% (Figure 8).  WT and 
WT∆GPI molecules are found at the lowest sucrose density fractions, indicating that they 
are likely monomeric and do not form large aggregates.  PG14, however, is found at low- 
and mid-density fractions, as well as in the pellet, demonstrating that a range of aggregate 
sizes are found in cells.  The density profile for PG14∆GPI was similar to that of full 
length PG14, signifying that loss of the GPI anchor did not drastically affect aggregate 
sizes in cells as determined by this assay.  Differences in sizes of aggregates within the 
pellet could not be distinguished by this assay.   
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Figure 7.  Intracellular PG14ΔGPI is partially insoluble. Cell lysates (A) and media (B) from cells 
expressing vector (lanes 1,2), WT PrP (lanes 3,4), PG14 (lanes 5,6), WTΔGPI (lanes 7,8), and 
PG14ΔGPI (lanes 9,10) were spun at high speeds in detergent buffer to separate soluble (S) from 
pelleted insoluble (P) fractions, then analyzed by Western blotting with 3F4 antibody.  In cell lysates, 
WT and WTΔGPI molecules are entirely soluble, while PG14 and PG14ΔGPI are partially insoluble.  
In media, WT and WTΔGPI molecules are also soluble; the little PG14ΔGPI that escapes is also 
soluble.  Lanes 11 & 12 show PG14ΔGPI at a darker exposure.  Molecular size markers are given in 
kilodaltons.  
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Figure 8.  PG14ΔGPI forms large aggregates. Cell lysates from cells expressing WT PrP (lanes 
3,4), PG14, WTΔGPI, and PG14ΔGPI were placed atop a sucrose step gradient (densities indicated 
by percentage), then centrifuged at high speeds separate aggregated molecules from monomers.  
Fractions from each step in the gradient were methanol-precipitated, then analyzed by Western 
blotting with 3F4 antibody.  WT and WTΔGPI molecules monomers colocalize with low-density 
fractions, while PG14 and PG14ΔGPI can be found in higher density fractions and within the pellet 
(P), indicating the formation of large aggregates.  There is no difference in the aggregate size profile 
between PG14 and PG14ΔGPI.  Molecular size markers are given in kilodaltons.  
117
3.5  Discussion 
 We have demonstrated that PG14∆GPI expressed in mammalian cells is primarily 
unglycosylated and retained intracellularly.  Furthermore, deletion of the GPI anchor in 
mutant PG14 does not affect intracellular localization, or ability to aggregate.  
Collectively, these results reveal that the GPI anchor does not play a major role in 
determining the aberrant biochemical and cellular trafficking characteristics that are 
particular to the PG14 familial mutant prion protein.  These data provide initial insights 
of PG14∆GPI molecular behavior, paving the way for future studies investigating the role 
of the GPI anchor in PG14 toxicity in transgenic mice.    
 
Loss of GPI anchor affects mutant PrP glycosylation.  It is well documented 
that GPI anchorage and membrane attachment are crucial for proper N-linked 
glycosylation of PrP (Walmsley et al. 2001; Walmsley et al. 2003).  In its absence, 
WT∆GPI is expressed mainly as unglycosylated both in cells and in vivo (Rogers et al. 
1993; Chesebro et al. 2005; McNally et al. 2009).  It is speculated that the loss of 
membrane attachment may localize PrP away from its protein interactors or 
oligosaccharyltransferases within the ER lumen, thus leading to impaired glycosylation.  
It is also possible that the lack of a GPI anchor causes PrP to adopt a differential 
conformation that renders the glycosylation sites inaccessible (Walmsley et al. 2001). 
We demonstrate here for the first time that deletion of a GPI anchor also impairs 
glycosylation of a disease-associated familial mutant PrP in the same manner, wherein 
the vast majority of PG14ΔGPI molecules are not glycosylated (Figure 2).  The 
deglycosylation effect observed is due solely to the lack of the GPI anchor and not the 
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PG14 mutation itself, because full-length PG14 is present in several different glycoforms 
when expressed in cells (Figure 1).  Interestingly, even though a subset of PG14∆GPI 
molecules are retained within the ER, where molecules have prolonged exposure to the 
site of oligosaccharyltransferase activity, glycosylation enzymes are still unable to 
recognize and/or transfer carbohydrate attachments to the PrP molecule.   
 
Loss of GPI Anchor Does Not Affect PG14 Intracellular Localization.  Like 
WT PrP, PG14 is synthesized and translocated into the ER, where it is glycosylated and 
fitted with a GPI anchor.  It is further modified in the Golgi apparatus and presumably 
packed into secretory vesicles bound for the plasma membrane (Lehmann and Harris 
1995; Drisaldi et al. 2003) .  In neurons, PG14 can traverse within neurites, but remain 
intracellular, suggesting a defect in PG14-carrying secretory vesicles to fuse with the 
plasma membrane (Medrano et al. 2008).  Although some PG14 reaches the surface, the 
majority remain retained intracellularly, partially within the ER and Golgi apparatus 
(Ivanova et al. 2001).   
Though cell surface localization in PG14 and PG14∆GPI is limited, the fraction 
of PG14∆GPI molecules released into the media is noticeably higher than full-length 
PG14 (Figure 3), demonstrating that PG14∆GPI that reaches the cell surface is more 
easily dissociated from the plasma membrane.   
However, the vast majority of PG14 and PG14∆GPI molecules are retained 
intracellularly and within the same organelles, emphasizing that PG14 and PG14∆GPI 
have the same deficiency in the release of molecules to the plasma membrane.  The main 
conclusion derived from these results is that the mechanism responsible for mutant 
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retention does not rely on membrane attachment by a GPI anchor.  It is possible that 
PG14∆GPI also associates with the membrane intracellularly, as does WT∆GPI 
(Campana et al. 2007).  Our studies thus far have not been able to distinguish whether the 
protein floats within the lumen of organelles and vesicles, or joins with the lipid bilayer 
by a GPI anchor-independent mechanism.  Although the mechanism for retention is 
ambiguous, it is possible that mutant protein retention does not rely on GPI anchorage, 
but on the state of aggregation.  In support of this hypothesis, only a small pool of soluble 
PG14 and PG14∆GPI molecules reach the cell surface and are secreted (Figure 8).  
Additionally, aggregation and retention may be exacerbated by the lack of glycosylation, 
which can intensify PrPC misfolding and accumulation within the Golgi (Lehmann and 
Harris 1997).   
 
Loss of a GPI Anchor Does Not Affect PG14 Misfolding and Aggregation.  In 
cells, both anchorless PG14ΔGPI molecules and PG14 proteins spontaneously aggregate 
when expressed in transfected mammalian cells (Figures 8, 9), demonstrating that 
aggregation is not dependent on either membrane attachment or glycosylation state for 
inherited prion mutants.  This conclusion is supported by previous evidence showing that 
even recombinant PG14 molecules assemble into proteinase K-resistant structures 
(Gauczynski et al. 2002).  This evidence supports the notion that the repeat expansion 
itself is sufficient to augment prion conversion, independent of a GPI anchor.   
Although lack of the GPI anchor does not interfere with PG14 aggregation, it is 
possible that the aggregate structures are modified.  Tg(WT∆GPI) mice inoculated with 
RML-PrPSc form dense thioflavin-S positive plaques within the central nervous system 
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(Chesebro et al. 2005).  These amorphous aggregates are a stark contrast from the highly 
structured fibrils that are usually detected in RML-inoculated wild-type mice. 
Conformational differences in molecules, the lack of attached carbohydrates, or both, 
may contribute to the disparity between WT and WT∆GPI aggregate formations in vivo.  
Similarly, PG14∆GPI aggregates may form and expand in different structural 
conformations as well when compared with PG14.  Although our assays show no 
difference between the PG14 and PG14∆GPI aggregate biochemical properties in 
detergent insolubility and sucrose gradient assays (Figures 7,8)—and thus no drastic 
differences in aggregate formation—further investigations will be necessary to determine 
whether the loss of the GPI anchor affects the structural properties of the inherited PrP 
mutant.   
 
Does the GPI anchor play a role in the pathogenesis of PG14 familial prion 
disease?  We have demonstrated that the loss of the GPI anchor of the PG14 mutant does 
not affect PG14 localization or ability to aggregate.  However, it is difficult to ascertain 
whether GPI anchor deletion would affect disease onset and progression in vivo.  The 
prion field lacks a model that can mimic PG14 toxicity in cell culture, thus the role of the 
GPI anchor in PG14 disease can only be fully appreciated in vivo in transgenic mice 
expressing PG14∆GPI.  We are currently generating these mice, confident that further 
investigation into the role of the GPI anchor in the context of a familial prion disorder 
would clarify mechanisms of cellular and physiological.   
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4.1 Summary 
 
Post-translational or genetic aberrations in prion protein (PrP) are associated with 
a set of progressive neurodegenerative diseases termed prion disorders, marked clinically 
by cognitive decline and pathologically by PrP deposition, glial proliferation, and 
neuronal loss.  The molecular, cellular, and physiological processes underlying sporadic 
or infectious, and inherited prion diseases remain ambiguous, although accumulation of 
PrPSc, or a toxic byproduct of conversion, is generally assumed to trigger pathology in 
sporadic and infectious cases. 
In familial cases of prion disease, over 50 mutations have been identified as 
pathological forms of PrPPM.  One such mutant, PG14, is a 217 base pair insertion that 
results in the extension of the five endogenous proline- and glycine-rich octapeptide 
motifs found in PrP, from five repeats to fourteen.  In transgenic mice, PG14 causes 
spontaneous neurological disease marked by cerebellar granule degeneration and 
astrogliosis.  Localization of the mutant prion protein is necessary to elucidate the 
mechanisms responsible for disease pathology.  However, due to the PrPSc-like aggregate 
nature of PG14, visualization of PG14 requires potentially damaging antigen retrieval 
(AR) techniques.  To circumvent the need for AR protocols and visualize PG14 directly, 
we generated transgenic mice expressing a PG14-EGFP fusion protein that can be 
detected readily using fluorescence microscopy.   
In Chapter 2, I find that Tg(PG14-EGFP) mice, but not Tg(WT-EGFP) mice, also 
develop spontaneous neurological illness similar to their Tg(PG14) counterparts, thus 
demonstrating their value as a model system in which to study familial prion disease.  
Furthermore, I find that PG14-EGFP derived from brain homogenates retains the same 
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biochemical characteristics as PG14, including detergent insolubility, PK resistance, and 
reactivity with PrP aggregate-specific antibody 15B3.  In cerebellar granule neurons and 
brain sections of Tg(WT-EGFP) animals, PrP distribution is uniformly even throughout 
the cell soma and neurites, indicating normal localization in vivo (Barmada et al. 2004).  
In contrast, brain sections of Tg(PG14-EGFP) mice display ubiquitous fluorescent puncta 
ubiquitous within the neuropil of the cerebrum and cerebellum, which correspond to 
accumulated PG14-EGFP protein.  These presumed aggregates were found at the highest 
densities in axon-rich regions of both the central and peripheral nervous systems, 
including the dentate gyrus of the hippocampus, the molecular layer of the cerebellum, 
the striatum, and the sciatic nerve.  Additionally, in primary neurons derived from 
transgenic pups, PG14-EGFP, but not WT-EGFP, demonstrated intracellular 
accumulation, with little or no mutant protein reaching the cell surface.  These studies 
highlight the aberrant trafficking patterns of aggregated PG14 in vivo without the use of 
AR, and demonstrate that intracellular PG14 aggregation within axons may contribute to 
inherited prion disease pathology. 
In a further attempt to understand what cell biological properties mediate mutant 
PG14 mislocalization, aggregation, and toxicity, I explore the role of the GPI anchor in 
PG14 cell behavior in transfected cells.  In cells and in transgenic mice, the GPI anchor 
has demonstrated a regulatory role in proper WT PrP cell surface localization, and in 
PrPSc aggregate formation and disease toxicity (Walmsley et al. 2003; Chesebro et al. 
2005; Sim and Caughey 2008).  However, what processes the GPI anchor might mediate 
in a mutant PrP have not yet been investigated.  To this end, I generated a PG14 construct 
lacking the C-terminal end genetic signal sequence encoding the attachment of a GPI 
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anchor, then expressed the protein in mammalian cells under a strong CMV promoter.  I 
found that in contrast to its effect on WT PrP, deletion of the GPI anchor did not alter 
normal PG14 localization.  PG14∆GPI, like PG14, was retained intracellularly within the 
ER and Golgi, and failed to localize at the cell surface or in endosomes.  PG14∆GPI also 
displayed detergent insolubility and fractionated with dense sucrose fractions, 
demonstrating that, like PG14, the molecule aggregates spontaneously.  This work 
establishes that GPI-mediated membrane attachment does not affect mutant PrP 
localization or aggregation in cells, thus initiating further investigation on its effect on 
PG14 toxicity.    
* * * 
 These studies tackle two very relevant and related issues in the field of prion 
biology, including the possible mechanisms of familial prion disease pathogenesis, and 
whether the same molecular and cellular pathways underlie inherited and infectious prion 
diseases.  The contributions of my research are discussed within the context of these 
issues below.   
 
4.2 What Causes Familial Prion Disease?   
A.  The Role of Aggregation 
 Cell and mouse studies highlighting the aberrant cellular trafficking and abnormal 
accumulation of untagged PG14 suggests that aggregation is involved with the PG14 
cellular pathogenesis.  Indeed, many protein aggregates are associated with a wide variety 
of neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and Huntington’s 
Disease (Dimakopoulos 2005).  The length of OR expansion correlates directly with rate 
of aggregation (Moore et al. 2006; Yin et al. 2006; Yu et al. 2007) and inversely with age 
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of onset and disease duration in familial CJD patients (Mead 2006; Mead et al. 2006), 
suggesting that increased numbers of ORs leads to greater aggregation, which in turn 
results in increased mutant toxicity.  In support of this idea, sick Tg(PG14) mice display 
higher levels of insoluble material within their brain homogenates compared with mice 
that are subclinical, indicating a correlation between aggregation and familial prion 
disease in transgenic animals.  Additionally, Tg(PG14) lines expressing low amounts of 
the mutant protein demonstrate mostly soluble PG14 protein molecules and remain 
healthy.  In Chapter 2, I find that aggregation correlates with disease in Tg(PG14-EGFP) 
mice, supporting the notion that degree of insolubility is associated with clinical illness.  
Sick animals qualitatively displayed higher densities of punctate deposits within neuropil 
and axons, especially those within the mossy fibers of the dentate gyrus and the 
molecular layer of the cerebellum, compared with healthy transgenic littermates, which 
presented with the same depositions, but to a lesser extent.   
 However, the presence of insoluble material in healthy animals demonstrates that 
protein aggregation in and of itself is insufficient to cause toxicity in familial prion 
disease.  Tg(PG14) animals exhibit insoluble material within brain homogenates as young 
as five days old.  Because Tg(PG14) mice do not develop neurological illness for ~270 
days, they develop into adulthood without any major physical constraints, and remain 
healthy for ~9 months before onset of symptoms even with aggregates present.  Insoluble 
material is present during early stages of development, then accrues over the duration of a 
lifetime, indicating that a possible threshold of accumulation needs to be breached before 
the onset of symptoms—large amounts of aggregation may be necessary in order to cause 
sufficient cellular and physiological pathology to cause onset of clinical symptoms.  
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Consistent with this data, I detect fluorescent punctate deposits within the soma and 
neurites in cerebellar granule neurons derived from healthy Tg(PG14-EGFP) four day-old 
pups (Chapter 2).  Tg(PG14-EGFP) heterozygotes display conspicuous amounts of 
aggregation, but remain healthy for over two years.  Additionally, brain sections of ill 
mice display increased amounts of fluorescent deposits in axon-dense regions compared 
with healthy controls.  
   Accumulating evidence suggests a role for PrP in synaptic development and/or 
function (see Introduction).  Wild-type PrP travels both anterogradely and retrogradely 
within axons and is enriched along axons and pre-synaptic regions, indicating that its 
localization at these points may be crucial for its function.  We find that mutant PG14-
EGFP is also prominently located in axons, especially within the dentate gyrus of the 
hippocampus, the alveus oriens, and the molecular layer of the cerebellum, regions where 
PrP is expressed very strongly (Medrano et al. 2008).  However, unlike soluble WT PrP 
and WT-EGFP, PG14-EGFP aggregates intracellularly within the soma and neurites of 
neurons, both in brain section and in cell culture.  Steady accumulation of mutant PrP 
within axons may lead to disruption of intracellular transport machinery (microtubules, 
kinesins, dyneins), thus preventing PrP, or other synaptic proteins, from reaching the 
presynaptic site (Figure 1).  Indeed, a decrease in synaptophysin-positive terminals was 
observed in Tg(PG14) animals, supporting this theory (Chiesa et al. 2005).  Axonal 
blockage has also been observed in flies overexpressing APP-like protein and several 
poly-Q mutants, associated with Alzheimer’s Disease and Huntington’s disease, 
respectively (Gunawardena and Goldstein 2001; Gunawardena et al. 2003; Gunawardena 
and Goldstein 2005).  It is speculated that blockage prompts or aids in neuronal  
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+Figure 1.  Axonal Blockage Model (A) WT PrP (blue) and synaptic proteins in vesicles (red) travel
along microtubule tracks (gray) toward the axon terminal.  (B)  PG14 (green star) accumulation in the 
axon blocks axonal transport, preventing synaptic proteins from reaching the presynaptic site.
A.
B.
131
dysfunction and subsequent neuronal cell death.  It would be informative to compare 
axonal rates of transport in WT PrP and mutant PrPs to determine whether abnormal 
trafficking patterns of mutants also disrupts delivery of other synaptic proteins and leads 
to neurotoxicity.  For example, one may be able to co-transfect polarized primary neurons 
with green fluorescently tagged WT or PG14 PrPs along with red fluorescently tagged 
proteins that use fast axonal transport mechanisms, such as synaptophysin or kinesin-I, 
then use kymograph analysis to measure the speed and/or number of particles that travels 
through axons.  If PG14 does cause blockages in axonal transport, we would expect that 
PG14 itself would show slower rates of travel compared with WT PrP.  A decrease in 
speed or efficiency of transport of other axonal proteins co-transfected with PG14 would 
suggest that the mutant PrP is able to affect trafficking of other proteins as well.  Work 
attempting such experiments is described in Appendix 3, and further investigations,  
similar to the experiments listed above, will be necessary to solidly support or refute the 
axonal blockage model.     
 Although aggregation seems well-correlated with transgenic PG14 models of 
disease, this is not the case with many other disease-associated PrPM mutants.  P101L, 
D197N, and V209I exhibit detergent solubility and some PK-sensitivity, much like 
endogenous PrPC.  They also exhibit normal rates of synthesis and degradation, as well as 
proper cell-surface localization when expressed in transfected mammalian cell lines, 
indicating that formation of large aggregates is not necessary in order to produce toxicity.  
It is possible that the PG14 mode of toxicity is entirely different from other soluble PrPM 
counterparts, and that aggregation alone induces clinical symptoms.  This viewpoint, 
however, is too simplistic and unlikely, given the number of soluble and insoluble 
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mutations that result in the same clinical symptoms.  It is more likely that every one of 
the 50+ PrP mutant utilizes a common mechanism of disease, and interferes with the 
same as-of-yet unidentified pathways in all familial prion disorders.  If this platform is 
taken as an assumption, then protein aggregation can be considered a factor that may 
contribute to disease, but is neither necessary nor sufficient to induce PrPM toxicity.      
  
B.  PrPM Toxicity 
What then, could be the cause of PrPM toxicity?  One clue may be found in the 
size of toxic PrPSc particles.  Beta-oligomers synthesized from recombinant PrP or from 
thermal refolding were both able to induce neurotoxicity when introduced into cell 
cultures and to primary neurons (Novitskaya et al. 2006; Simoneau et al. 2007), 
demonstrating that both small and large PrP aggregates had the ability to confer toxicity.  
Indeed, oligomeric forms of disease-associated proteins have demonstrated increased 
neurotoxicity compared with larger fibrillar or amorphous aggregates in several 
neurodegenerative disease, including amyloid β protein in Alzheimer’s disease, α-
synuclein in Lewy Body disease, and huntingtin protein in Huntington’s Disease 
(Dimakopoulos 2005; Haass and Selkoe 2007).  It is feasible then, that PG14 and other 
PrP mutants confer toxicity by forming PK-soluble or slightly PK-insoluble oligomers 
which interfere with normal cellular processes.  The work accomplished in Chapter two 
does not exclude this possibility.   
 Alternatively, aberrations in signal transduction may also play a role in prion 
toxicity.  The GPI anchor, attached at the C-terminal end of PrP, tethers the protein to the 
outer leaflet of the lipid bilayer of the plasma membrane.  Because of the high affinity of 
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GPI anchors for saturated lipid species, PrPC is concentrated in lipid raft domains along 
with several cell-signaling proteins, including Fyn and Src (Taylor and Hooper 2006), 
and several studies have implicated PrP as a neuroprotective cell signaling molecule (see 
Introduction).  In one model of PrPSc disease, once PrPC transforms into PrPSc, the normal 
signal is subverted into one that is toxic (Figure 2A).  In support of this hypothesis, 
transgenic mice expressing anchorless PrP demonstrate robust PrPSc propagation, but no 
appearance of clinical illness.  These combined results led to the hypothesis that the lack 
of GPI-mediated PrP attachment to the plasma membrane interferes with the delivery of 
neurotoxic signals induced by PrPSc formation (Figure 2B) (Brandner et al. 1996; 
Solforosi et al. 2004).   
Whether GPI anchorage is necessary to transduce toxic signals induced by PrPM 
remains ambiguous.  Chapter three describes work that lays the foundation for answering 
this question.  PG14∆GPI retains the same cellular localization, aggregate patterns, and 
biochemical characteristics as PG14 in cells, with the main structural difference being the 
absence of a membrane-bound anchor.  Thus, we can use PG14∆GPI to test the specific 
effects of GPI anchor loss on toxicity in vivo without affecting any of the abnormal 
properties associated with the PG14 mutant.  These experiments are presently under way. 
The prion field lacks a model that can mimic PG14 toxicity in cell culture, thus 
the role of the GPI anchor in PG14 disease can only be fully appreciated in transgenic 
mice expressing PG14∆GPI.  We are currently generating these animals, confident that 
further investigation into the role of the GPI anchor in the context of a familial prion 
disorder would clarify mechanisms of cellular and physiological pathology.  If the GPI 
anchor does indeed mediate toxicity, either by transducing signals itself or by properly  
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PrPC
PrPSc
PrPSc
TOXIC!
Figure 2.  The GPI Anchor Mediates Toxic Signal Transduction in Prion Disease.  (A) In WT 
mice, PrPC is capable of transducing a signal to the cell.  Upon exposure to PrPSc, anchored PrPC is 
converted to PrPSc, thus stimulating toxic signals into the cell.  (B)  In Tg(PrPΔGPI) mice, untethered
PrPC is secreted into extracellular space and does not stimulate any signal transduction.  Upon 
exposure to PrPSc, PrPΔGPI is converted to PrPSc, and because of a lack of membrane attachment, 
does not produce any toxic signal. 
A.  PrPSc + PrPC
B.  PrPSc + PrPΔGPI
PrPΔGPI
PrPSc PrPScΔGPI
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localizing PrPs for interaction with other signaling molecules, PG14∆GPI will propagate 
aggregated PrP but will be unable to confer the toxic signals that result in a physiological 
display of clinical symptoms.  Conversely, if transgenic PG14∆GPI mice develop illness, 
we can conclude that GPI-mediated membrane attachment is unnecessary for toxic signal 
transduction. 
 
4.3 Are PrPSc and PrPM Pathways of Disease the Same? 
PrPM is commonly assumed to mimic an PrPSc intermediate molecule.  Support 
for this theory comes in the form of shared clinical symptoms between patients suffering 
from inherited and infectious prion disease and from biochemical similarities between 
some PrP genetic mutants and PrPSc.  Patients from both PrPM and PrPSc groups display 
many overlapping subsets of clinical symptoms.  For example, sporadic and infectious 
CJD patients often present with rapidly progressive dementia, involuntary muscle 
contractions, and abnormal EEG readings.  These same features are also found in patients 
carrying familial mutations of CJD.  Additionally, the biochemical characteristics of 
some PrP mutants resemble those which define PrPSc.  For example, PrPSc is resistant to 
up to 50 μg/mL protease K, while PrP mutants PG14, D177N, and E199K are partially 
resistant to protease K, albeit to a lesser degree, maintaining protein structure in up to two 
μg/mL PK.  These same mutants also have the tendency to aggregate and are insoluble in 
detergents, like PrPSc.  Additionally, aggregated familial mutants react with PrPSc-specific 
antibodies 15B3 and G19 (Biasini et al. 2008), suggesting that PrPM and PrPSc 
conformations are similar enough that some shared epitopes are exposed.  These data 
suggest that both infectious PrPSc and some inherited PrP mutants are similar in 
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biochemical characteristics and induced pathologies, and thus may interfere within the 
same pathways to induce prion disease toxicity.   
 However, PrPSc inoculation of mice expressing disease-associated prion mutants 
does not hasten progression of PrPSc disease, strongly arguing that PrPM is not solely an 
intermediate destined for PrPSc replication (Chiesa et al. 2003).  Additionally, there are 
many other cell biological and biochemical differences between some PrP mutants and 
PrPSc, suggesting that there are variable factors and pathways that mediate infectious 
versus inherited prion pathology.  One of the most obvious discrepancies is the non-
infectivity of inherited prion mutants.  PrPSc by definition must be infectious.  In contrast, 
in cells and in transgenic mice, P101L and PG14 are unable to bind and convert wild-type 
PrPs into a mutant conformation bearing the same biochemical properties or toxic effects 
(Telling et al. 1996; Lehmann et al. 1997; Chiesa et al. 2003) (see Appendix 1).  At least 
one prion mutant demonstrates infectivity when brain homogenates from human patients 
carrying the mutation and disease are inoculated into transgenic mice (Piccardo et al. 
2007).  However, many PrP mutants differ from PrPSc in that they are not infectious. 
 Differences in subcellular localization also argue against similar origins of 
toxicity.  PrPSc aggregate formation requires PrPC exposure at the extracellular interface 
or within the endosomal pathway (Caughey and Raymond 1991; Borchelt et al. 1992; 
Marijanovic et al. 2009).  PrPSc has been detected mainly in endosomes and the Golgi 
apparatus in scrapie-infected neuroblastoma cells and brains, and aggregated in 
extracellular spaces within neuropil in vivo.  However, PG14 is synthesized within the 
ER, aggregates spontaneously, and is retained intracellularly, with little to no PG14 
molecules at the surface and no co-localization within endosomes either in cells or in vivo 
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(Daude et al. 1997; Ivanova et al. 2001).  Studies in Tg(PG14-EGFP) mice confirm these 
findings and further report that that majority of aggregates are found in axon-dense 
regions.   
Ultimately, whether PrPM and PrPSc share the same pathways of toxicity is 
unclear.  There are many arguments that suggest that the pathological mechanisms 
between the two may be variable, such as differential localization, dissimilar biochemical 
properties, and inability of PrPM to affect PrPSc disease progression in inoculated PrPM-
expressing animals.  However, because the routes of pathogenicity for both PrPM and 
PrPSc are undefined, comparisons between modes of inherited versus infectious prion 
toxicity remain conceptual.  Clearly, additional investigation is necessary to elucidate the 
cellular and physiological pathways involved with prion pathogenesis.     
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WT PrP-EGFP does not bind PG14 aggregates 
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A1.1 Summary 
 Aggregated forms of infectious scrapie prions (PrPSc) and familial mutant PG14 
PrP, which contains a 217 base pair insertion, are difficult to detect by standard 
immunohistochemical techniques due to epitope burial, a phenomenon whereby antigens 
are concealed by protein misfolding and accumulation.  EGFP-tagged wild-type prion 
protein (WT-EGFP) was able to bind untagged infectious scrapie prion (PrPSc) aggregates 
in vivo, although WT-EGFP molecules themselves remained unconverted.  PrPSc 
aggregate detection by this method revealed intracellular PrPSc accumulation in the Golgi 
apparatus of cells, via fluorescence microscopy of brain sections of RML-inoculated 
Tg(WT-EGFP) mice (Barmada and Harris 2005).  This pool of molecules had not 
previously been identified by traditional scrapie detection protocols such as electron 
microscopy or antigen retrieval techniques, suggesting that detection of aggregates by 
fluorescently-tagged WT-EGFP allowed for greater sensitivity.   
To determine whether WT-EGFP could detect aggregates of familial mutant 
PG14 PrP, we crossed Tg(WT-EGFP) with Tg(PG14) animals and analyzed bi-transgenic 
offspring both clinically and neuropathologically.  We find that WT-EGFP does not 
interfere with PG14 disease onset or progression.  In contrast with findings for PrPSc 
aggregates, WT-EGFP is unable to bind to and tag aggregated PG14, as assayed by 
fluorescence microscopy of cerebellar granule neurons and of brain sections from bigenic 
mice expressing both WT-EGFP and PG14.  The difference in WT-EGFP molecules’ 
capability to bind PrPSc but not PG14 aggregates suggests that PrPSc infectivity may be 
facilitated by the ability to directly interact with WT PrP whereas PG14 non-infectivity 
may be explained by the lack of this interaction.   
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A1.2 Introduction 
 Prion diseases are a group of neurological disorders characterized by dementia, 
ataxia, and intracerebral prion protein (PrP) deposition.  In humans, illness can be 
acquired sporadically, inherited by genetic mutation of the PrP gene, or obtained by 
exposure to infectious scrapie prions (PrPSc) (Prusiner 1998).  Normal cellular PrP (PrPC) 
is a GPI-anchored sialoglycoprotein of ambiguous function that may be involved with 
cell signaling and/or neuroprotectivity (Westergard et al. 2007).   
 PG14 is a 217 base pair insertional mutation of the prion protein (PrP) that results 
in a repeat expansion of endogenous octapeptide motifs that are known to bind copper 
(Brown et al. 1997).  These repeats are rich in proline and glycine, and are extended from 
5 to 14 in the PG14 mutation.  This dominantly inherited mutation is associated with a 
familial form of Creutzfeldt-Jakob Disease (CJD), a progressive neurological disorder 
characterized clinically by dementia and ataxia, and pathologically by mutant PrP 
aggregation in the form of cerebellar plaques (Owen et al. 1992; Duchen et al. 1993; 
Krasemann et al. 1995).  Transgenic mice that express PG14 develop a similar illness, 
displaying ataxia, kyphosis, and marked PrP deposition within the cerebellum and other 
regions of the brain (Chiesa et al. 1998; Chiesa et al. 2000; Chiesa et al. 2001).  The 
molecular pathogenesis of disease remains poorly understood.   
To gain a better understanding of the cellular, and consequently physiological, 
mechanisms of pathology underlying familial prion disorders, it is crucial to identify the 
subcellular and anatomical localization of the insoluble PG14 PrP protein, which 
accumulates over the course of the time (Chiesa et al. 1998).  However, visual 
identification of the mutant protein within the brain proves to be challenging, due in part 
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to the burial of normally accessible epitopes within aggregated molecules or irregularly 
folded protein structures.  Several techniques have been adopted to overcome this 
difficulty.  Antigen retrieval procedures, such as treatment with guanidine thiocyanate or 
hydrolytic autoclaving, denature proteins to help expose hidden epitopes.  Brain sections 
of both scrapie-inoculated and Tg(PG14) mice that undergo antigen retrieval treatments 
before immunohistochemistry reveal plaque formations within the brain.  However, the 
abrasive nature of these techniques easily damages the integrity of the tissue, and may 
introduce a number of potential artifacts.   
Further attempts to localize PG14 in vivo included the generation of transgenic 
mice expressing a PG14 construct carrying an enhanced green fluorescent protein 
(EGFP) tag inserted at the C-terminal end of the protein (Medrano et al. 2008).  These 
mice developed clinical illness similar to untagged Tg(PG14) mice.  When analyzing 
brain sections, PG14-EGFP displayed irregular and punctate patterns of localization, 
similar to the synaptic-like deposition detected in the cerebellum of untagged Tg(PG14) 
animals (Chiesa et al. 1998; Chiesa et al. 2005).  Additionally, we found that PG14-EGFP 
aggregates were discovered at the highest densities in axon-rich regions of the brain, a 
previously unidentified feature of pathology indicating axonopathy as a possible mode of 
pathology.  Studies in cerebellar granule neurons cultured from Tg(PG14-EGFP) mice 
offered more detailed localization reports at the subcellular level, displaying for the first 
time intracellular mutant PrP localization and accumulation within cell soma and 
neurites.  However, PG14-EGFP in this work was expressed at 0.15 X that of endogenous 
PG14 and it remains unclear how protein expression level affects protein distribution 
(Medrano et al. 2008).  To determine localization of PG14 in mice that express 
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physiological levels of the mutant protein, we sought yet another method to visually 
detect PG14 aggregates.     
Previous work from our lab has demonstrated that fluorescently-tagged wild type 
prion protein (WT-EGFP) has the ability to recognize and bind infectious PrPSc 
aggregates in vivo without itself being converted (Barmada and Harris 2005).  Tg(WT-
EGFP) animals inoculated with scrapie display delayed onset of scrapie disease 
compared with wild type animals, indicating a significant interaction between the WT-
EGFP molecule and scrapie particles.  In brain sections of diseased animals, we observed 
intracellular accumulation of PrPSc in the Golgi apparatus of cells, highlighting a pool of 
molecules that had not previously been identified by traditional scrapie detection 
protocols such as electron microscopy or immunohistochemistry with antigen retrieval 
techniques.  This finding suggests that detection of aggregates by fluorescently-tagged 
WT-EGFP allowed for greater sensitivity when compared with standard 
immunohistochemistry.   
To expand our repertoire of tools for mutant PrP aggregate detection in vivo, we 
crossed Tg(WT-EGFP) mice with Tg(PG14) animals and analyzed bigenic offspring that 
expressed both proteins.  In contrast to PrPSc-induced illness, the presence of WT-EGFP 
did not affect PG14 disease age of onset.  In brain sections of bigenic mice, WT-EGFP 
failed to co-aggregate with PG14 cerebellar deposits, instead maintaining the smooth and 
uniform distribution of WT PrP throughout the neuropil and molecular layers of the 
cerebellum.  WT-EGFP was also unable to recognize and bind PG14 accumulations in 
primary neuronal cultures derived from bigenic mice.  Whereas PG14 accumulated 
intracellularly in the cell soma and along neurites, WT-EGFP again adopted the 
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localization pattern of WT PrP, normally located on the surface of the cell soma and 
neuritic extensions.  The ability of WT-EGFP to bind and tag PrPSc, but not PG14, 
aggregates suggests that there may be a structural or conformational difference between 
the two molecules, which influences their ability to interact with other PrP molecules.  
This distinction may help explain why PrPSc, but not PG14, is infectious.   
 
A1.3 Materials & Methods 
Transgenic Mice.  Construction of Tg(WT-EGFP), Tg(PG14-EGFP), and 
Tg(PG14) mice have been described previously (Chiesa et al. 1998; Barmada et al. 2004; 
Medrano et al. 2008).  Tg(WT-EGFP+/o) mice, A line, were maintained on a mixed 
CBA/C57BL6 PrP+/+ background.  These were crossed with Tg(PG14+/o) animals, A2 
line, kept on a recombinant inbred CBA/C57BL6 PrPo/o background.  F1 progeny were 
genotyped and classified into the following groups:  (1)  PG14+/o WT-EGFP+/o, (2) 
PG14+/o WT-EGFPo/o, (3) PG14o/o WT-EGFP+/o, or (4) PG14o/o WT-EGFPo/o.  All F1 
progeny had a PrP+/o background.  At least 13 animals from each genotype group were 
collected.  Tg(PG14-EGFP+/o) mice on a PrP+/+ background were used as positive 
controls for fluorescent aggregates in brain sections and cerebellar granule neurons.   
Clinical Evaluation.  Mice were checked biweekly for symptoms of neurological 
dysfunction.  Kyphosis, foot clasp, and hyperexcitability were determined by visual 
observation, while ataxia was tested by placing mice in the center of a horizontally 
oriented grill (45 x 45 cm) consisting of 3 mm diameter steel rods spaced 7 mm apart.  
Mice unable to maneuver around the grid were scored as ataxic.  Animals that exhibited 
at least two symptoms were scored as ill.   
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Brain Sections.  Animals were fixed by intracardiac perfusion as described 
previously (Medrano et al. 2008).  Brains were then removed and then post-fixed in the 
same solution for 2 hrs before transfer to 0.1M sodium phosphate buffer (pH 7.2) 
containing 0.02% sodium azide for storage at 4°C.  A Vibratome (The Vibratome 
Company, St. Louis, MO) was used to cut the tissue into 60 μm thick sagittal sections.  
Sections were mounted on glass slides using Gel/Mount (Biomeda, Foster City, CA).  
Intrinsic EGFP fluorescence was imaged using a Zeiss LSM 510 inverted confocal 
microscope with an Axiovert 200 laser scanning system.   
Primary Neurons.  Cerebellar granule neurons (CGNs) were isolated from 4 day 
old mouse pups according to methods detailed previously (Medrano et al. 2008).  CGNs 
were imaged live using a Zeiss LSM 510 inverted confocal microscope with an Axiovert 
200 laser scanning system.   
 
A1.4  Results  
Construction of Tg(WT-EGFP+/o PG14+/o) mice.  To study whether WT-EGFP 
molecules are able to tag PG14 aggregates in vivo, we crossed existing lines of Tg(WT-
EGFP) and Tg(PG14) mice to obtain bigenic mice expressing both proteins.  Tg(WT-
EGFP+/o) mice kept on a PrP+/+ background (Barmada et al. 2004) were crossed with 
Tg(PG14+/o) mice maintained on a PrP null background (Chiesa et al. 1998).  F1 progeny 
were grouped according to genotype: (1) WT-EGFP+/o PG14+/o, (2) WT-EGFP+/o, (3) 
PG14+/o, and (4) WT-EGFPo/o PG14o/o.  F1 progeny from the expressing one or both 
transgenes were used for experimentation in these studies (Groups 1-3).  Mice negative 
for both transgenes were discarded (Group 4).  Previous investigations demonstrate that 
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both Tg(WT-EGFP) and Tg(PG14) mice express transgenic protein at 1X endogenous 
PrP level, and are presumably expressed at equal levels in bigenic mice.   
 
WT-EGFP does not interfere with PG14 disease onset.  All transgenic and 
bigenic mice were checked for the following neurological symptoms biweekly: kyphosis, 
foot clasp, hyperexcitability, and ataxia.  Mice testing positive for at least two of these 
symptoms were scored at ill.  Tg(PG14) mice that were heterozygous for the transgene 
developed spontaneous neurological illness at 317±21 days (Table 1).  This statistic is 
much later than the age of onset previously recorded (235±10 days; (Chiesa et al. 2000)), 
and is likely due to two factors: 1) genetic changes over the course of a decade of 
inbreeding, and 2) slight variability in methods for determining disease.  These 
differences do not affect results from these experiments since mice used in these studies 
are littermates and  are assessed for illness in a consistent manner. 
 Mice expressing both PG14 and WT-EGFP developed disease at 321±28 days, 
similar to mice expressing only PG14 (Table 1).  This result reveals that WT-EGFP does 
not hinder disease onset of this familial PrP mutant.  As expected, 100% of all Tg(WT-
EGFP+/o) mice remained healthy for the duration of the experiments, confirming previous 
results (Barmada et al. 2004).  These animals ranged in age from 448 to 623 days.   
 
WT-EGFP does not tag aggregated familial PrP mutant PG14.  PG14 
molecules form insoluble aggregates within 1 hour of synthesis in mammalian cells 
(Daude et al. 1997) and Tg(PG14) transgenic pups as young as 4 days old exhibit 
protease-resistant, detergent insoluble PG14 aggregates (Chiesa et al. 1998).  These  
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Table 1.  Disease onset in Tg(WT-EGFP+/o PG14+/o) animals
Genotype Age of Onset
WT-EGFP+/o >448 (0/15)
PG14+/o 317±21 (19/19)
PG14+/o WT-EGFP+/o 321±28 (13/13)
Age of onset is recorded in  days.  Numbers in parentheses indicate the number of ill mice 
over the total number of animals observed.   
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aggregates can be visualized in cerebellar granule neurons derived from transgenic mice, 
of the same age, expressing EGFP-tagged PG14 (Figure 1B and (Medrano et al. 2008))  
Aggregates are displayed in primary neuronal culture as small, bright puncta that 
accumulate within the cell soma and in neurites.  This aberrant distribution is easily 
distinguished from WT-EGFP, which is uniformly distributed along the surface of 
neurons (Figure 1A and (Medrano et al. 2008))  To investigate whether WT-EGFP 
molecules are able to recognize and bind to PG14 aggregates, we analyzed cerebellar 
granule cells derived from pups co-expressing both WT-EGFP and PG14 (Figure 1C).  
These cultures show a uniform pattern of expression identical to cultures expressing only 
WT-EGFP, indicating that the fluorescent WT protein does not bind with PG14 
aggregates in primary neuronal culture.   
 Insoluble PG14 aggregates accumulate over the course of time in vivo in 
transgenic mice and are distributed throughout the cerebellum in a synaptic-like pattern 
(Chiesa et al. 1998; Chiesa et al. 2000).  This aberrant localization is visible in brain 
sections of mice as young as 71 days of age by standard immunohistochemistry after 
treatment with antigen retrieval techniques (Figure 2A).  In brain sections from mice that 
express inherently fluorescent PG14-EGFP, punctate spots that correlate with 
accumulated PG14-EGFP are detectable as young as 100 days using confocal 
fluorescence microscopy (unpublished data).  Earlier ages had not been checked, 
although punctate distribution of PG14-EGFP is likely at all ages, given that PG14-EGFP 
aggregates are detected in cerebellar granule neurons of pups as young as four days old 
(Medrano et al. 2008).   
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Tg(WT-EGFP+/o) Tg(PG14-EGFP+/o) Tg(PG14+/o WT-EGFP+/o)
A. B. C.
Figure 1.  WT-EGFP does not tag PG14 aggregates in cerebellar granule neurons. Live cerebellar 
granule neurons from mice expressing WT-EGFP (A), PG14-EGFP (B), or both untagged PG14 and 
WT-EGFP (C) were observed via fluorescence microscopy.  WT-EGFP uniformly coats the surface of 
cell soma and neurites (A), wherease PG14-EGFP displays punctate distribution along neurites (B).  
Cells expressing both PG14 and WT-EGFP display the same localization as (C), demonstrating that the 
two proteins do not co-aggregate.  This work was published in Biasini et al., 2008. 
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Tg(PG14+/o)
A.
Tg(WT-EGFP+/o)
B.
Tg(PG14-EGFP+/o)
Tg(PG14+/o)
Tg(PG14+/o WT-EGFP+/o)
D.
C.
*
E.
ML
PCL
GCL
Adapated from Chiesa et al. (1998) Neuron 21(6):1339-1351 
Figure 2. WT-EGFP does not tag PG14 aggregates in cerebellar brain sections. A paraffin brain 
section derived from a 71 day old Tg(PG14) cerebellum was treated with 3M guanidine thiocyanate and 
hydrolytic autoclaving before staining with monoclonal PrP antibody 3F4, showing synaptic-like PG14 
distribution in the molecular and cerebellar granule layers (A, from Chiesa 1998).  Vibratome sections 
(b-e) from mice expressing WT-EGFP (B), untagged PG14 (C), PG14-EGFP (D), or both PG14 and 
WT-EGFP (E) were analyzed by fluorescence microscopy.  WT-EGFP distribution in the bigenic 
mouse (E) is uniform, similar to that of WT-EGFP expressed alone (B), but not aggregated like PG14-
EGFP (C), revealing that WT-EGFP does not colocalize with PG14 aggregates.  ML = molecular layer; 
PCL = Purkinje cell layer; GCL = granule cell layer.  Asterisk indicates autofluorescent dots.  This 
work was published in Biasini et al., 2008.  
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Knowing that PG14 aggregates are readily detectable by 100 days by both these 
methods, we investigated whether we could detect the aggregates by WT-EGFP binding 
to them in brain sections of mice expressing both PG14 and WT-EGFP (Figure 2).  
Vibratome sections from a Tg(WT-EGFP mouse) at 175 days reveals a smooth, uniform 
pattern of expression throughout the molecular layer (ML) and granule cell layer (GCL) 
of the cerebellum.  Autofluorescent dots in the Purkinje cell layer (PCL) are evident in all 
sections, including that of a transgenic mouse expressing untagged non-fluorescent PG14 
(Figure 2C, asterisk).  The distribution pattern of WT-EGFP remains the same in an age-
matched Tg(PG14+/o WT-EGFP+/o) mouse (Figure 2E), in contrast to Tg(PG14-EGFP) 
sections that show the synaptic-like distribution pattern in the molecular and cerebellar 
granule layers, similar to that of Tg(PG14) (Figure 2A,D).  These results demonstrate that 
WT-EGFP is unable to recognize and bind PG14 aggregates in vivo.   
 
 
A1.5  Discussion 
 Bigenic mice expressing WT-EGFP and PG14 were created in order to attempt 
PG14 aggregate visualization by WT-EGFP recognition and binding.  Here we 
demonstrate that co-expression of WT-EGFP and PG14 does not hinder PG14 disease 
onset.  Furthermore, WT-EGFP molecules do not bind PG14 aggregates either in primary 
neuronal cell culture or in brain sections of bigenic animals as assayed by fluorescence 
microscopy.  These results demonstrate that PG14 aggregates are unable to interact with 
the WT-EGFP marker, in contrast with PrPSc aggregates, which are capable of binding 
with and sequestering WT-EGFP molecules (Barmada).  Together, these data emphasize 
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the difference that PrPPSc, but not PG14, has the ability to interact with another PrP 
molecule, which give clues as to why PrPSc, but not PG14, is infectious in vivo.   
 
PG14 does not interact with other PrP molecules.  In our experiments, WT-
EGFP does not bind PG14 mutant prion protein aggregates in vivo, suggesting that both 
pools of PrP do not directly interact.  Previous work has demonstrated that untagged 
PG14 and WT PrP maintain their separate biochemical identities when co-expressed in 
cells (Lehmann et al. 1997); that PG14 disease age of onset and progression are 
unaffected by endogenous PrP level (Chiesa et al. 2000); that PG14 aggregates are unable 
to seed the misfolding of WT PrPC in an in vitro protein misfolding cyclic amplification 
(PMCA) reaction (Biasini et al. 2008); and that PG14 brain homogenates are unable to 
transmit disease when inoculated into mice expressing WT PrP (Chiesa et al. 2003).  
Collectively, these data indicate that there is minimal, if any, significant physical 
interaction or signaling between the PG14 mutant and wild type prion protein, which may 
help explain why PG14 is not infectious.   
 
 Infectivity is a distinguishing feature between PrPSc and PG14.  In scrapie-
inoculated Tg(WT-EGFP) animals on a PrP+/+ background, WT-EGFP acts as a dominant 
negative inhibitor of PrPC to PrPSc conversion.  WT-EGFP recognizes and binds to 
scrapie aggregates, thus slowing PrPSc accumulation and delaying disease in WT-EGFP+/o 
PrP+/+ animals (Barmada and Harris 2005).  This delay in disease onset was not observed 
when WT-EGFP was co-expressed with a similar amount of PG14 protein (Table 1), 
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indicating that PrPSc and PG14 aggregates differ in their ability to interact with other PrP 
molecules.    
It is possible that distinctions in aggregate structure may explain the disparity 
between PG14’s and PrPSc’s ability to interact with WT and WT-EGFP PrP.  However, 
previous studies using brain homogenates demonstrate that both spontaneously 
aggregated PG14 and infectious PrPSc from RML-inoculated wild type mice share many 
similar biochemical properties, including detergent insolubility, protease K resistance, 
and PIPLC-resistance (Lehmann and Harris 1996; Lehmann and Harris 1996; Lehmann 
et al. 1997).  Like PrPSc, PG14 can also be precipitated by sodium phosphotungstic acid, 
recognized by PrPSc –specific antibodies, and replicate protease-resistant PrP in vitro 
from a PrPC template using the protein misfolding cyclic amplification (PMCA) 
technique (Biasini et al. 2008; Biasini et al. 2008).  All these properties are distinct from 
normal healthy cellular PrPPC and argue that indeed, PG14 shares enough structural 
homology with PrPSc to mimic its biochemical profile.  However, in order to completely 
rule out  significant structural variation between the two, accurate molecular 
reconfigurations obtained from crystallographic studies, such as x-ray crystallography, 
will be necessary.   
Though non-infectivity is a trait shared by several familial PrP mutants, some 
mutations, such as E200K and V210I, have been shown to transmit disease when brain 
homogenates from diseased patients are inoculated into transgenic mice susceptible to 
human prions (Telling et al. 1994; Mastrianni et al. 2001).  Further investigations will be 
necessary in order to define the variable that modulates infectivity in these familial 
mutants and PrPSc but not in PG14.   
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A2.1 Summary 
 
Identifying the trafficking pattern of infectious scrapie prions (PrPSc) is essential 
for understanding the mechanism of transmission in prion disease.  However, PrPSc 
detection usually requires specimen fixation, followed by treatment with hydrolytic 
autoclaving or other harsh antigen retrieval (AR) techniques that have the potential to 
damage tissue and redistribute proteins.  In order to facilitate visual detection of PrPSc 
without AR, we attempted to convert an EGFP-tagged murine wild-type PrP (WFP) into 
the infectious conformation through inoculation of prion molecules into Tg(WFP) mice.  
In this chapter, I describe three separate experiments attempting to detect or generate 
WFPSc.  Our efforts were unable to produce infectious, aggregated, PK-resistant EGFP-
tagged PrP material.  These collective results demonstrate that WFP is highly resistant to 
conversion. 
 
 160
A2.2 Introduction 
Transmission of prion disease occurs most efficiently through intracranial 
injection of infected material into the host. However, disease also spreads naturally 
through ingestion, or experimentally via intraperitoneal infection, scarified skin, or nasal 
contraction (for review, see (Weissmann et al. 2002)).  Regardless of type of exposure, 
the end result is neurodegeneration caused by PrPSc-associated toxicity in the central 
nervous system (CNS), indicating that PrPSc molecules are able to replicate and traverse 
peripheral biological systems before neuroinvasion.  When introduced non-cerebrally in 
animal hosts, PrPSc replicates and accumulates on follicular dendritic cells (FDCs) in 
lymphoid tissues, and proceeds along the peripheral nervous system (PNS) to reach the 
brain, presumably by intracellular transfer (Mabbott and MacPherson 2006).   
However, the mode of intracellular transfer and propagation of PrPSc is 
ambiguous.  Recently, PrPPSc transmission has been detected in the transfer from bone 
marrow-derived dendritic cells to primary neurons via tunneling nanotubes (TNTs) 
(Gousset et al. 2009).  TNTs are a recently discovered cell communication device 
consisting of long protruding tunnel-like membrane extensions connecting two separate 
cells (reviewed in (Gurke et al. 2008)). However, there is other evidence showing that 
PrPSc can be transferred without direct cell contact.  Scrapie-infected epithelial cells have 
been shown to secrete infectious PrPSc associated with exosomes (Fevrier et al. 2004), 
and media incubated with an infected neuronal cell line is capable of inducing PrPSc 
propagation when placed over healthy cells (Schatzl et al. 1997).  Although several 
studies strongly suggest that the PrPC conversion process takes place once PrPSc and PrPC 
are colocalized within endocytic recycling compartments (Marijanovic et al. 2009), how 
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and where PrPSc travels when initially associated with a newly exposed cell is unclear.  
Imaging of PrPSc in living cells and in animals would provide a beneficial tool to study 
the behavior of intercellular PrPSc trafficking.    
Our lab has generated a transgenic mouse line expressing fluorescently-tagged 
wild-type prion protein (WFP).  Tg(WFP) animals synthesize and produce a fusion 
protein consisting of a murine PrP with an enhanced green fluorescent protein (EGFP) 
tag inserted near the C-terminal end, upstream of the GPI-anchor attachment signal.  The 
resulting transgene is properly synthesized as a glycosylated, GPI-anchored molecule, 
and like endogenous PrP, localizes to the cell surface of neurons.  Neuroanatomically, 
WFP is expressed in a spatio-temporal pattern comparable with endogenous PrP, 
displaying highest concentrations in axon-dense regions.  WFP also proves to be 
functional in vivo, acting as a neuroprotective agent against a truncated form of PrP that 
induces neurological illness (Barmada et al. 2004).   
In order to visualize PrPSc trafficking in real time, we attempted to generate 
fluorescently-tagged PrPSc in vivo by inoculating Tg(WFP) PrP+/+ animals with scrapie 
prions through intracerebral injection.  Although endogenous PrP rearranged into the 
PrPSc conformation, WFP itself was unable to adopt protease resistance and detergent 
insolubility after RML prion inoculation.  Interestingly, WFP was able to recognize and 
bind to PrPSc derived from PrPC, while maintaining its own structural integrity.  RML-
inoculated Tg(WFP) PrP+/+ also developed prion disease, but much later than RML-
inoculated PrPP+/+ animals, demonstrating that WFP binding to PrPSc  had a negative effect 
on the conversion of endogenous PrPC.   Additionally, RML-inoculated Tg(WFP) 
animals on the PrP-null background failed to demonstrate any symptoms of prion disease, 
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arguing that WFP was resistant to PrPSc conversion and toxicity (Barmada and Harris 
2005).   
In this work, we describe our continued efforts to generate fluorescently-tagged 
PrPSc through conversion of WFP molecules to infectious, protease-resistant isoforms 
(WFPSc).  We extend our previous study by attempting to detect WFPPSc in RML-
inoculated Tg(WFP) brain homogenate using a more sensitive bioassay.  We had 
previously found no trace of PK-resistant WFPScP  material in RML-inoculated Tg(WFP) 
PrPo/o brain homogenates (Barmada and Harris 2005), perhaps because the amount of 
WFPSc was too small to detect biochemically.  We describe here a more sensitive assay 
that tests for any infectivity in RML-inoculated Tg(WFP) brain homogenates by 
inoculation intoTga20 mice, which express 10X the amount of endogenous PrP and 
provide a sensitized background for detection of prion transmissibility (Fischer et al. 
1996).   
We also endeavor to generate WFPPSc by 1) inoculating Tg(WFP) mice with 22L, a 
different prion strain able to convert PrPC in cell culture and neural stem cells (Nishida et 
al. 2000; Milhavet et al. 2006); and 2) sequentially passaging RML-inoculated Tg(WFP) 
brain homogenate into a second round of Tg(WFP) recipients, in an attempt to overcome 
a possible species barrier.  In each experiment, we recorded clinical data to observe any 
WFPSc toxicity, and we assayed brain homogenates from experimental animals to 
biochemically detect GFP-tagged PrPSc.  None of our efforts yielded successful 
conversion of WFP to infectious, aggregated, or protease-resistant WFPSc, indicating that 
WFP is highly resistant to prion conversion. 
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A2.3 Materials & Methods 
Transgenic Mice.  Construction of Tg(WFP), Tg(PG14-EGFP), Tga20, and PrP 
knockout mice have been described previously (Bueler et al. 1992; Fischer et al. 1996; 
Barmada et al. 2004; Medrano et al. 2008).  
Injections & Clinical Evaluation.  RML inoculum was prepared as previously 
described (Barmada and Harris 2005).  22L inoculum was derived from the brain of a 
terminally ill CD-1 mouse infected with 22L scrapie (a gift from the lab of Su Priola).  
Brains from three healthy Tg(WFP+/+)/PrPo/o (age > 600 days) that had been infected with 
E1-passaged RML scrapie were isolated and pooled to produce E1-injected 
Tg(WFP+/+)/PrPo/o inoculum.  Brains from three healthy PrP knockout mice that had been 
injected with E1-passaged RML scrapie were pooled to produce RML-injected PrPo/o 
inoculum.  Brains from two severely ill Tg(WFP+/o)/PrP+/+ mice injected with E1-
passaged RML scrapie were pooled to produce RML-injected Tg(WFP+/o)/PrP+/+ 
inoculum.   
For all inocula samples, ten percent (w/v) brain homogenates were prepared in 
cold sterile PBS using a Teflon-glass tissue homogenizer with pestle revolving at 3500 
rpm, 10 strokes.  (Wheaton Science Products, Millville, NJ).  Homogenates were 
centrifuged at 1000 x g for 5 min to obtain a postnuclear supernatant.  For inocula 
derived from multiple brains, post-nuclear supernatants were pooled in equal volumes 
before dilution with sterile PBS to a final concentration of 1% brain homogenate.  30µL 
of these solutions was injected intracerebrally into 4- to 6-week old mice using a 25 
gauge needle.   
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Mice were checked biweekly for symptoms of neurological dysfunction.  
Kyphosis, foot clasp, and hyperexcitability were determined by visual observation, while 
ataxia was tested by placing mice in the center of a horizontally oriented grill (45 x 45 
cm) consisting of 3 mm diameter steel rods spaced 7 mm apart.  Mice unable to 
maneuver around the grid were scored as ataxic.  Animals that exhibited at least two 
symptoms were scored as ill.  Animals showing extreme pruritis were sacrificed when 
scratching became chronically severe. 
Biochemistry.  To assay protease resistance, frozen brain hemispheres were 
homogenized in detergent buffer (DB: 10 mM Tris-HCl, pH 7.4, 0.5% sodium 
deoxycholate, 0.5% NP-40, 150 mM NaCl), then assayed for protein concentration as 
described above.  Protein concentration was determined using a BCA assay (Pierce, 
Rockford, IL).  Two hundred μg of total protein were diluted in DB to a final 
concentration of 1 μg/μl.  The solution was mixed for 10 min at 4°C, then centrifuged at 
1,500 x g for 5 min at 4°C.  20 μg/ml of proteinase K was added to the supernatant and 
the mixture was incubated at 37°C for 30 min.  Phenylmethylsulfonyl fluoride (PMSF; 10 
mg/ml) was added to terminate digestion.  Proteins were isolated using methanol 
precipitation, then analyzed by SDS-PAGE and Western blotting.  
To immunoprecipitate aggregated PrP with antibody 15B3, we followed the 
procedure recommended by Prionics (Zurich, Switzerland), utilizing the buffers supplied 
by them.  First, a 100 μl aliquot of mouse anti-IgM Dynabeads (Dynal, Carlsbad, CA) 
was coated with 20 μg of mAb 15B3.  Ten μl of 15B3-coated Dynabeads were then 
added to 200 μg of total protein from brain homogenates.  Samples were incubated on a 
rotating wheel for 2 hr at 25°C, after which beads were washed three times with 1 ml of 
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15B3 Wash Buffer (Prionics, Zurich, Switzerland).  Washed beads were suspended in 40 
μl of 2X 15B3 Loading Buffer (Prionics) and heated for 5 min at 96°C. 
Immunoprecipitated proteins were resolved by SDS-PAGE followed by Western blotting 
with 6D11 antibody (Pankiewicz et al. 2006) or α-GFP antibody (gift from M. Linder).   
 
A2.4  Results  
RML-injected Tg(WFP+/+) PrPo/o brain homogenate does not contain 
infectious, aggregated, PK-resistant WFPSc.  Transgenic animals expressing 
fluorescently-labeled murine PrP (WFP) are denoted as Tg(WFP) mice.  Tg(WFP) PrPo/o 
mice inoculated with murine prion strain RML exhibit no symptoms of prion disease, and 
do not produce detectable amounts of PK-resistant WFPSc (Barmada and Harris 2005).  In 
order to test whether any infectious WFPSc was produced, we injected RML-inoculated 
Tg(WFP) PrPo/o brain homogenate into Tga20 animals.  Tga20 mice express wild-type 
PrP at 10X endogenous levels Because of the heightened levels of PrP expression, Tga20 
animals produce PrPSc more rapidly and succumb to prion disease twice as fast as wild-
type mice when inoculated with RML (Fischer et al. 1996).  Thus, these mice provide a 
sensitized background on which we can test for the presence of small amounts of 
infectious material.  Our inoculum was derived from RML-injected Tg(WFP) mice 
homozygous for the transgene array to maximize detection of any WFPPSc.  
 As a positive control, we injected Tga20 animals with the RML prions.  One 
hundred percent of RML-inoculated Tga20 animals developed rapid onset of illness at 79 
± 9 days (Table 1), similar to ages of onset recorded previously (Fischer et al. 1996).  
Infected mice were sacrificed when they reached the terminal stage of disease, defined by 
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severe kyphosis and paralysis.  Disease progression was rapid, and mice became terminal 
within one week of symptom onset.     
It is possible that residual RML from the original Tg(WFP) infection may trigger 
disease during the second passage of inoculation in Tga20s.  To control for this 
phenomenon, we used inoculum from RML-injected PrP-null mice as a negative control.  
PrP null mice are resistant to prion disease, and do not propagate PrPSc (Bueler et al. 
1993).  Thus, the presence of any residual RML molecules in the primary inoculation 
would be detected upon passage into Tga20 mice.   
Tga20 mice inoculated with RML-injected PrPo/o inoculum did not develop prion 
disease.  However, these mice did display kyphosis and severe pruritis as they aged 
(Table 1).  These symptoms were discovered to be an artifact of our Tga20 mouse line, 
which had been maintained on a PrP knockout background.  We discovered, as a result of 
these experiments, that approximately 60% of animals in our Tga20s and our particular 
line of knockout mice develop the same symptoms beginning at around 5 months of age 
(data not shown).  The illness is likely due to the effect of prolonged inbreeding and not 
the lack of PrP, as multiple lines of independently-generated PrP Po/o mice maintain good 
health throughout the duration of their lives (Bueler et al. 1992; Manson et al. 1994).  
Unlike the positive controls, mice in our negative control group did not develop rapidly 
progressive ataxia, or exhibit symptoms definitive for prion-related illness.  While 
infectious PrPScP  usually displays complete penetrance, only 9 of 20 mice were affected by 
pruritis, and the others remained healthy.  These data argue strongly against the presence 
of prion disease in Tga20 mice inoculated with brain homogenate from PrP-null mice.   
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Our experimental group, Tga20 mice injected with RML-injected Tg(WFP) PrPo/o 
inoculum, developed pruritis similar to negative controls at approximately the same age.  
However, mice did not display progressive ataxia or prion-related disease(Table 1), 
indicating that the inoculum did not contain any infectious WFPSc.  This conclusion is 
supported by the following biochemical studies. 
Brain homogenates from age-matched Tga20 mice in the positive control, 
negative control, and experimental groups were analyzed for presence of WFPSc by 
reactivity with PrPSc–specific antibody 15B3.  15B3 is a motif-grafted antibody that 
recognizes insoluble PrPSc and aggregated PrP familial mutants, but not soluble PrPC 
(Moroncini et al. 2004; Biasini et al. 2008).  Brain homogenates were incubated with 
Dynabeads coated with antibody 15B3 for 2 hours to immunoprecipitate any aggregated 
PrPSc.  Beads and homogenates were then analyzed by Western Blot to detect the 
presence of any aggregated PrP (Figure 1A).   As expected, 15B3 was able to pull down 
aggregated PrPSc from RML-inoculated Tga20 animals, but not animals injected with 
RML-inoculated PrPo/o.  Mice injected with RML-injected Tg(WFP) PrPo/o homogenate 
did not yield any PrPSc detectable by 15B3, arguing that there was little or no WFP PSc in 
the inoculum capable of converting endogenous PrPC in Tga20 mice. 
We also tested brain homogenates for presence of PK-resistant PrPSc material 
(Figure 1B).  Homogenates were subjected to treatment with 20 μg/mL protease K, then 
analyzed by Western Blot with PrP antibody 6D11.  Only RML-injected Tga20 brains 
demonstrated PK-resistant PrPC, but not the negative control or experimental group.  This 
is further evidence confirming that RML-injected Tg(WFP) inoculum did not instigate 
PrPSc conversion in Tga20 animals.  Collectively, results from our clinical data and  
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Inoculum Recipient Genotype Age of Onset (dpi)
RML Tga20+/+ PrPo/o 78 ± 9 (18/18)
RML-injected PrPo/o brain 
homogenate Tga20
+/+ PrPo/o 242 ± 43 (9/20) a
RML-injected 
Tg(WFP+/+)/PrPo/o brain 
homogenate 
Tga20+/+ PrPo/o
290 ± 46 (15/20) a
a Mice exhibited kyphosis and extreme pruritis.  These symptoms were not due to prion-related illness 
because negative controls also exhibited the same defects.  
Table 1.  RML-inoculated Tg(WFP+/o) brain homogenates do not contain 
infectious scrapie.
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Figure 1.  RML-inoculated Tg(WFP+/o) brain homogenates do not contain PrPSc. Brain 
homogenate from Tga20 mice inoculated with RML (lanes1,2), RML passaged through Tg(WFP+/+) 
mice (lanes 3,4), and RML passaged through PrP knockouts (lanes 5,6) were subject to 
immunoprecipitation with aggregate PrP-specific antibody 15B3 (A).  Immunoprecipitated material 
(IP) was analyzed along with a fraction of the input solution (S) by Western blot.  Only homogenates 
from mice injected with RML demonstrated reactivity with 15B3.  Brain homogenates from the same 
samples were treated with 20μg/mL protease K, and analyzed by Western Blot with α-PrP antibody 
6D11 (B). Brackets indicate non-specific bands and PrPSc.  Molecular weight is marked on the left in 
kilodaltons.  Data in each of the panels are from the same gel, spliced for organizational purposes.
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biochemical assays argue that RML-injected Tg(WFP) PrPo/o inoculum did not contain 
any aggregated WFPPSc capable of transmitting prion disease.   
 
Sequential passaging of RML-inoculated Tg(WFP) brain homogenate does 
not generate infectious, aggregated, PK-resistant WFPSc.  PrPSc generated from wild-
type PrPC may not be able to efficiently convert WFP due to the “species barrier” effect, 
whereby conversion is delayed or inhibited by non-homologous amino acid sequences 
between PrPSc and template PrPC molecules (Horiuchi et al. 2000).  The species barrier 
can at times be overcome in vivo by sequential passaging.  This phenomenon is attributed 
to PrPSc strain adaptation to the new host.  To overcome a potentially obstructive species 
barrier between GFP-tagged PrPC templates and untagged PrPSc inoculum, we 
sequentially passaged RML-inoculated Tg(WFP) brain homogenate into Tg(WFP+/o) 
PrPo/o mice. 
 As controls, we injected RML into Tg(WFP+/o) mice  either on a PrP+/+ or PrP-
null background.  Mice expressing endogenous PrP along with the transgene developed 
disease at 215 days, while mice on the null background remained healthy past 460 days 
(Table 2).  These results are similar to previously published results (Barmada and Harris 
2005).  On the PrP+/+ background, endogenous PrPC is converted to infectious and toxic 
PrPSc, causing disease in Tg(WFP) PrP+/+ animals.  The WFP transgene is not converted 
at this initial inoculation and RML-inoculated Tg(WFP) PrPo/o mice remain disease-free.  
To ensure that injection of WFP molecules themselves would not cause disease, we 
inoculated Tg(WFP) PrPo/o mice with brain homogenate from non-injected Tg(WFP) 
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PrP+/+ animals as negative controls.  As expected, these mice did also not develop prion 
disease (Table 2).   
 To determine whether WFPSc could be generated after sequential passaging, we 
injected brain homogenates from RML-inoculated Tg(WFP+/o) PrP+/+ animals into 
Tg(WFP+/o) recipients expressing only transgenic WFP and not endogenous PrP.  We 
checked mice biweekly for ataxia, kyphosis, foot clasp, and hyperexcitability.  Clinically, 
these mice did not develop any prion disease symptoms and remained healthy until death 
(Table 2), showing that sequential passaging did not produce clinical disease in mice.   
 Brain homogenates from these animals did not contain any aggregated PrP 
material, as demonstrated by a 15B3 immunoprecipitation assay (Figure 2A, lanes 3,4).  
WFP from the same samples seem to show mild resistance to protease K treatment 
(Figure 2B, lane 2), but these bands are not specific to WFPPSc.  This is demonstrated by 
lack of aggregated 15B3 material and by Western Blotting PK-treated brain homogenates 
with an α-GFP antibody (Figure 2C), which shows that although the ~30kDa GFP tag 
itself is PK-resistant when detached from PrP (Figure 2C, all lanes), no GFP-tagged PrP 
is detected at the 60-70kDa range.  In contrast, RML-injected Tg(WFP) PrP+/+ mice 
demonstrated aggregated PrPSc  by both 15B3 immunoprecipitation (Figure 2A, lanes 7,8) 
, PK resistance (Figure 2B, lane 4), and exhibited infectivity in vivo (Table 2).  The PrPSc 
here is derived solely from the non-tagged PrPC, since WFP did not react with 15B3 
(Figure 2A, lanes 7,8) was not detected by 15B3 reactivity nor PK-resistance (Figure 2B, 
lane 4).   
 These results reveal that WFPSc generation by a single round of sequential 
passaging was unsuccessful.     
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Table 2.  Sequential passaging does not induce prion disease in Tg(WFP) 
animals.
Inoculum* Recipient Genotype Age of Onset (dpi)
RML WFP+/o PrPo/o >460 (15/15)
RML-injected 
Tg(WFP+/o)/PrP+/+
brain homogenate  
WFP+/o PrPo/o >451 (19/19) 
RML WFP+/o PrP+/+ 215±18 (13/13)
Non-injected 
Tg(WFP+/o)/PrP+/+
brain homogenate 
WFP+/o PrPo/o
>399 (16/16)
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Figure 2. Sequential passaging of brain homogenates from inoculated Tg(WFP) mice does not 
produce WFPSc.  Brain homogenate from Tg(WFP+/o) PrPo/o mice inoculated with RML (lanes 1,2), 
RML passaged through Tg(WFP+/+) PrP+/+ mice (lanes 3,4), and untreated Tg(WFP+/+) PrP+/+ brain 
material (lanes 5,6) were subject to immunoprecipitation with aggregate PrP-specific antibody 15B3 
(A).  Brain homogenate from Tg(WFP+/o) PrP+/+ mice inoculated with RML were used as a positive 
control (lanes 7,8).  Immunoprecipitated material (IP) was analyzed along with a fraction of the input 
solution (S) by Western blot.  Only homogenates from mice injected with RML demonstrated reactivity 
with 15B3.  Brain homogenates from the same samples were treated with 20μg/mL protease K, and 
analyzed by Western Blot with α-PrP antibody 6D11 (B) or α-GFP antibody (C). Brackets and arrows 
indicate non-specific bands, PrPSc, and the GFP tag when cleaved from PrP.  Molecular weight is 
marked on the left in kilodaltons.  Data in each of the panels are from the same gel, spliced for
organizational purposes.
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Injection of prion strain 22L into Tg(WFP) mice does not generate infectious, 
aggregated, PK-resistant WFPSc.  Murine strains of scrapie differ in their incubation 
times, patterns of neuropathology, and rates of PrPSc accumulation.  It was possible then, 
that another prion strain may be more successful for facilitating WFP conversion.  The 
22L strain was a prime candidate because of its ability to produce infection in a wide 
range of cell culture systems, including neuroblastoma and fibroblast cell lines (Nishida 
et al. 2000; Vorberg et al. 2004), as well as neuronal stem cells derived from embryonic 
mice (Milhavet et al. 2006).  Additionally, 22L proved to be more robust in its ability to 
sustain persistent infection in fibroblast cell culture, whereas RML, ME7, and 87V strains 
could only prompt acute infection (Vorberg et al. 2004).   
 22L injection into wild-type PrP+/+ mice, or non-transgenic littermates of 
Tg(WFP) mice, results in onset of scrapie symptoms at ~ 146 days (Table 1).  22L 
inoculation of mice expressing endogenous PrPC as well as a single copy of the WFP 
transgene also succumbed to disease at a similar time, 124 ± 22 days.  This time frame is 
not significantly different from non-transgenic PrP+/+ animals inoculated with 22L, 
indicating that in this case, WFP did not act as an inhibitor of disease onset, as was the 
case in RML-injected animals (Barmada and Harris 2005).  Like RML-induced disease, 
22L prion illness progresses rapidly, with animals reaching terminal stages within seven 
days (data not shown).  Tg(WFP) animals on the PrP null background were injected with 
22L, but did not develop prion disease (Table 3).   
 Analysis of 22L-inoculated Tg(WFP+/o) PrP+/+ brain homogenates by 15B3-
reactivity showed only the generation of PrPSc, but not WFPPSc (Figure 3A, lanes 5,6).  
Additionally, WFP in brain homogenates from Tg(WFP+/o) PrPo/o animals was not 15B3-
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reactive (Figure 3A, lanes 7,8).  22L-injected PrP+/+ positive controls showed the 
presence of aggregated PrPSc (Figure 3A, lanes 3,4), and injected PrPo/o negative controls 
did not express any PrP (Figure 3A, lanes 1,2).   
PK-resistance assays also confirm that endogenous PrPC can be converted to 
PrPSc, but WFP cannot (Figure 3b, lanes 2 vs 3, 4).  The smear at the 50 kDa marker in 
lane 3 where WFP migrates is non-specific because it is also present in lane 2, which 
contains non-transgenic brain homogenate.  No PK-resistant WFPSc was detected by α-
PrP or α-GFP antibodies in brain homogenates of 22L-inoculated Tg(WFP)+/o PrPo/o mice 
(Fig 3B, lane 4 and Fig3C, lane 4).  Some non-specific banding was seen in PrP knockout 
brain homogenate (Fig 3B, lane 1).   These data demonstrate that Tg(WFP) inoculation 
with prion strain 22L does not induce conversion of the GFP-tagged protein.   
 
A2.5  Discussion  
 We demonstrate here that fluorescently-tagged PrP fitted with an EGFP moiety at 
the C-terminal end is impervious to conversion to an infectious scrapie form in vivo.  Our 
attempts to generate WFPPSc by inoculation with prion strains RML and 22L, and by 
sequential passaging of RML-inoculated brain homogenate from Tg(WFP) mice, were 
unsuccessful.  Difficulty in converting the WFP fusion protein is likely due to the 
addition of the EGFP tag, whose structural presence interferes with the conversion 
process. 
 Previous studies have demonstrated that sequence heterology between PrPSc and 
template PrP PC molecules can profoundly interfere with prion formation in cells and in  
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Inoculum Recipient Genotype Age of Onset
22L
22L
22L
22L
22L
22L
PrP+/+ 146 ± 3 (11/11)
PrPo/o > 379 (20/20)
PrP-EGFP+/o PrPo/o > 264 (7/7)
PrP-EGFP+/+ PrPo/o > 469 (3/3)
PrP-EGFPo/o PrP+/+  a 148 ± 17 (17/17)
PrP-EGFP+/o PrP+/+ 124 ± 22 (5/5)
a  Non-transgenic littermates of Tg(PrP-EGFP+/o)/PrP+/+ animals.
Table 3.  22L-inoculated Tg(WFP+/o) mice do not acquire prion disease.
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Figure 3.  22L-inoculated Tg(WFP) mice do not produce WFPSc.  Brain homogenate from PrP 
knockout mice (lanes 1,2), wild-type mice (lanes 3,4), Tg(WFP+/o) PrP+/+ mice (lanes 5,6), and 
Tg(WFP+/o) PrPo/o mice, all inoculated with 22L prions, were subject to immunoprecipitation with 
aggregate PrP-specific antibody 15B3 (A).  Immunoprecipitated material (IP) was analyzed along with 
a fraction of the input solution (S) by Western blot.  Only homogenates from mice injected with RML 
demonstrated reactivity with 15B3.  Brain homogenates from the same samples were treated with 
20μg/mL protease K, and analyzed by Western Blot with α-PrP antibody 6D11 (B) or α-GFP antibody 
(C). Brackets and arrows indicate non-specific bands, PrPSc, and the GFP tag when cleaved from PrP.  
Molecular weight is marked on the left in kilodaltons.  Data in each of the panels are from the same 
gel, spliced for organizational purposes.
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vivo, sometimes even when the difference is a single amino acid (Priola et al. 1994; 
Horiuchi et al. 2000).  This “species barrier” is thought to stem from a deficiency in 
either the initial binding step between heterologous PrPSc and PrPC proteins, or the 
subsequent reaction whereby the PrPC template undergoes the conformational 
rearrangement for transformation to PrPSc.  WFP withstands structural reconformation to 
the WFPPSc form even in the abundant presence of RML PrPSc (Figure 1 & Figure 2), but 
can physically interact and tag RML PrPSc (Barmada and Harris 2005).  Thus, its 
conversion to WFPScP  is likely impeded in a reaction that takes place after the initial 
binding step.  
WFP binds to RML-PrPSc and acts as a dominant negative inhibitor of 
endogenous PrPC conversion in mice expressing both WFP and PrPC, as demonstrated by 
immunofluorescence studies in brain section showing accumulation of punctate 
fluorescent aggregates, and by the delayed onset of disease in RML-inoculated animals 
(Barmada and Harris 2005).  The ability of WFP to bind with the 22L strain of PrPSc was 
not investigated by immunofluorescence.  However, any significant interaction between 
the two molecules is unlikely, given that the presence of the WFP transgene did not 
interfere with 22L disease progression (Table 3).  WFP is also unable to bind or inhibit 
PG14 familial prion disease (See Appendix 1).  The ability for WFP to interfere with 
RML disease progression, but not 22L or PG14, is consistent with the idea that each 
PrPSc strain or aggregated PrP has a unique structure that leads to conformation-specific 
interactions with PrPC.  Possibly, RML PrPSc binds WFP with higher affinity than 22L 
PrPSc, resulting in the delay in endogenous PrPC conversion.  Although 22L was not able 
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to stimulate WFP conversion using this model system, we cannot rule out that other PrPSc 
strains may be capable of inducing WFP re-conformation and aggregation.   
 Why is WFP resistant to conversion?  There are several potential explanations.  
EGFP folds into a stable barrel-like structure, composed of eleven β sheets and several α-
helices (Yang et al. 1996).  The rigidity of the molecule may inhibit the range of 
flexibility and fold of PrPC, thus impeding structural reconformation of the protein.  It is 
also possible that inhibition is not related to the structure of the GFP protein, but its 
placement at the C-terminal end of PrPC.  We chose to insert the tag at a location where 
interference with proper PrPC folding and localization would be minimal.  The tag was 
placed at codon 223 at the end of the third α-helix, to allow for GPI anchor attachment.  
However, PrPC conversion to PrPSc can be effectively blocked when PrPC substrates are 
incubated with an antibody directed toward PrP epitope 219-232 (Horiuchi and Caughey 
1999), indicating that this area is crucial for proper PrPSc/PrPC interaction and PrPC re-
conformation.  It is possible that WT PrP-EGFP conversion was restricted because the 
GFP tag was placed directly within this epitope.  Additionally, the GFP tag is flanked by 
only 7 and 12 amino acids at the N- and C-terminal side, respectively.  The linkers are 
short, and are not designed specifically to give flexibility between PrP and the GFP motif.  
Because of these factors, GFP may partially block PrPSc access to PrPC, leading to 
inefficient conversion.  GFP may also deter intermolecular aggregation if oligomerization 
is highly dependent on interlocking structures at PrP’s C terminal end.   
Alternate experiments with fusion proteins with variable GFP placement has been 
attempted in cells and in yeast by our laboratory.  GFP placement at the N-terminal end 
of PrPC reveals that a significant portion of proteins are cleaved, separating the tag and 
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PrP (Christensen, Westergard, & Harris, unpublished data).  Because this separation may 
cause differential localization between GFP and GFP-tagged PrP, this construct is ill-
suited to study PrPSc trafficking.  We have constructed several other GFP-tagged PrP 
constructs, varying insertion site and linker lengths, to continue our endeavors to convert 
GFP-tagged PrP using a cell culture-based system, although none yet have demonstrated 
adoption of the scrapie conformation.  Continued development of fluorescently tagged 
PrPSc technology will facilitate investigations into PrPSc routes of infection at both the 
physiologic and cellular levels, in vivo and in cell culture.   
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A3.1  Introduction 
 
Prion protein (PrP), a cell surface glycoprotein of unknown function, is located 
along the plasma membrane of cell soma and axons of neurons, and at the presynaptic 
terminal.  Expression of mutant PrP containing an expansion of the octapeptide repeat 
region, designated PG14, causes spontaneous neurological illness in both mice and 
humans.  Evidence demonstrating PG14 aggregation along axons suggest that PG14 
aggregates may be forming axonal blockages, which hinder normal transport of proteins 
to and from the synapse.  I hypothesized that PG14 aggregation within neurons causes 
blockages that disrupt normal axonal transport of synaptic proteins, which then 
contributes to inherited prion disease. 
In order to test this theory in primary neurons, I attempted to measure anterograde 
and retrograde rates of EGFP-tagged WT PrP and EGFP-tagged PG14 PrP transport via 
live imaging microscopy of cultured neurons.  There are two main branches to this 
project: the first is setting up the cultures for imaging, and the second is imaging and 
analysis.  Below I describe in mainly chronological order the progress achieved for each 
branch, and the factors that ultimately limited further advancement of the project. 
 
A3.2 Materials & Methods 
 
Cerebellar granule neuron (CGN) cultures. CGNs were isolated from 4 day old 
mouse pups according to methods described previously (Miller and Johnson 1996).  
Neurons were plated in CGN medium (basal medium Eagle’s with Earle’s salts, 10% 
fetal calf serum, 2 mM glutamine, 25 mM KCl, 0.1 mg/ml gentamycin).  Cells were 
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plated at a density of 375,000-450,000/cm2 onto 35 mm glass-bottom dishes pre-coated 
with poly-D-lysine.   
Hippocampal Cultures (Mennerick Lab).  Hippocampal cells were isolated from 
mouse pups similar to methods described previously (Mennerick et al. 1995).  
Hippocampi were dissected from animals within 1 day of age, sliced into 500μm-thick 
transverse sections, and then digested by 20 minute immersion at 37°C in an oxygenated 
solution containing 1 mg/mL papain in Leibovitz L-15 medium.  Hippocampi were then 
triturated in modified Eagle’s medium containing 5% horse serum, 5% fetal calf serum, 
17mm D-glucose, 400 μM glutamine, and antibiotics penicillin and strepotomycin, by 
passage through a flame-polished glass pipette.  Cells were plated in the same modified 
Eagle’s medium at a density of 1500 cells/mm2 onto glass coverslip-bottom 35 mm 
dishes pre-coated with collagen microdroplets sprayed onto a layer of 0.15% agarose.  
Each dish was then supplemented with Insulin-Transferrin-Sodium Selenite (ITSS).  
Aphidicolin was added on the third day post-culture to minimize glial proliferation.  
Hippocampal Cultures (Goldstein Lab).  Hippocampi were dissected from 
animals within 1 day of age, then transferred into cold Hank’s buffer solution modified to 
include D-glucose, HEPES, and antibiotics.  Hippocampi were digested in PBS 
containing 10U/mL papain solution, for 10 min at 37°C.  0.05% DNAseI was added to 
stop digestion.  Hippocampi were shaken at 100rpm at 37°C for 20 min, washed twice 
with Dulbecco’s Modified Eagle Medium (DMEM), then triturated in the same DMEM 
using a plastic 1 mL pipette tip.  Cells were allowed to settle to the bottom of the tube for 
3 minutes and supernatant was transferred to collect only single-cell suspension.  Cells 
were plated at 200,000/cells per well onto coverslips within a 24-well dish.  Coverslips 
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had been pre-sterilized with acetone, ethanol, and sterile ddH2O washes, followed by 
coating with poly-L-lysine.  Three hours post-plating, media was replaced with 
Neurobasal-A/B27 supplemented with 0.5 μM L-glutamine.   
Dorsal Root Ganglia (DRG) Cultures.  Embryonic day 13 pups were removed 
from the maternal uterus, then cleaned in DMEM.  Pups were decapitated, and DRGs 
were obtained by first isolating the spinal cord, then plucking DRGs directly from the 
spinal cord.  For explant cultures, DRGs were placed directly into 24-well plates pre-
coated with poly-D-lysine and laminin at 1-2 DRG explants/well, in media containing 
DMEM supplemented with 10% fetal bovine serum, 50 ng/mL nerve growth factor, and 
penicillin & streptomycin.  For dissociated cultures, DRGs were dissociated by a 25 
minute incubation with trypsin at 37°C, then triturated using a 1 mL pipette tip.  Cells 
were plated onto 24-well dishes pre-coated with matrigel, using Neurobasal media 
supplemented with 1:50 B27 and 50ng/mL nerve growth factor.  For both explant and 
dissociated cultures, aphidicolin was added at 24 hours to prevent glial cell proliferation.      
Transfection.  Lipofectamine 2000 (Invitrogen) was used to transfect primary 
neuronal cultures with PrP-EGFP and EGFP-PrP constructs within the pCDNA3.1(+) 
Hygro plasmid, as per protocol provided by the manufacturer.   
Lentiviral Preparation & Transduction.  Construction of N-terminally tagged 
EGFP-WT PrP and EGFP-PG14 has been described previously (Medrano et al. 2008).  
Constructs were subcloned into lentiviral plasmid pRRLsinCMV by PCR and restriction 
enzyme digest.  HEK293 cells were transfected with this plasmid, along with viral 
plasmids pMD-G, pMD-LG, and REV, using Lipofectamine 2000 (Invitrogen) as per 
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protocol supplied by the manufacturer.  Cells were incubated for 48 hours, after which 
supernatant was collected and used to transduce DRG dissociated cultures.   
Microscopy and image analysis.  Primary neurons were imaged in the living state 
using a Zeiss LSM 510 inverted confocal microscope with an Axiovert 200 laser 
scanning system using LSM Image Browser software.  For kymograph analysis, we used 
a Nikon TE-2000E inverted fluorescence microscope, and images were captured and 
analyzed with Metamorph imaging software. 
 
A3.3 Results 
 
 Primary Cultures from Transgenic Mice.  The first attempts to track EGFP-
tagged PrP particles were in cerebellar granule cells cultured from Tg(WT-EGFP) line A 
mice and Tg(PG14-EGFP) line X mice.  The protocol we use fosters neuritic extension 
and growth in CGNs in primary culture, but does not stimulate differentiation into axons 
and dendrites.  Using confocal microscopy, I was able to easily observe both stationary 
and moving particles within or on neurites of CGNs from Tg(PG14-EGFP) primary 
cultures (Figure 1).  In contrast, WT-EGFP was much more difficult to image.  On one 
(and only one) rare case was I able to track what was presumably a moving WT-EGFP 
particle in CGN neurites (Figure 1).  This movie was obtained only after dozens of hours 
on the confocal and days/weeks spent culturing CGNs.   
Movies were obtained by capturing images at regular intervals over the course of 
3 to 5 minutes.  CGNs were able to survive at room temperature without CO2 regulation 
for approximately 10 min, after which they began to visibly deteriorate.  Several attempts 
to use heating stages and a microscope-fitted apparatus for CO2 regulation were 
unsuccessful at extending CGN culture longevity. 
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Figure 1.  Axonal Transport in CGNs. Mobile fluorescent particles (red arrows), presumably 
corresponding to PrP-EGFP traveling in vesicles, were observed in CGNs cultured from WT-EGFP 
(top panels) and PG14-EGFP (bottom panels).  Images of the same field were recorded at different 
time points (indicated in blue, seconds) 
0.0 sec 8.9 26.6 44.4 62.1
0.0 sec 26.6 53.2 79.8 106.4
WT-EGFP
PG14-EGFP
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Upon capturing movies, several difficulties were at once evident.  First, WT-
EGFP molecules coated the surface of CGN neurites, thus making visualization of any 
distinct particles within the extensions near impossible.  This continued to be one of the 
main difficulties encountered throughout this project.  Attempts to clear peripheral WT-
EGFP by PIPLC cleavage was unsuccessful.  Enzymatic cleavage seemed incomplete, 
leaving many fluorescent puncta on the neurites which were stationary.  These were 
presumably not intracellular vesicles being shuttled within neurites because the majority 
of fluorescent puncta were stationary.  I was unable to distinguish between what was 
vesicular and what was cell surface PrP.  In contrast, because PG14 does not reach the 
cell surface, intracellular fluorescent puncta could easily be observed, in both stationary 
and mobile forms. 
A second technical problem came from the fact that the CGN cultures had to be 
grown at high densities in order to survive ex vivo.  This led to a dense meshwork of 
overlapping neurites crisscrossing at wildly variable angles, making particle tracking 
extremely difficult.  Neurites were packed so tightly that they could not easily be defined 
even by phase contrast.  I attempted to troubleshoot this difficulty by 1) culturing CGNs 
at lower densities, and 2) diluting transgene-positive CGNs with non-fluorescent 
transgene-negative CGNs at 1:10, 1:100, and 1:1000.  Culturing CGNs at lower density 
led to poor cell survival and overall neuronal health.  Diluting fluorescent cells onto non-
fluorescent cells resulted in healthy cultures, but no detectable fluorescence.  The reason 
for loss of fluorescence may be due in part to the fact that C-terminally tagged PrP-EGFP 
constructs are very dim (leading to lower signal to noise ratios), or because overlapping 
from non-fluorescent neurites prevented excitation of hidden GFP-laden neurites.   
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 Given the relative dimness of constructs and over-crowding of neurites, we 
decided to explore other cell culture systems to use as models of axon-specific transport.  
I tried culturing hippocampal neurons first, which have the ability to differentiate into 
dendrites and axons in culture, and can be grown at low enough densities for imaging and 
particle tracking.  The two main protocols I worked with came from the labs of Steve 
Mennerick and Larry Goldstein.  These procedures were accomplished with post-natal 
pups, and were easier to work with compared with protocols that required pre-natal pups, 
because no mothers had to be sacrificed.   
A technician named Ann Benz from Steve Mennerick’s lab was able to help me 
culture hippocampal cells derived from Tg(WT-EGFP) and Tg(PG14-EGFP) mice.  The 
result was that WT-EGFP, but not PG14-EGFP molecules, were detectable above 
background (Figure 2A). The protocol from postdoc Sandra Encalada in Larry 
Goldstein’s lab was high maintenance, with very finicky outcomes in terms of culture 
survival.  I was unable to culture neurons reliably using this protocol, and Sandra herself 
admitted to the same.   
Dorsal root ganglia (DRGs) are pseudo-monopolar cells that extend a single 
bifurcated axon both in vivo and in cell culture.  With the help of MSTP student Craig 
Press from Jeff Milbrandt’s lab, I was able to successfully culture DRGs from E13 pups 
routinely, as both explants and dissociated cultures.  Because DRGs extend only one 
forked axon, neuritic meshwork is not a problem, and the cultures could be grown at low 
enough densities that each axon could be traced to a cell body for retrograde/anterograde 
orientation.  However, DRG explants harvested from Tg(PrP-EGFP) mice demonstrated 
that WT-EGFP was only dimly fluorescent, and that PG14-EGFP was not detectable over 
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background (data not shown).  Inability to detect PG14-EGFP in hippocampal neurons 
and DRGs from Tg(PG14-EGFP) animals is likely due to the low expression level in 
these mice.  
 
Cell Transfection & Transduction of PrP-EGFP and EGFP-PrP.  Because 
neurons obtained from the Tg(PrP-EGFP) mice did not express high enough levels of 
fluorescent protein for detection in these cell systems, I tried introducing EGFP-tagged 
PrP into primary neurons cultured from non-transgenic animals via transfection.  This 
method had been initially used by the Goldstein lab in their efforts to determine whether 
kinesin I was the main motor responsible for PrP axonal transport.  Preliminary findings 
from their lab were shared at a conference in 2005 (Encalada et al. 2008), but more 
complete findings have yet to be published.   
In these experiments, I used N-terminally-tagged EGFP-PrP constructs driven by 
a CMV promoter to increase protein expression for better fluorescence detection.  N-
terminally-tagged constructs are, in general, brighter than the C-terminally tagged PrP-
EGFP molecules used in the transgenic mice.  However, it was also discovered at the 
time that significant fractions of EGFP-PrP are cleaved at the junction connecting the 
fluorescent tag and the PrP protein.  Because large pools of EGFP molecules were 
separate from their PrP substrates, it became unreliable to use this construct to accurately 
track fluorescent PrP particles without confusing them for cleaved GFP particles.  To add 
injury to insult, neurons had very poor survival outcomes post-transfection.   
I then generated lentiviral constructs carrying WT-EGFP and PG14-EGFP fusion 
proteins and transduced these into DRGs.  I had concurrently made lentivirus carrying  
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A.  Hippocampal Neurons
EGFP-WT EGFP-PG14
B.  DRGs
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Figure 2.  EGFP-tagged PrPs in hippocampal cells and DRGs. (A) Hippocampal neurons derived 
from transgenic mice expressing WT-EGFP(top left panel), PG14-EGFP (bottom left panel), or from 
non-transgenic littermates (right panels) were cultured, then analyzed by fluorescence microscopy.  
Fluorescent signal above background could be detected in cells expressing WT-EGFP, but not PG14-
EGFP.  (B)  DRGs were transduced with lentivirus carrying N-terminally tagged EGFP-WT (left 
panel) or EGFP-PG14 (right panel).  Expression of EGFP-WT could be detected mainly in the soma 
of DRGs, but EGFP-PG14 expression was not detected.  
WT-EGFP
PG14-EGFP
Non-Tg
Non-Tg
DNA encoding only cytosolic GFP as a positive control.  I exposed dissociated DRG 
cultures to several serial dilutions of low-titer lentivirus (from supernatant of packaging 
HEK293 cells) and found that DRGs expressed cytosolic GFP very well.  At high titers, 
WT-EGFP expressed well enough to detect a dim fluorescence over background, but 
PG14-EGFP could not be detected with fluorescence microscopy (Figure 2B).  Part of the 
reason is likely due to the repeated observation that PG14 constructs in general are 
expressed at lower levels than WT PrP constructs.   
  
A3.4 Discussion  
 
Several large technical difficulties hinder the progress of this project.  The first 
and most formidable difficulty is establishing a suitable assay in which to measure axonal 
transport.  Multiple obstacles include: 1) the fluorescence intensity of C-terminally 
tagged PrP-EGFP fusion proteins are extremely dim and can be difficult to detect and 
measure; 2) WT PrP coats the surface of the neurites, obstructing the view of any moving 
intracellular particles; 3) anterograde and retrograde directions are difficult to distinguish 
in some cultures, as neurites are not easily traceable to a cell body of origin, and 4) 
imaging live neurons can be difficult, as they are very sensitive to the temperature and 
CO2 levels of their environment.   
Assuming successful resolutions can be found and applied to the technical 
challenges of the project, there are several experiments that could test whether mutant 
PrP PG14 aggregates induce axonal blockage.  The first would be to measure rates of 
transport of WT and PG14 protein particles, then compare the average velocity in the 
anterograde and retrograde directions.  Additionally, particles could be counted and 
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classified as moving or stationary.  A decreased average particle speed, or decreased 
percentage of mobile particles, in PG14-expressing cells would suggest deficiencies in 
axonal transport.  A second experiment involving measuring speeds of fluorescently-
tagged synaptic vesicle proteins, i.e. synaptophysin, co-transfected with either WT PrP or 
PG14, would help determine whether axonal transport of non-PrP proteins is affected by 
mutant PrP expression as well.  These investigations could be conducted at either steady-
state in fully mature neurons, or in developing cells in the process of polarization.  
Because WT PrP has been implicated in axon development and regeneration (Sales et al. 
2002; Moya et al. 2005, and see Introduction), it would be interesting to know whether 
expression of a PrP mutant would interfere with this process.   
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